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ABSTRACT 
Acute lymphoblastic leukemia (ALL) is the most common cancer affecting in 
childhood. It occurs typically in early B-lineage cells and is characterized by a few 
specific initiating genomic alterations. One of the most common alterations is the 
translocation resulting in the ETV6-RUNX1 (E/R) fusion gene. Progression to 
overt ALL requires additional genetic abnormalities that are recurrently found at 
essential B-cell lineage identity determining genes. Besides DNA, alterations in 
various RNA species and proteins could also have marked unwanted effects on cell 
behavior. E/R functions as an aberrant transcription factor but its direct target genes 
have thus far remained uncertain. 
We set out to study genome-wide gene regulation in childhood precursor B-ALL 
(preB-ALL) by studying nascent RNA transcription in cell lines and patient samples. 
For the examination of target sites, we generated a cell line model with an inducible 
E/R. We detected enhancer regions by the expression of eRNA transcripts and 
deciphered a possible target gene by correlating between expression level changes. 
Two thirds of the E/R-regulated genes were repressed by direct regulation via 
RUNX1 DNA binding. We further showed E/R-mediated downregulation of B-cell 
specific super-enhancers. Some of the regulated genes were observed to be 
differentially expressed among E/R patients when compared to other preB-ALL 
patients.  
RAG and AID are enzymes that have been linked to the genesis of secondary 
genetic alterations in B-cell leukemia. We explored the nascent RNA transcription 
across B-lymphoid cells at the genomic sites that are often deleted in childhood 
precursor B-ALL and noticed significant association with specific transcriptional 
features, namely RNA polymerase II stalling and convergent transcription. These 
features seem to expose the DNA to double strand breaks especially by revealing 
RAG recombination signal sequences. We noticed high RAG1 expression in the 
E/R subtype, and abnormal expression of AICDA among the non-classified 
precursor B-ALL cases. 
This thesis identifies genome-wide targets of the E/R fusion and specific 
transcriptional features that are associated with recurrent DNA breakpoint sites in 
childhood precursor B-ALL. 
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TIIVISTELMÄ 
Akuutti lymfoblastileukemia (ALL) on lasten yleisin syöpä. Useimmiten se saa 
alkunsa epäkypsästä B-solusta (preB), jossa tapahtuu tietty altistava geneettinen 
muutos. Yksi yleisimmistä muutoksista on translokaatio, joka johtaa ETV6-RUNX1 
(E/R) fuusiogeenin syntymiseen. Leukemian puhkeamiseen vaaditaan lisäksi muita 
geneettisiä muutoksia, jotka usein osuvat B-solun identiteetille tärkeisiin geeneihin. 
DNA-vaurioiden lisäksi solun toiminta voi häiriintyä RNA-molekyylien ja 
proteiinien toiminnan muutoksista. E/R on epänormaali transkriptiotekijä ja sen 
suorat säätelykohteet ovat vielä jääneet epäselviksi. 
Tässä työssä tutkimme lasten prekursori B-ALL:ssa (preB-ALL) tapahtuvaa 
genominlaajuista geeniensäätelyä tarkastelemalla varhaista RNA-transkriptiota 
solulinjoissa ja potilasnäytteissä. E/R-fuusion kohdegeenien kartoittamista varten 
teimme solulinjamallin, jossa fuusion tuotantoa voidaan säädellä. Määritimme 
tehostaja-alueet tehostaja-RNA:iden (eRNA) ilmentymisen perusteella sekä niiden 
mahdolliset kohdegeenit perustuen signaalimuutosten samankaltaisuuteen. E/R-
fuusion säätelemistä geeneistä kaksi kolmasosaa hiljeni suoran RUNX1-välitteisen 
DNA-sitoutumisen kautta. Lisäksi E/R vähensi B-solu-spesifisten tehostaja-
alueiden luentaa. Osa geeneistä myös ilmentyi eri tavalla E/R-potilaiden 
leukemiasoluissa verrattuna muiden preB-ALL alityyppien potilaiden soluihin. 
RAG ja AID entsyymit on liitetty DNA-katkosten syntymiseen B-solu-
leukemiassa ja niiden toimintaan tiedetään liittyvän avoimena oleva kromatiini. 
Tutkimme RNA-transkriptiota B-linjan soluissa keskittyen lasten leukemiassa usein 
nähtäviin DNA-katkoskohtiin. Huomasimme, että katkoskohtiin assosioituvat tietyt 
transkriptionaaliset ominaisuudet: RNA-polymeraasin pysähtyminen sekä 
yhtäaikainen geenienluenta päällekkäisiltä DNA-juosteilta. Nämä piirteet näyttävät 
altistavan DNA:n katkoksille erityisesti paljastamalla RAG-entsyymin 
rekombinaatiosignaalisekvenssejä. Huomasimme myös korkean RAG1-geenin 
luennan erityisesti E/R-potilailla sekä AID-entsyymiä koodaavan geenin 
epätavallisen luennan osalla korkean riskin preB-ALL potilaita. 
Tässä väitöskirjassa tunnistettiin E/R-fuusion genominlaajuisia säätelykohteita 
sekä toistuvien DNA-katkosten kohdille ominaisia transkriptionaalisia piirteitä lasten 
leukemiassa. 
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1 INTRODUCTION 
Acute leukemia is a type of blood cancer which is characterized by rapid proliferation 
and growth of abnormal cells that fill the bone marrow. Leukemia is the most 
common cancer in childhood and is diagnosed in approximately 4000 children each 
year in Europe. The incidence peak of acute lymphoblastic leukemia (ALL) is at 2-5 
years of age and most cases arise in precursor B-cells. Remarkable progress has been 
made in the treatment of childhood ALL during the past decades, with the current 
cure rate of over 90%. This success is mainly brought about by the use of 
conventional cytotoxic chemotherapy that is also associated with major short- and 
long-term side-effects. Treatment is currently tailored according to risk grouping, 
which is partly defined by the underlying genetics and the treatment response. 
The genomic diversity of childhood ALL has been investigated in several studies 
and the classification of leukemia subtypes has progressed rapidly during the recent 
years. These improvements have been made possible by the advances in genomics, 
including novel technologies and integration of data types such as DNA alteration, 
RNA expression, and epigenetic data. Relatively few secondary genomic alterations 
are typically found in childhood ALL but, curiously, they seem to accumulate to 
certain genomic sites. 
The ETV6-RUNX1 subtype comprises approximately 25% of childhood B-ALL 
cases. The translocation between chromosomes 12 and 21, first noticed in the early 
1990s, occurs in utero during fetal hematopoiesis at an early B-cell progenitor cell, 
and additional alterations accumulate before leukemia initiation during early 
childhood. Precursor B-ALL subtypes differ by sensitivity to chemotherapeutic 
drugs and by the overall gene expression profiles. This implies that the initiating 
alteration, including the ETV6-RUNX1 fusion, induces unique genetic and 
molecular features in the leukemic cell. 
Many studies have aimed at revealing the role played by the ETV6-RUNX1 
fusion in leukemia, but many details are yet to be elucidated. The research presented 
in this thesis was aimed at gaining further knowledge on the transcriptional 
regulation and molecular biology of this subtype of childhood ALL. 
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2 REVIEW OF THE LITERATURE 
2.1 Cancer in children 
 
There are 17 million new cancer cases and 9.6 million cancer deaths worldwide each 
year. Less than 1% of cancers occur in children. (Cancer Statistics for the UK). Although 
the 5 year survival rate of all cancers is over 80%, almost a hundred thousand 
children die for it every year worldwide (Sullivan et al., 2013). In Finland, around 150 
children (age < 15 years) are diagnosed with cancer each year, and cancer causes 
around 15% of childhood deaths (in 2017, 24 of the 182 deaths) (SVT, 
kuolleisuustilasto). The most common cancer in children is leukemia (around 35%), 
followed by central nervous system tumors and lymphomas (Madanat-Harjuoja et al., 
2014). Mutational load is significantly lower in pediatric cancers than in adult cancer 
types (Gröbner et al., 2018). Treatment of leukemia in children is characterized as 
one of the major successes of chemotherapy of cancer.  
2.1.1 Childhood acute lymphoblastic leukemia 
 
Childhood acute leukemia incidence is around 40-50 per one million children per 
year (Syöpä Suomessa Syöpärekisteri; Steliarova-Foucher et al., 2017). The proportion of 
leukemia of all cancers is the highest among children (35% among 0-9 years old) and 
decreases by age (15% of cancers among 15-19 of age and 3% among adults), while 
the proportion of epithelial cancers increases (Cancer Statistics for the UK; Steliarova-
Foucher et al., 2017). Most leukemia cases in children are acute lymphoblastic (ALL), 
in contrast to myeloid leukemias or chronic types. In contrast, only 10% of the adult 
leukemias are ALLs (most being chronic lymphocytic or acute myeloid diseases). 
Approximately the same number of adults and children are diagnosed with ALL each 
year (Cancer Statistics for the UK; Syöpä Suomessa - Syöpärekisteri).  
Childhood ALL can be divided into subgroups based on cell lineage (B- or T-
cells), differentiation status (early progenitors or precursors), and genetics. Ninety 
percent of early childhood ALL arise in B-cells (Toft et al., 2018). Symptoms include 
fever, fatigue, hemorrhage, and paleness. Patients in the Nordic countries receive 
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standard chemotherapy treatment according to the contemporary NOPHO (Nordic 
Society for Pediatric Hematology and Oncology) protocol (Toft et al., 2018). 
Treatments are tailored based on age, white blood cell counts, minimal residual 
disease after induction chemotherapy, and specific genetic subtypes. High risk 
patients are often defined by the age over 10 years, white blood cell count over 
50 000/?l, and/or by having hypodiploid or BCR-ABL1 genetics. These features 
were reported to identify 12% of preB-ALL patients with less than 50% relapse-free 
survival. (Harvey et al., 2010.) However, advances in treating BCR-ABL1-positive 
patients with tyrosine kinase inhibitors have increased the survival of this subgroup 
up to 70% (Biondi et al., 2019). 
Treatment protocol for adults has been adapted from pediatric protocols, 
however, lower doses of drugs are needed to avoid induction related deaths 
(Terwilliger and Abdul-Hay, 2017). By applying pediatric protocol, almost 70% of 
adult ALL patients achieve long-term remission (Jabbour et al., 2015; Toft et al., 
2018). Poorer overall survival is partly due to higher proportion of poor prognostic 
genetic subtypes in adults: KMT2A-rearranged, low hypodiploid, and kinase-driven 
ALLs account for more than 65% of adult cases (Iacobucci and Mullighan, 2017; Gu 
et al., 2019). 
Childhood leukemia incidence has risen 15% worldwide from the 1980s to 2010 
and the reasons are unknown (Steliarova-Foucher et al., 2017). Ionizing radiation 
exposure is the clearest causal factor for childhood leukemia, especially increasing 
the risk of B-cell leukemias. Other factors include Down syndrome, germ-line 
variations in genes linked to B-cell development or DNA repair, and the use of 
chemotherapy agents (Saida, 2017). On the contrary, breast feeding and daycare 
attendance are associated as protective factors (Infante-Rivard, Fortier and Olson, 
2000; Ma et al., 2002; Greaves, 2018). Evidence supporting the relevance of timing 
of infections in early childhood has been gained from epidemiological studies and 
more recently from animal models (Rodríguez-Hernández et al., 2017; reviewed in 
Greaves, 2018). It has even been suggested that a significant part of leukemias could 
be prevented (Greaves, 2018). 
Relapse in ALL has approximately 10% of incidence and is associated with 
positive minimal residual disease at the end of induction (Pui and Campana, 2017; 
Toft et al., 2018). The recurrence of ALL is the most frequent cause of premature 
death (1% incidence at 10 years from diagnosis), however, patients also have 
increased risk of non-relapse mortality compared to normal population. Survivors 
are at increased risk in developing growth hormone deficiency, neuropathy, 
hypogonadism (related to fertility), and, if treated with anthracyclines, cardiac-related 
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effects. Late effects in long-term survivors are dependent on treatment regimen and 
life-threatening effects are no longer as common, although long-term risk based 
follow-up is needed. (Essig et al., 2014; Ford et al., 2019; Mulrooney et al., 2019.)  
Up to 80% of pediatric leukemia cases occur in resource-limited (low- or middle 
income) countries and survival rates differ between countries (Sullivan et al., 2013; 
Bonaventure et al., 2017). The differences may reflect differing diagnostic 
characterization, risk stratification, restrictions in overtreatment, and adherence to 
protocols by oncologists. Because of the discrepancy, the highest impact globally will 
come from not only more efficient but also more cost-efficient and local options for 
examination and care. 
2.1.2 B-cell differentiation and leukemia 
Billions of blood cells are produced each day in hematopoiesis in human body 
through proliferation, differentiation and maturation. B-cell differentiation is 
characterized by specific cell surface markers and recombination of immunoglobulin 
genes. All blood cells originate from pluripotent hematopoietic stem cells (HSCs). 
HSCs develop towards lymphoid-primed multipotent cells (LMPPs) and 
subsequently to common lymphoid progenitor (CLP) population, which can direct 
differentiation toward either T- or B-cells under specific transcription factor 
guidance. B-lymphoid directed progenitors remain plastic until an activation loop 
containing TCF3, FOXO1, EBF1, and PAX5 is complete, after which progenitor-B 
cells are produced. (Lin et al., 2010; Jacobsen and Nerlov, 2019.) Differentiation 
towards B-cell lineage is also characterized by the expression of certain genes (Figure 
1). After successful rearrangement of immunoglobulin heavy chain (IGH) and preB-
cell receptor formation (containing IgH; surrogate light chains VPREB1 and IGLL1; 
and proximal CD79A/B signaling molecules) on the surface, the cell can enter 
stroma-dependent proliferating large preB state (Joshi et al., 2014). Differentiation is 
then continued towards small preB and immature B-cell state, at which point cells 
leave the bone marrow for maturation in secondary lymphoid organs. 
Immunoglobulin heavy chain genes are recombined during pro-B states by 
recombination activating gene (RAG1 and RAG2) mediated cleavage activity. RAG 
enzymes are produced specifically in lymphoid lineage precursor cells for the crucial 
process called VDJ-recombination, which eventually leads to production of antibody 
repertoire needed in mature B-cell mediated immune response. Recombination and 
cleavage of DNA requires multiple interactions between proteins and DNA features. 
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RAG1 anchors at recombination signal sequence (RSS) nonamer site in the genome 
(ACAAAAACC), whereas RAG2 surveys nearby spacer and RSS-heptamer 
sequences (CACAGTG), binds with methylated H3K4 (Matthews et al., 2007), and 
serves as a cofactor for RAG1. Cleaved sites are ligated by non-homologous end 
joining. (Reviewed in Schatz and Swanson, 2011.) RAG1 prefers to bind to single-
stranded DNA and the binding affinity is influenced by conformational accessibility 
to RSS site and by sequence variations exhibited especially in the spacer and the 
nonamer sequences. Even transcription factors have been suggested to function in 
targeting the enzyme, such as PAX5 that binds RSS sites in heavy chain variable 
regions (Zhang et al., 2006).  
As in many cancers, cells in leukemia are immature. PreB-ALL cells display a 
differentiation block at pro- or preB cell state. PreB-ALL blast immunophenotype 
is usually CD19+, TdT+ (DNTT), CD22+, CD79A+ and variably CD10+ and CD34+. 
Precursor cell states are characterized by the activity of RAGs and on-going IGH 
rearrangement. RAG activity is suggested to be an important mechanism for 
oncogenic structural variations in ALL by illegitimate off-targeting (Aplan et al., 1990; 
Zhang and Swanson, 2008; Papaemmanuil et al., 2014). 
 
 
 
Figure 1.  A diagram of the major B-cell states during differentiation in the bone marrow. The bars 
depict the expression of chosen genes that characterize B-cell differentiation. 
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2.2 Genetic subtypes of preB-ALL 
Childhood B-cell leukemia can be divided in groups based on recurrent structural 
variations (Figure 2). These groups also differ in their overall transcriptome signal. 
All risk stratifying changes in chromosomal copy numbers, specific deletions, 
rearrangements, and fusion genes are assessed in the clinics by SNP arrays, FISH, 
G-banding, and/or PCR (NOPHO protocol). Studies are on-going to identify new 
molecules and variations for an improved outcome prediction. 
2.2.1 The classical subtypes 
The six classical genetic subtypes of precursor B-cell leukemia include: 1) high 
hyperdiploidy with 51-67 chromosomes; 2) hypodiploidy with less than 44 
chromosomes; 3) t(12;21)(p13;q22) translocation encoding ETV6-RUNX1; 4) 
t(1;19)(q23;p13) translocation encoding TCF3-PBX1; 5) t(9;22)(q34;q11.2) 
translocation encoding BCR-ABL1; and 6) KMT2A- (previously called MLL) 
rearrangements, particularly the t(4;11)(q21;q23) (KMT2A-AF4). 
High hyperdiploid subtype has a good prognosis and is present in around 25% 
of preB-ALL, similarly to ETV6-RUNX1 subtype. Contrary to hyperdiploidy, low 
or near-haploid hypodiploidy is rare (around 2%) and is presented with poor 
prognosis (Nachman et al., 2007). Five percent of preB-ALL belong to TCF3-PBX1 
group, which has a good prognosis with intensified treatment but which may be 
associated with increased risk of central nervous system relapse (Jeha et al., 2009).  
BCR-ABL1, also called Philadelphia chromosome, is present in 3% of pediatric 
preB-ALL, and was associated with dismal prognosis before the addition of tyrosine 
kinase inhibitors to treatment (Druker et al., 2001; Biondi et al., 2019). KMT2A-
rearrangements are rare in children (1%), mostly occurring in infants (< 1 years of 
age). This subtype has a very low frequency of somatic mutations, although half of 
the KMT2A-rearranged cases carry activating mutation in a PI3K-RAS pathway 
component (Andersson et al., 2015). KMT2A is a histone methyl transferase, and 
many of the KMT2A-fusion partners in infant leukemia are also known to bind with 
factors playing central roles in transcriptional processes (Mullighan, 2012). 
KMT2A-AF4 (Gale et al., 1997), ETV6-RUNX1 (Hjalgrim et al., 2002; Zuna et 
al., 2011; Schäfer et al., 2018), TCF3-PBX1 (Hein et al., 2019), and hyperdiploidy 
(Taub et al., 2002; Maia et al., 2003) alterations have been suggested to occur in utero 
during fetal hematopoiesis. 
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2.2.2 New subtypes 
Until recently, up to 30% of pediatric B-ALL could not be classified as being any of 
the known subtypes. New findings based on cytogenetics and gene expression-based 
classification in B-ALL have identified additional groups and recurrent expressional 
changes. 
Two new subtypes were added into the official WHO classification in 2016: BCR-
ABL1-like and iAMP21 (Arber et al., 2016). The BCR-ABL1-like group is 
characterized by alterations in IKZF1 and in other kinase genes than BCR or ABL1 
(e.g. ABL2, PDGFRB, and CSF1R). It was identified by gene expression profiling in 
which the cases resembled samples that contained the BCR-ABL1 fusion (Den Boer 
et al., 2009). The subgroup comprises of around 8% of pediatric preB-ALL patients 
(Iacobucci and Mullighan, 2017). Many of these cases are sensitive to tyrosine kinase 
inhibitor treatment. Intrachromosomal amplification of chr 21 (iAMP21) was first 
characterized as multiple copies of RUNX1 gene in FISH studies (Coniat et al., 2001; 
Soulier et al., 2003). However, RUNX1 is not expected to be a driver in this 
abnormality, and these cases do not usually differ from other subgroups by gene 
expression profile (Harrison, 2009). Pediatric patients with iAMP21 are typically 
older and treated on intensive therapy due to initial poor survival. (Harrison, 2009, 
2015). These two new classifications have had immediate benefit on prognostication 
and tailoring the treatment regimen.  
Similar to the BCR-ABL1-like group, novel ETV6-RUNX1-like and DUX4-
rearranged cases were identified by RNA-sequencing (Lilljebjörn et al., 2016). The 
E/R-like group was characterized by clustering with the E/R samples and by 
coexisting ETV6 and IKZF1 alterations without the E/R translocation. They are 
also enriched with ARPP21 deletions (Zaliova et al., 2019). Some cases without the 
fusion were observed to cluster with E/R cases based on DNA methylation earlier 
(Nordlund et al., 2015). E/R-like group has approximately 4% incidence among 
pediatric B-ALL. DUX4 subgroup is associated with ERG deletions and has 
approximately 5% incidence. In addition, ALL cases with CRLF2 alterations (Russell 
et al., 2009), and MEF2D-, ZNF384-, or PAX5-rearrangements, were characterized 
fairly recently and have been classified as their own groups. (Iacobucci and 
Mullighan, 2017). 
Recently, expression profiling and genomic analyses from 1223 B-ALL (children 
and adults) patients resulted in characterization of six groups not specifically 
characterized before: 1) PAX5 and CRLF2 fusions (9%), 2) PAX5 p.P80R (2%), 3) 
IKZF1 p.N159Y (< 1%), 4) ZEB2 p.H1038R/IGH-CEBPE (<1%), 5) TCF3/4-
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HLF (<1%), and 6) NUTM1 fusions (2%) (Li et al., 2018). The group with PAX5 
and CRLF2 fusions was associated with intermediate risk. As the number of patients 
in other groups were small, prognosis for them were not yet analyzed. In addition, 
further classification of B-ALL cases into a total of 23 groups was recently 
performed using RNA-seq data on a group of 1988 patients of which 1140 were 
children (< 16 years of age) (Gu et al., 2019). Like in Li et al., this work describes 
groups for PAX5alt (7% of children), PAX5 P80R (1.3%), IKZF1 N159Y (0.4%), 
HLF (0.5%), and NUTM1 (0.9%), in addition to previously described subtypes. As 
many as 13% of cases in this cohort were classified as BCR-ABL1-like. A part of the 
CRLF2-altered cases was classified within the BCR-ABL1-like subgroup and another 
part separately (CRLF2 (non-Ph-like), 1%). Now, only five percent of the pediatric 
cases remained unclassified (“other” subtype). It remains to be seen whether further 
classification will improve risk stratification and identification of targetable 
vulnerabilities in each individual’s leukemic genome.  
 
 
 
 
Figure 2.  Cancer in childhood. B-cell acute lymphoblastic leukemia (B-ALL) subtype percentages 
represent patients under 16 years of age in the dataset from Gu et al., 2019. 
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2.2.3 Secondary genetic alterations 
Co-drivers in preB-ALL leukemogenesis have only been started to comprehend. 
DNA structural variations in ALL cluster in pathways related to transcription factors 
(TFs), lymphoid cell differentiation, cell cycle, RAS signaling, JAK/STAT signaling, 
PI3K/AKT/mTOR signaling, chromatin structure modifiers, and epigenetic 
regulators (Montaño et al., 2018). Recurrently altered genes in preB-ALL include 
PAX5, IKZF1, CDKN2A/B, EBF1, RAG1/2, BTG1, TBL1XR1, TCF3, and LEF1 
(Mullighan et al., 2007; reviewed in Sun, Chang and Zhu, 2017). Secondary alterations 
are usually not specific to any pediatric preB-ALL subtype and can also be found in 
adult cases. However, some alterations are enriched to or lack in certain subtypes. 
For example, alterations in histone modifiers and RAS pathway genes are missing 
from the ETV6-RUNX1 subtype (Alexandrov et al., 2013; Papaemmanuil et al., 
2014). Some studies have aimed to infer the sequential order of secondary mutations 
in order to decipher significance of each in the clonal process (Anderson et al., 2011). 
For example, in the E/R disease, PAX5 and CDKN2A/B deletions were shown to 
occur early in the leukemogenic process. Deletion in the other ETV6 allele was also 
shown to occur early, but did not seem to be necessary for any subsequent alterations 
(Lilljebjörn et al., 2010). 
2.3 ETV6-RUNX1 
ETV6-RUNX1 (E/R) translocation is found in the cancer cells of 20-25% of child 
patients diagnosed with B-cell acute lymphoblastic leukemia. The peak incidence is 
at 2-5 years of age. E/R patients have almost excellent prognosis with the current 
treatment and minimal residual disease (MRD) follow-up strategies. The 10 year 
event-free survival was reported to be 95.3%  for the E/R-positive preB-ALL 
patients (Piette et al., 2018). However, E/R subtype is known to have a relatively 
high late relapse rate, with estimations ranging from 3 to 10%, which correlates with 
the MRD level after induction treatment (Harbott et al., 1997; Forestier et al., 2008; 
Bokemeyer et al., 2014; O’Connor et al., 2018). This chapter highlights known 
characteristics of E/R-positive cells. 
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2.3.1 Cell of origin 
There are two types of evidence for prenatal origin of the E/R translocation. First, 
E/R has been found in as many as 5% of healthy newborns in cord blood studies, 
with reports between 0 - 0.01% (Lausten-Thomsen et al., 2011) to 1 - 5% (Mori et al., 
2002; Zuna et al., 2011; Schäfer et al., 2018). The prevalence has been under debate 
between claims of virtually non-existence to a relatively high percentage of newborns 
that would carry E/R-cells. The most recent work reporting 5% incidence was 
obtained by studying CD19-enriched mononuclear cells from cord blood with an 
improved method that, unlike in all the previous reports, investigated DNA rather 
than the presence of the fusion RNA molecule (Fueller et al., 2014). Despite 
precursor cells being rare in peripheral blood and cord blood (Kurzer and Weinberg, 
2018), it has been possible to detect E/R even in old, dried peripheral blood spots 
collected from newborns (Guthrie cards) of patients that later developed leukemia 
(Wiemels, Cazzaniga, et al., 1999; Hjalgrim et al., 2002; Morak et al., 2013). 
The second evidence for prenatal occurrence is that if monochorionic twins both 
get leukemia, they usually have the same E/R breakpoint in their leukemic cells (Ford 
et al., 1998; reviewed in Ford and Greaves, 2017). This suggests that the preleukemic 
clone emerges during pregnancy and transfers between the two individuals. A few 
preleukemic E/R cells have also been detected in samples from the healthy twin of 
a diseased sibling (Wiemels, Ford, et al., 1999; Hong et al., 2008). The concordance 
rate in monozygotic twins is 10% (i.e. the healthy sibling has 10% chance of also 
developing E/R leukemia) (Greaves et al., 2003). 
Evidence on cell state origin have been gained from studying immunoglobulin 
and TCR rearrangements. Most reports have shown similar IGH/TCR 
rearrangements in the cancer cells of twin siblings (Ford et al., 1998; Alpar et al., 
2015). As no polyclonal rearrangements were found, it was thought to be unlikely 
that E/R occurred in a non-committed (RAG- and CD19-negative) cell. In addition, 
a cell population characterized with CD34+/CD19+/CD38low/- was suggested as the 
cancer-propagating cells in E/R-leukemia (Castor et al., 2005; Hong et al., 2008). A 
small fraction of these cells, interpreted as E/R preleukemic cells, was found in the 
blood of the healthy twin sibling of a leukemic patient, but not in other healthy 
individuals (Hong et al., 2008).  
Fetal hematopoiesis differs from adult hematopoiesis (Böiers et al., 2013; Popescu 
et al., 2019). Human fetal liver CD19-positive cells were shown to differ from cord 
blood (neonatal) CD19-positive cells in the expression levels of genes, especially with 
higher IL7R, KIT, and LIN28B, and far lower DNTT expression (Böiers et al., 2018). 
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At a specific time, 40% of fetal bone marrow cells are proB-cells, of which one third 
are characterized as being CD10-/CD34+/CD19+, named as pre-pro-B cell 
population, which was almost undetectable in adults (O’Byrne et al., 2019). In 
addition, when E/R was expressed in a human induced pluripotent stem cell model, 
a CD19-negative, IL7R-positive cell compartment was expanded (Böiers et al., 2018). 
These E/R expressing cells were suggested to lie upstream of the pre-proB-cell state 
(O’Byrne et al., 2019). In conclusion, the translocation is now suggested to occur in 
either multipotent stem cell or very early committed progenitor during fetal 
hematopoiesis. 
2.3.2 Structure 
A reciprocal translocation t(12;21)(p13;q22), rearrangement between ETV6 (TEL) 
and RUNX1 (AML1), was found in lymphoid leukemias in the 1990s (Romana, Le 
Coniat and Berger, 1994; Kobayashi and Rowley, 1995). The translocation fuses 
almost the entire RUNX1 and the five first exons of ETV6 (Golub et al., 1995) 
(Figure 3). Breakpoints cluster relatively closely between patients in introns between 
exons 1 and 2 of RUNX1, and exons 5 and 6 of ETV6 (Thandla et al., 1999; Wiemels 
and Greaves, 1999; Wiemels et al., 2000). No specific mutational signature is yet 
found close to these regions, however, signs of non-homologous end joining repair 
have been reported (Wiemels and Greaves, 1999; Eguchi-Ishimae et al., 2001; 
Papaemmanuil et al., 2014). 
Both ETV6 and RUNX1 are normally expressed in hematopoietic stem cells and 
progenitor cells. RUNX1 protein is essential for normal fetal hematopoiesis, and in 
adults the knockdown of RUNX1 results in expansion of stem and progenitor cell 
states in addition to impaired B- and T-cell formation (reviewed in Mevel et al., 2019). 
RUNX1 was known to be recurrently rearranged in myeloid leukemias before it was 
found in preB-ALL, and mutations in it are also found in T-cell ALL (Grossmann et 
al., 2011). ETV6 is crucial in transitioning hematopoiesis from fetal liver to bone 
marrow. In addition, ETV6 appears non-essential to lymphoid differentiation but 
important in maintaining a normal progenitor pool in the bone marrow, thus 
functioning more in promoting self-renewal than differentiation. (Wang et al., 1998; 
Hock et al., 2004; reviewed in Rasighaemi and Ward, 2017). ETV6 is also seen deleted 
and translocated in other cancers, especially in 25% of early T-cell leukemias (ETP-
ALL) (Zhang et al., 2012).  
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Protein structures in both ETV6 and RUNX1 have been associated with E/R 
function. The PNT domain in ETV6 (sometimes called HLH domain, for its helix-
loop-helix structure) functions in protein-protein interactions, binding with e.g. 
another ETV6, other ETS factors, or histone deacetylases (HDACs), resulting 
mostly in transcriptional repression. The PNT domain was reported essential for 
differentiation impediment at proB cell state in a mouse E/R model (Fischer et al., 
2005). This domain has been found to bind repressor proteins also in the fusion 
format (ETV6-RUNX1) (Fenrick et al., 1999). Repressive function of the PNT 
domain in E/R has been shown in reporter gene assays in a T-cell line with IL3 gene 
(Uchida et al., 1999) and in fibroblasts with TCR? gene (Hiebert et al., 1996). All the 
initially tested E/R-regulated genes were previously deciphered as RUNX1 targets 
(listed in Kitabayashi et al., 1998). Functional relevance of the interaction with 
HDACs have been tested using an HDAC inhibitor (Wang and Hiebert, 2001; 
Starkova et al., 2007). Expression of the reporter genes and some of the putative 
E/R-regulated genes (from Fine et al., 2004) were released upon HDAC inhibition 
(Starkova et al., 2007). 
The RHD (Runt-homology domain) mediates DNA-binding in RUNX1 and in 
E/R. Transduction with a DNA-binding deficient, RHD mutant version (R201Q) 
of E/R did not lead to enhanced colony formation ability in mouse hematopoietic 
stem cells like the normal E/R, indicating that E/R directly disturbs RUNX1 targets 
and not only sequesters co-activators (Morrow et al., 2007). The RHD domain is also 
needed for heterodimerization with core binding factor beta CBFB, which is 
important for RUNX1 (also called CBF?) function. For effective binding of RUNX1 
to DNA, CBFB blocks inhibition mediated by an adjacent region called NRDB. 
(Kanno et al., 1998.) Both ETV6 and RUNX1 domains in E/R are reported to bind 
corepressor Sin3A and to contribute to repression (Fenrick et al., 1999).  
The transactivation domain (also called proline, serine, and threonine rich region, 
PST) interacts with p300, CREBBP, and other transcriptional activators, which are 
likely to mediate association between multiple transcription factors. The ID domain 
inhibits the transactivation domain that is located next to it. In addition, the extreme 
C-terminal VWRPY domain mediates interaction with TLE co-repressor. (Kanno et 
al., 1998; Kitabayashi et al., 1998). 
E/R lacks the ETS domain from ETV6, which, in addition to importantly 
mediating DNA-protein-interactions, interacts with proteins such as HLH- and 
Runt-domain proteins (reviewed in Sharrocks, 2001). A small part of patients lack 
exon 5 of ETV6 (known as the central region) in the E/R protein which was 
reported to be redundant for E/R mediated transcriptional regulation by a reporter 
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gene assay and in clinical data (Zaliova et al., 2011), although it has been suggested 
to be essential to activate progenitor expansion in HSCs (Morrow et al., 2007). NCoR 
corepressor and HDAC3 have been reported to bind the ETV6 central region (Wang 
and Hiebert, 2001). 
 
 
Figure 3.  Schematic structure of the ETV6-RUNX1 fusion protein and its wild type partners. AML1c 
(NP_001745) variant of RUNX1 is visualized. Runt = RHD domain. From Teppo, 
Heinäniemi and Lohi, 2017. 
2.3.3 Alterations in genes and pathways 
E/R functions as an aberrant transcription factor. The effects on gene expression 
have been deduced from comparisons of profiles between the E/R and the other 
preB-ALL subtypes (Moos et al., 2002; Ross et al., 2003; Fine et al., 2004; Andersson 
et al., 2005; van Delft et al., 2005; Gandemer et al., 2007) or between E/R-silenced 
and control cell line with endogenous E/R (Starkova et al., 2007; Fuka et al., 2011; 
Zaliova et al., 2011; Ghazavi et al., 2016). Few of the reported genes are shared 
between the studies. 
One recurrently reported gene is EPOR, which is around 7-fold more expressed 
in the E/R-subtype than others and its promoter is bound by E/R (Ross et al., 2003; 
Inthal et al., 2008; Torrano et al., 2011). EPOR is usually restricted to myeloid lineage 
(Baruchel et al., 1997). JAK inhibitors have been suggested for E/R patients to target 
EPOR downstream effectors (Chatterton et al., 2014). Another example, PIK3C3 
(Vps34) belonging to a phosphoinositide 3-kinase (PI3K) family, is upregulated in 
E/R leukemia and there is some evidence that its function in the inhibition of 
autophagy could be targeted (Polak et al., 2019). PI3K/AKT/mTOR signaling 
pathway was reported to be active in the E/R subtype and silencing of the E/R led 
to its inactivation (Fuka et al., 2012). PI3K pathway acts downstream of many 
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receptors (including EPOR) and its function could be inhibited by e.g. rapamycin 
(Harrison, 2013). Some other efforts have been made to go beyond individual target 
genes and understand perturbed pathways and interactions in the E/R disease. For 
example, using microarray gene expression data and B-cell interactome datasets, 
MYC was found the most perturbed transcription factor in E/R disease, and cell 
adhesion genes were specifically targeted in the E/R subtype (Hajingabo et al., 2014). 
At cell phenotype level, the silencing of E/R in REH cells led to reduced 
proliferation (Zaliova et al., 2011). Induction of ETV6-RUNX1 has been shown to 
enhance the self-renewal of progenitor B cells and expand hematopoietic cells or 
early B-cell progenitors in a fetal mouse cell model (Morrow et al., 2004) and in a 
human iPS cell model (Böiers et al., 2018).  
Recurrent secondary events in E/R-leukemia are most often copy number 
alterations, mostly deletions, which is characteristic of the E/R subtype (Mullighan 
et al., 2007; Papaemmanuil et al., 2014). More than 80% of the diagnosed E/R cases 
display additional alteration in either the non-rearranged alleles of ETV6 (deletion, 
70%) and RUNX1 (extra copy, 20%), or the derivative chromosome der21(t12;21) 
(10%, duplication) (Cavé et al., 1997; Stams et al., 2006; Al-Shehhi et al., 2013). 
Structural alterations comprising the ETV6 and RUNX1 genes are sometimes 
gained in relapse (Peter et al., 2009; Kuster et al., 2011). Loss of NR3C1, a gene coding 
for the receptor responding to glucocorticoid drugs, is present in approximately 10% 
of the E/R-leukemia relapses and is associated with the E/R subtype (Mullighan et 
al., 2008; Kuster et al., 2011; Bokemeyer et al., 2014). In a study, all the E/R cases 
with an NR3C1 aberration had positive MRD at the end of induction and went to 
stem cell transplantation (Bokemeyer et al., 2014). Loss of VPREB1 and CDKN1B 
in relapsed cases is also associated with inferior outcome (Kuster et al., 2011; 
Bokemeyer et al., 2014). VPREB1 deletion prevalence was reported to be the highest 
in cases with E/R (Mangum et al., 2014). However, the so-called NCI risk (MRD 
ratio, white blood cell count, age, etc.) was shown to be a better prognostic factor in 
long-term follow-up of E/R patients than any secondary mutation (Enshaei et al., 
2013). 
All “driver” copy number alterations have been reported to be dissimilar between 
E/R twins  (Bateman et al., 2010). Based on expression profiles, E/R twins were 
reported to cluster with the other E/R-cases but not specifically with each other 
(Teuffel et al., 2004). As evidence suggests that E/R-positive precursor cells are 
found in 1:100 newborn (Mori et al., 2002; Zuna et al., 2011; Schäfer et al., 2018), and 
the leukemia incidence is in the order of 1:10000, secondary events leading to 
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leukemia occur much more rarely than the E/R translocation. This also indicates 
that although E/R occurs in utero, all the secondary variations occur after birth. 
2.4 Transcription of the genome 
Transcription is the process of preparing functional RNA molecules by the 
instructions encoded in DNA. Regulation of RNA transcription is an important 
process that guides cell fates during cell differentiation and maintains molecular 
homeostasis and function throughout cell life. Regulation occurs especially at the 
enhancer and promoter areas. Technological improvements have made it possible to 
realize the pervasively transcribed genome: 50 - 80% of the genome is thought to be 
transcribed in at least some cell type, while still a big part of DNA is repetitive and 
normally inert (Djebali et al., 2012; Hangauer, Vaughn and McManus, 2013).  
One aim in the functional genomics field is to assign a molecular phenotype for 
each genetic variation. The sequence of the human genome was solved in 2003 but 
annotation of the various regions is still on-going. Approximately 300 000 human 
enhancers (12% of the genome) with putative target genes were annotated in 2017, 
combining data from different sources including Ensembl and FANTOM projects 
(Fishilevich et al., 2017). Additional works have defined a few millions of enhancers 
in over a hundred cell types (Gao et al., 2016; Gao and Qian, 2019). Enhancer regions 
can be localized at several kilobases from transcription start sites. Looping of DNA 
brings the distal enhancers in the proximity of promoters. Insulators (CTCF) can be 
situated in between enhancers and promoters and are thought to act as borders of 
topologically associating domains (TADs) in chromosomes (Dixon et al., 2012). 
2.4.1 Transcription factors 
Gene expression is regulated through combinatorial action of promoters and 
regulatory elements which are bound by transcription factors (TFs). TFs orchestrate 
the regulation of transcriptional networks in cells. Enhancer is a regulatory element 
that amplifies transcription, is typically a few hundred base pairs long, and contains 
binding motifs for several TFs. These motifs are 6-12 bp long DNA sequences that 
are recognized and favored for binding by specific TFs. (Spitz and Furlong, 2012). 
TFs can cooperate in regulating the genes by directly interacting with each other 
or indirectly by recruiting common cofactors or different components of 
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multiprotein complexes. They can also help in unwinding the chromatin, e.g. as a 
pioneering TF, or prevent folding and thus serve as a place-holder factor. A 
pioneering TF, such as PAX5 in B cells (McManus et al., 2011), recruits chromatin 
modifiers to facilitate binding of other factors, and may not cause any immediate 
response to gene expression by itself. Place-holder function has been suggested for 
e.g. SOX proteins: SOX2 is a general TF bound to many sites in embryonic stem 
cells, potentially keeping these sites open, but later in B-cell development some of 
the sites are replaced by SOX4. Different modes of actions may explain for the 
relatively low correlation found between binding of a TF and the expression of the 
nearby genes. In one study, only 4% of the genes bound by MYOD1 had changes 
in expression after removing the TF; however, its occupancy was associated with 
increased level of H3K27ac at the sites. (Spitz and Furlong, 2012.) Transcription 
factors can also change their influence in a manner that is dictated by chromatin 
landscape. This has been seen in IKZF1-deficient high-risk preB-leukemia, in which 
normally supportive EBF1 can be redirected to incorrect enhancer regions and 
promote an altered B-cell faith (Hu, Yoshida and Georgopoulos, 2017). In addition, 
binding of a TF with a cofactor protein may change the preference of binding motif 
even though the cofactor does not contain a DNA binding domain (Siggers et al., 
2011). 
2.4.2 RNA polymerase II 
RNA polymerase II (pol II) is the main enzyme reading the genome and binds to a 
50- to 100 bp stretch of DNA. RNA pol II is accumulated in promoters of almost 
all genes, especially in many developmentally regulated and stimulus-responsive 
genes (Guenther et al., 2007; Muse et al., 2007). Upon transcription initiation, RNA 
pol II pre-initiation complex forms with general transcription factors (e.g. GTF2B) 
(Parvin and Sharp, 1993). RNA pol II releases contact with the general transcription 
factors at the promoter, and serine residues within the pol II are phosphorylated, 
resulting in early elongation and subsequently to productive elongation, which are 
regulated by kinases and other factors. (Nechaev and Adelman, 2011.) 
RNA polymerase II that is situated at a promoter is called poised, regardless of 
its initiation or elongation status. Some of the poised polymerases can be stalled, 
meaning the elongation complex has stopped RNA synthesis. On the other hand, 
some of the stalled polymerases can be paused, which specifies that the stalled RNA 
pol II is expected to continue transcription after a temporary pause. (Nechaev and 
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Adelman, 2011). Stalling of RNA pol II occurs during elongation at promoter-
proximal regions, and is regulated by certain protein factors and DNA signal of the 
transcribed gene (Nechaev et al., 2010). Stalling is also considered to act as a damage 
check-point when the machinery encounters transcription-blocking DNA lesions 
(reviewed in Lans et al., 2019). Pausing of pol II can also poise a gene for activation 
by maintaining open chromatin near its TSS. Locations of stalled RNA pol II in 
genomes have been detected by using permanganate which detects single-stranded 
thymines in DNA (Kainz and Roberts, 1992), by RNA pol II ChIP (Kim et al., 2005), 
or by analyzing local elevations in nascent RNA signals (Core, Waterfall and Lis, 
2008).  
Transcriptional phase of the genome-wide RNA pol II complexes can be 
predicted by ChIP-seq targeting specific domain modifications in the polymerases. 
Serine residue 5 is phosphorylated (ser5P) during early elongation near the promoter 
and its abundance decreases toward productive elongation or termination, whereas 
ser7P and ser2P phosphorylation levels increase towards the end of the process, 
activating splicing and 3’ end processing (Egloff, Dienstbier and Murphy, 2012). 
H3K36me3 can also serve as a marker for elongation (Bannister et al., 2005). 
(Adelman and Lis, 2012).  
2.4.3 Convergent transcription and DNA:RNA hybrids 
Convergent transcription (convT) is defined as overlapping sense and antisense 
transcription and is a widespread transcriptional feature. Antisense transcripts have 
been detected in approximately half of the transcribed genes (Core, Waterfall and 
Lis, 2008). It has been suggested as a mechanism that interrupts transcription by 
causing collision of RNA pol II molecules moving in the opposite directions (Ward 
and Murray, 1979). Convergent transcription was also found to be associated with 
AID enzyme’s off-target sites (Meng et al., 2014). 
Nascent RNA transcripts can anneal back to the DNA template, forming 
DNA:RNA hybrid, and displacing the coding strand as single-stranded DNA (Drolet 
et al., 1995). These structures are called R-loops and they associate with convergent 
transcription and open chromatin regions. (Reviewed in Skourti-Stathaki and 
Proudfoot, 2014). R-loop formation is enriched at transcription start and termination 
sites (TSS and TTS) of genes. It was estimated that approximately 5% of the genome 
is engaged in R-loops (Lim et al., 2015; Sanz et al., 2016). Although R-loops are part 
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of the normal processes, they are also actively suppressed by topoisomerase, helicase, 
RNase H1 activity, and by the rapid processing of RNA. 
Genome-wide R-loop distribution has been characterized by using hybrid specific 
antibody S9.6 based DNA:RNA immunoprecipitation (DRIP-seq) (Ginno et al., 
2012; Sanz et al., 2016; Sanz and Chédin, 2019). In addition, inactive RNase H1 
ChIP-seq has been used (Chen et al., 2017). R-loops are associated with G-rich RNA 
(repeats such as CGG/GCC) and intra-strand structure formation. Based on the 
characteristic structure, R-loop forming sequences (RLFS) have been predicted 
genome-wide (Jenjaroenpun et al., 2015).  
2.4.4 Long non-coding and enhancer RNAs 
RNA can act as an important housekeeping molecule (ribosomal RNA and transfer 
RNA); in messaging and translation (messenger RNA); in regulation (microRNAs, 
enhancer RNAs); or in RNA processing (small nucleolar RNAs). Long non-coding 
RNAs (lncRNAs) are a heterogenous group in size (two hundred to one million 
nucleotides) and function. It is unclear whether they will eventually be subclassified 
based on their mechanism of action or by active domains, or whether they have some 
other character to group by (de Hoon, Shin and Carninci, 2015). LncRNAs also 
encompass the relatively unstable RNA transcripts - enhancer RNAs (eRNAs) and 
promoter upstream transcripts (PROMPTs; also called promoter antisense 
transcript, pat, or upstream antisense RNA transcription, uaRNA) (Core, Waterfall 
and Lis, 2008; Preker et al., 2008). The roles of these transcripts are not clear, 
however, in some cases the mere transcription has been found to be functionally 
more relevant than the transcript product (Engreitz et al., 2016). 
Genome-wide transcriptional features are able to be captured after invention of 
high-throughput strand-specific RNA-sequencing (reviewed in Levin et al., 2010) and 
nascent RNA sequencing methods (Core, Waterfall and Lis, 2008). RNA molecules 
are transcribed from active enhancer and promoter sites. Enhancer RNAs may keep 
the chromatin in open conformation and attract components for looping 
(Kaikkonen et al., 2013) as well as participate in bridging promoter-enhancer 
connections (Jensen, Jacquier and Libri, 2013; Lai et al., 2013). Enhancers are 
especially associated with divergent transcription (transcription from both strands to 
different directions). Genome-wide abundance of genes with bidirectional 
promoters was reported as 10% in the beginning of 2000 (Trinklein et al., 2004) and 
later suggested to occur in 80% of active gene promoters (Core, Waterfall and Lis, 
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2008). Enhancer and lncRNA signals have more recently been studied using single-
cell sequencing methods (Kouno et al., 2019). This improved resolution revealed that 
a subpopulation of cells may only transcribe enhancer from one strand 
(unidirectional), although enhancers are classically defined as being bidirectional. 
Promoters and enhancers share many features like divergent transcription and 
both are bound by TFs (Core, Waterfall and Lis, 2008). In addition, enhancers can 
initiate transcription, and promoters can enhance transcription at another promoter. 
The two are therefore suggested to belong to the same functional unit (Core et al., 
2014; Andersson, Sandelin and Danko, 2015). Promoters and transcription start sites 
(TSSs) can be predicted using histone marker associations. In addition, promoters 
often have stalled or paused RNA polymerase II. Modifications of histone tails at 
enhancer and promoter regions reflect their transcriptional activity state. (Spitz and 
Furlong, 2012). Especially, H3K27ac and H3K4me1/3 correlate with active 
transcription sites, together with transient H3K79 methylation at enhancers 
(Bernstein et al., 2002). DNA accessibility measurements (e.g. DNase- or MNase-
seq) and the presence of coactivators (e.g. p300) can also guide in enhancer 
recognition. 
Enhancer RNA landscape is highly cell type specific. In addition to different 
genes being transcribed and regulated, enhancer usage can differ for the same gene, 
as was shown for the gene SPI1 (PU.1) in B cells vs. myeloid cells (Leddin et al., 
2011). In another example, one enhancer of the 14 detected for CEBPA gene was 
found to regulate the gene expression in myeloid cells only (Avellino et al., 2016). 
This highly differentiated regulatory system may partly explain how genetic diseases 
end up being tissue specific. On the other hand, redundancy in enhancer usage has 
also been reported: another enhancer can replace the function of another, which 
makes gene regulation less dependent on individual variations (Osterwalder et al., 
2018). Large, highly active regions of chromatin called super-enhancers regulate 
genes critical to cell identity. Super-enhancers differ from typical enhancers in 
transcription factor density and sensitivity to perturbation (Whyte et al., 2013). 
Molecular mechanisms as to how lncRNAs affect transcription include signaling, 
guiding chromatin modifying enzymes, scaffolding multiple proteins, and acting as a 
decoy to trap TFs from regulatory sites (reviewed in Wang and Chang, 2011). The 
functions for most lncRNAs is unknown, although some have been addressed 
recently e.g. with the help of CRISPR genome editing technique. For example, Liu 
et al. screened 10 000 lncRNAs using sgRNA mediated silencing, and found 230 of 
them crucial for CML cell line survival (Liu et al., 2018). The on-going FANTOM6 
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(functional annotation of the mammalian genome) project is focusing on lncRNAs 
with some preliminary data (Ramilowski et al., 2019 preprint).  
Antisense transcription at the coding gene loci is widespread in the genome. 
Perturbance in antisense transcript can alter the expression of the sense mRNA 
(Katayama et al., 2005). Antisense transcripts initiate from promoter, terminator, or 
intronic sequences, and are associated with R-loops. R-loop formation is thought to 
promote a substantial amount of antisense lncRNA transcription (Tan-Wong, Dhir 
and Proudfoot, 2019). Antisense transcript expression profiles across cancers have 
been elucidated from strand-specific RNA-seq (Balbin et al., 2015). One mechanism 
for the concordantly regulated antisense gene is the stabilization of the sense 
transcript. Some atlases for lncRNAs have been produced (Hon et al., 2017). Based 
on a study, 20% of lncRNAs are eRNAs, although this might be underestimation as 
eRNAs are relatively unstable (Sigova et al., 2013). 
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3 AIMS OF THE STUDY 
ETV6-RUNX1 translocation, resulting in an aberrant transcription factor fusion 
protein, characterizes the second most common subtype of precursor B-cell acute 
lymphoblastic leukemia in children. In this thesis, we set out to study the genome-
wide transcriptional regulation and features to gain insights for the underlying 
mechanisms in this disease. 
The aims of this study were: 
 
 
1) to investigate genomic targets and transcriptional regulation by the ETV6-
RUNX1 fusion in preB-ALL (I-II); 
 
2) to probe genome-wide nascent RNA profiles from the ETV6-RUNX1 
preB-ALL cell lines and patient samples, as well as other preB-ALL subtypes 
(I-III); and 
 
3) to explore transcriptional features at the recurrent structural variation sites 
in the ETV6-RUNX1 subtype (III). 
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4 MATERIALS AND METHODS 
Detailed information can be found in the online supplemental materials of the 
original publications which are referred to in by Roman numerals (I-III). 
4.1 Molecular cloning, virus production and transduction (I) 
ETV6-RUNX1 cDNA was cloned into inducible LentiX pLVX-Tight-Puro 
expression vector (Clontech, Mountain View, CA, USA). Point mutation G1553A 
was implemented using site-directed mutagenesis PCR resulting in R518Q in ETV6-
RUNX1 protein (R201Q in normal RUNX1). In addition, short hairpin RNA 
(shRNA) oligos targeting ETV6-RUNX1 (target sequence 
GAATAGCAGAATGCATACTT) were cloned into pLVX-shRNA1-vector 
(Clontech). Transfection grade plasmids were purified using Midiprep PureYield kit 
(Promega, Madison, Wisconsin, USA) and viruses were produced in HEK293T 
(ATCC CRL-3216) cells using HTX packaging mix and Xfect reagent (Clontech). 
Nalm6-cells (ACC 128) were infected with the regulatory vector TetOn Advanced 
and subsequently with one of the response vectors: pLVX-Tight-Puro-ETV6-
RUNX1 (E/R), pLVX-Tight-Puro-ETV6-RUNX1-mutated (E/Rmut), or pLVX-
Tight-Puro-LUC (luciferase control) (Clontech). REH cells (ACC 22) were co-
infected with viral particles containing the pLVX-shE/R and a construct targeting 
N-terminus of ETV6 (clone TRCN0000003855, Sigma Aldrich, Saint Louis, MO, 
USA). Control cell line was produced using shRNA virus against luciferase 
(SCH007V, Sigma Aldrich). Stably transduced cells were selected with puromycin 
(0.5 ?g/ml or 1 ?g/ml, Clontech). 
4.2 Cell culture and mononuclear cell extraction (I-III) 
Nalm6-cells (ACC 128), REH cells (ACC 22), and KOPN-8 cells (ACC 552) were 
bought from DSMZ, Braunschweig, Germany) were cultured in RPMI 1640 
(#31870074, Gibco, Thermo Fisher Scientific, Waltham, MA, USA), with 2 mM L-
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glut, 100 U penicillin, 100 ?g/ml streptomycin, and 10% Tet System Approved FBS 
(Clontech) (Nalm6-Tet-cells) or 10% FBS (Gibco) (normal Nalm-6, REH, and 
KOPN-8) at 37°C in 5% CO2 and split every 2-3 days. Mycoplasma was routinely 
measured in the cell lab and found negative (PCR Mycoplasma Test Kit I/C, 
PromoCell GmbH, Germany). The cell lines were authenticated by short tandem 
repeats (STR) genotyping (Eurofins Genomics, Ebersberg, Germany), and checked 
by PCR of the known fusion gene (ETV6-RUNX1 in REH). 
Induction of the E/R fusion gene or the control luciferase was done with 500 
ng/ml doxycycline (Clontech) for 4, 12 and 24 hours. Two independent replicates 
were included in the GRO-seq study. In assessing changes in proliferation of E/R-
positive cells, AlamarBlue reagent (Life technologies) was used and the reactions 
were measured with Tecan fluorometer (Tecan, Switzerland). 
Mononuclear cells were extracted freshly using Ficoll-Paque Plus from primary 
bone marrow samples collected in EDTA tubes (GE Healthcare, Chicago, Illinois, 
US). Samples were diluted 1:1 in Hank’s balanced salt solution (HBSS) (Gibco) and 
centrifuged through Ficoll at 720 x g, 30 min at room temperature with breaks off. 
Extracted mononuclear cell layer was washed with cold HBSS 2-3 times and 
centrifuged at +4C, 400 x g with 5 min in between. Part of the cells were used for 
nuclei extraction directly while the rest were frozen in 15% dimethyl sulfoxide 
(DMSO) in 40% FBS/RPMI (Gibco). 
4.3 RNA extraction and quantitative PCR (I) 
Total RNA was extracted from cells using GeneJET RNA Purification Kit (Thermo 
Fisher Scientific). cDNA synthesis (reverse transcription) was performed using 
iScript (BioRad) with 1 ?g of RNA as a starting material. RT-qPCR was performed 
using SsoFast EvaGreen® Supermix (BioRad) and BioRad CFX96TM Real Time 
System (BioRad). Quantification was done using the relative 2-??CT method (Livak 
and Schmittgen, 2001). For ChIP-qPCR, enrichment was calculated relative to input 
chromatin sample. 
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4.4 Chromatin immunoprecipitation, western blotting and 
immunofluorescence staining (I-III) 
Crosslinking of proteins to chromatin was performed with 1.1% final concentration 
of formaldehyde (J.T. Baker, Avantor, Center Valley, PA, USA) for 10-15 min. Two 
antibodies against ETV6 were pooled in study I and used to detect ETV6-RUNX1 
binding to chromatin in cell lines: sc-166835 (Santa Cruz Biotechnology Inc., Dallas, 
TX, USA; RRID:AB_2101020) and HPA000264 (Atlas Antibodies, 
RRID:AB_611466), and DNA was sonicated using Covaris S220 (Covaris Inc., 
Woburn, MA, USA). In addition, antibodies against Ser2P (Abcam Cat# ab5095, 
RRID:AB_304749), Ser5P (Abcam Cat# ab5131, RRID:AB_449369) (Abcam, 
Cambridge, MA, USA), and H3K4me3 (Abcam Cat# ab8580, RRID:AB_306649) 
were used in study III and the chromatin was cut using MNase (cat# 88216, Thermo 
Fisher). Libraries were prepared for the latter and sequencing data was submitted to 
the Gene Expression Omnibus (GEO) database (GSE67540). 
For western blotting, proteins were extracted from cells with NE-PER nuclear 
and cytoplasmic extraction kit (Pierce, Life Technologies, Waltham, MA USA), 
separated on SDS-PAGE, and transferred onto a nitrocellulose membrane. Anti-
ETV6 (HPA000264, RRID:AB_611466, 0.4 ?g/ml) was used to detect the fusion 
protein. For immunofluorescence images, cells were spun onto slides, fixed with 
paraformaldehyde and permeabilized using Triton-X. Anti-ETV6 (1 ug/ml, Atlas 
Antibodies, HPA000264, RRID:AB_611466) was used to detect E/R fusion protein. 
 
4.5 Nuclei extraction and global run-on sequencing method (I-
III) 
Nuclei were isolated for run-on yielding ~5×106 nuclei per condition. Nuclear run-
on (illustrated in Figure 4) was done in the presence of Br-UTP (sc-214314A, Santa 
Cruz Biotechnology, Inc., Dallas, Texas, U.S.A.). After run-on, Trizol-LS 
(#10296010, Thermo) was added for RNA-extraction. The run-on products were 
treated with DNase I (TURBO DNA-free Kit, Invitrogen, Life Technologies), base 
hydrolyzed (RNA fragmentation reagent, Ambion, Life Technologies), 3-ends were 
dephosphorylated using PNK (New England Biolabs, Ipswich, MA, USA), and the 
RNA was immuno-purified using Br-UTP beads (Santa Cruz, CA, USA). Samples 
were then 3’ poly-A tailed (PolyA polymerase, New England Biolabs, Ipswich, MA, 
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USA) to allow first-strand cDNA synthesis with NTI223 library adaptor, containing 
poly-dT tail for priming. cDNA synthesis was performed (Superscript III RT) and 
the samples were treated with exonuclease I (20U/ul) to catalyze removal of excess 
index-oligos. RNaseH was used to break the RNA-strand from the DNA-RNA-
hybrids, and the resulting single stranded cDNA was circularized (CircLigase 100 
U/ul, EpiBio). The cDNA was amplified and then concentrated using ChIP DNA 
clean & concentrator kit (ZymoResearch, Tustin, CA, USA), and purified from 
Novex 10% TBE gel (180-300 bp). Sequencing was done with Illumina Hi-Seq2000 
(GenCore, EMBL Heidelberg, Germany). (Detailed process in the supplemental 
materials of studies I and III.) 
 
 
 
Figure 4.  Schematic presentation of the run-on method for GRO sequencing.  
4.6 Transcriptome data (I, III) 
The microarray gene expression data sets were retrieved from the NCBI GEO 
database, all measured on Affymetrix GeneChip Human Genome U133 Plus 2.0 
array. From a total of 1382 preB-ALL samples, 1004 with known cytogenetics (153 
E/R, 153 BCR-ABL1, 151 hyperdiploid, 198 KMT2A-rearranged, 82 TCF3-PBX1, 
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and 267 others) were included in study III, and 664 samples (137 E/R, 76 TCF3-
PBX1, 145 BCR-ABL1, 178 KMT2A-rearranged, and 128 hyperdiploid) were 
included in study I. The general analyses of processing the above data are presented 
in separate publications (Mehtonen et al., 2019; Pölönen et al., 2019). R-package 
‘mclust’ (Fraley, Raftery and Murphy, 2012) was used in the differential expression 
analysis of microarray probe signals. Genes with log2 fold change > 0.5 or < -0.5 
and with adjusted p-value (Mann-Whitney test) below 0.01 were considered 
differentially expressed. In study III, t-distributed stochastic neighbor embedding 
(t-SNE)-method was used for visualization of the expression data in two dimensions. 
In study I, RNA-seq data for preB-ALL patients was obtained from the GEO 
database (accession GSE79373) containing nine E/R patients, seven high 
hyperdiploids, and one other preB-ALL subtype. Aligned reads were summarized 
using featureCounts (Liao, Smyth and Shi, 2014) and differential expression was 
calculated using the DESeq2 package (Love, Huber and Anders, 2014). 
4.7 Sequencing data (I-III) 
Sequencing data that were used in the analyses are summarized in Table 1. Patient 
samples were chosen by availability to represent good GRO-seq signal in precursor 
B-cells. Blacklisted sequences were discarded (containing poorly mappable, rRNA, 
or snoRNA sequences; study III Supplemental file 6). BedGraph and bigWig files 
were generated with reads normalized to a total of 107 mapped reads. The bigWig 
files were further converted to track hubs and visualized as strand-specific custom 
Track Hub in the UCSC Genome browser. HOMER 
(http://homer.ucsd.edu/homer) findPeaks program was used in de novo transcript 
detection from GRO-seq data and in peak detection from ChIP-seq data. 
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Table 1.  Compilation of data produced and reanalyzed in studies I-III. Accession codes refer to 
NCBI Gene Expression Omnibus database. 
Data produced in studies I-II (Teppo et al., 2016; Teppo, Heinäniemi and Lohi, 2017) 
Sample Type Method Accession code Replicates Main application 
Nalm6-LUC 24 h preB-ALL cell line, control GRO-seq GSM1648604, -05 2 
Differential expression 
analysis 
Nalm6-LUC 0 h preB-ALL cell line, control GRO-seq GSM1648606, -07 2 
Signal observations Nalm6- E/R    4 h 
preB-ALL cell line, 
E/R induced 
GRO-seq GSM1648608, -09 2 
Nalm6- E/R  12 
h GRO-seq GSM1648610, -11 2 
Nalm6- E/R  24 
h GRO-seq GSM1648612, -13 2 
Differential expression 
analysis 
Nalm6-E/Rmut 
24 h 
preB-ALL cell line, 
E/Rmut induced GRO-seq GSM1648614, -15 2 
Differential expression 
analysis 
preB-ALL E/R+ Primary cells, bone marrow GRO-seq NA 
3 
patients Visualization of signal 
preB-ALL other Primary cells, bone marrow GRO-seq 2 
Other data used in studies I-II 
Sample Type Method Accession code Replicates Main application 
Normal bone 
marrow CD34+ cells (HSC) 
ChIP-seq / RUNX1, 
ERG, FLI1 
GSE45144 (Beck et al., 
2013) 1 Prediction of TF binding 
SEM preB-ALL cell line, KMT2A-re ChIP-seq / RUNX1 
GSE42075 (Wilkinson et 
al., 2013) 1 
Prediction of RUNX1 binding 
and open chromatin regions  
Normal bone 
marrow or cord 
blood 
CD19+, CD20+, or 
CD34+ cells ChIP-seq / H3K27ac 
GSM1027287, 
GSM1003459, 
GSM772870, -85, -94 
(Bernstein et al., 2010; 
Hnisz et al., 2013) 
1-3 
Super-enhancer data in 
Hnisz et al., 2013, prediction 
of open chromatin regions 
GM12878, 
CD34+ -cells, 
Kasumi-1 
Hematopoietic cells 
DNase-seq, ChIP-seq 
/ RUNX1, H3K4me1, 
H3K27ac, P300  
See Supplemental 
methods of study I 
(ENCODE Project 
Consortium, 2012; 
Ptasinska et al., 2012) 
24  
in total 
Prediction of open chromatin 
regions 
Leukemic cells preB-ALL patients RNA-seq GSE79373 (Neveu et al., 2016) 
17 
patients 
Differential expression 
analysis of transcripts 
Data produced in study III  (Heinäniemi et al., 2016) 
Sample Type Method Accession code Replicates Main application 
REH Cell line, ETV6-RUNX1 GRO-seq GSM1649155 - 62 8 Defining pol II stalling and 
convT in B-lineage Nalm6 Cell line, other preB-ALL GRO-seq 
GSM1649153 - 54, 
GSM1648604 - 05 4 
KOPN-8 Cell line, KMT2A-rearranged GRO-seq 
NA 
 
4 
Visualization of signal 
 
ALL patient 1 
(del12) 
Primary cells, other 
preB-ALL GRO-seq 2 
ALL patient 2 
(NK) 
Primary cells, other 
preB-ALL GRO-seq 1 
ALL patient 3 
(RUNX1 CNV) 
Primary cells, other 
preB-ALL GRO-seq 1 
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ALL patient 4 
(CRLF2+) 
Primary cells, other 
preB-ALL GRO-seq 1 
ALL patient 5 
(Hyperd P1) 
Primary cells, high 
hyperdiploid GRO-seq 1 
ALL patient 6 
(Hyperd P2) 
Primary cells, high 
hyperdiploid GRO-seq 1 
ALL patient 7 
(ETV6-RUNX1) 
Primary cells, 
t(12;21) GRO-seq 1 
Normal bone 
marrow 
CD19+ mononuclear 
cells GRO-seq 1 
Nalm6 
Cell line, other preB-
ALL 
ChIP-seq / phospho 
Ser2 RNA Pol II 
GSM2144895, 
GSM2144898 2 
Evaluating RNA pol II stalling Nalm6 ChIP-seq / phospho Ser5 RNA Pol II 
GSM2144896, 
GSM2144899 2 
Nalm6 ChIP-seq / input GSM2144894, GSM2144897 2 
Nalm6 ChIP-seq / H3K4me3 GSM2166074 1 
Analysis of overlap between 
the widest pol II stalling 
regions and the widest peaks 
REH 
Cell line, ETV6-
RUNX1+ preB-ALL 
ChIP-seq / phospho 
Ser2 RNA Pol II GSM2144901 1 
Evaluating RNA pol II stalling REH ChIP-seq / phospho Ser5 RNA Pol II GSM2144902 1 
REH ChIP-seq input GSM2144900 1 
REH ChIP-seq / H3K4me3 GSM2166075 1 
Analysis of overlap between 
the widest pol II stalling 
regions and the widest peaks 
Data reanalyzed in study III 
Sample Type Method Accession code Replicates Main application 
GM12878, 
GM12750, 
GM12004 
B-lymphoid cell lines GRO-seq 
GSM1480326, 
GSM980645, GSM980644 
(Core et al., 2014; I. X. 
Wang et al., 2014) 
3 Defining RNA pol II stalling and convT in B-lineage 
GM12878 B-lymphoid cell line HiC GSM1551571, -72, -74, -75 (Rao et al., 2014) 4 
Defining TADs in B-lymphoid 
cells 
H1 ESC Embryonic stem cell line GRO-seq 
GSM1006728, 
GSM1006729 (Sigova et 
al., 2013) 
2 Defining RNA pol II stalling and convT in ES-cells 
NT2 Embryonic stem cell line DRIP-seq 
GSM1108095 – 99 (Ginno 
et al., 2013) 
3 
 
Testing overlap between 
DNA:RNA hybrids and RLFS 
motifs or signal features 
Other data used in study III 
Sample Type Method Accession code Replicates Main application 
GM12878 B-lymphoid cell line DNase-seq 
GSM736496, 
GSM736620, 
GSE29692 
2 Comparison of DNase-seq 
peak width at sites with and 
without RNA pol II stalling H1 and H7 ESC Embryonic stem cell lines DNase-seq 
GSM736582, 
GSM736638, GSM736610 
(Thurman et al., 2012) 
3 
GM12878 B-lymphoid cell line ChIP-seq / histone modifications 
GSE29611 (ENCODE 
Project Consortium, 2012) 1-4 
Analysis of overlap between 
the widest RNA pol II stalling 
regions and the widest peaks 
in each ChIP-seq 
Leukemic cells ETV6-RUNX1 WGS Papaemmanuil et al., 2014 51 patients 
Structural variation 
breakpoints 
Leukemic cells KMT2A-re WGS Andersson et al., 2015 22 
Leukemic cells hyperdiploid WGS Paulsson et al., 2015 16 
Leukemic cells hypodiploid WGS Holmfeldt et al., 2013 20 
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4.8 Analysis of GRO-seq data (I) 
E/R-regulated novel transcripts were manually classified as either alternative TSSs, 
eRNAs (representing the most abundantly expressed eRNAs), antisense transcripts, 
promoter-associated transcripts (pats), or novel intergenic transcripts. Transcripts of 
<15 kb in length were considered as potential eRNAs. In addition to characteristic 
bidirectional enhancers, unidirectional enhancers were annotated but only those 
residing in putative open chromatin regions were accepted. 
Gene coordinates were retrieved for all the RefSeq transcripts from the 
iGenomes database (Illumina, San Diego, USA). When applicable, only intronic 
regions were quantified from GRO-seq data to accurately catch primary 
transcription. Differential expression was analyzed using R/Bioconductor package 
edgeR (Robinson, McCarthy and Smyth, 2009). Significantly regulated genes were 
defined by adjusted p-value < 0.05 (Benjamini-Hochberg methods using p-values 
from moderated t-test). Only genes that lacked change in the E/Rmut sample were 
included. Top 5 enhancers for each coding gene (transcript-centric analysis) were 
based on Euclidian distance score between the fold change values in the gene and 
the enhancer region with correlation > 0. Detection of enriched TF binding motifs 
in enhancer regions close to regulated genes was performed using the HOMER 
program findMotifsGenome.pl with binomial test. 
In the enhancer-centric approach, enhancer detection was based on GRO-seq 
signal at open chromatin regions (Table 1) and statistical analysis was done as for 
transcript-centric genes. Enhancer RNAs lacking response in the E/Rmut sample 
were included. Quantification of eRNA abundance in ChIP-seq mapped 
transcription factor binding sites was done using the HOMER annotatePeaks.pl 
program. Before the analysis, the TF peaks were centered by the respective TF motif.  
For predicting putative function of the E/R-regulated enhancers, or the E/R-
regulated coding transcripts, GREAT v.3.0 tool (McLean et al., 2010) and DAVID 
tool (Huang, Sherman and Lempicki, 2009) were used, respectively.  
4.9 Analysis of transcriptional features at structural variations 
(III) 
Data used in the analyses are summarized in Table 1. Breakpoint coordinates for 
structural variations were first retrieved from whole genome sequencing data of 51 
ETV6-RUNX1-positive patients (Papaemmanuil et al., 2014). Transcriptional 
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features at the breakpoint regions were then analyzed using GRO-seq signal in the 
context of topologically associated domains resolved from B-lymphoid cells (Rao et 
al., 2014). Breakpoint regions were annotated with RSS/heptamer sequence and the 
overlap with transcription start sites (TSS), RNA polymerase II stalling, R-loop 
forming sequences (RLFS), and convergent transcription (convT) was determined 
separately for the non-RSS- and RSS-breakpoints. For assigning breakpoint 
recurrence, breakpoints at 1 kb distance were stitched together. The overlap 
frequencies were compared to random sampling of genomic regions of similar size. 
Breakpoint coordinates were also retrieved from WGS data of high hyperdiploid, 
hypodiploid, and KMT2A-rearranged cases (Holmfeldt et al., 2013; Andersson et al., 
2015; Paulsson et al., 2015) and analyzed separately. 
Signal features (convergent transcription and pol II stalling) and de novo enhancers 
were defined from GRO-sequencing data based on deeply sequenced REH, Nalm6, 
and GM12878 cells. GRO-seq data from replicates were pooled for each cell and 
sample type (Table 1; study III Supplemental file 1). Convergent transcriptions were 
identified as overlapping transcription from both strands for at least 100 bp. A 
combined bed track was then used to analyze the level of convergence at these sites. 
The gene annotations from UCSC were retrieved (hg19, GRCh37 Genome 
Reference Consortium Human Reference 37). RNA pol II stalling was quantified 
from GRO-seq signal across the gene regions using a genome-wide change point 
analysis which searches for abrupt changes in signal (R-package ‘changepoint’) 
(Killick and Eckley, 2014). Signal level at changepoint was compared against the 
median from across the whole gene. In addition, ChIP-seq data on RNA pol II 
phosphorylated on serine 2 or 5 were used to analyze stalling regions. In addition, 
separate analysis for signal features was carried out for embryonic stem cells. 
R-loop potential was predicted from DRIP-seq data which is based on a 
structure-specific antibody that recognizes DNA-RNA-hybrid regions. The signal 
level from NT2 embryonic stem cells was quantified at transcription start site regions 
using HOMER. RLFS motif search was performed using the software QmRLFS-
finder that uses predictions based on structural models of known sequences 
(Jenjaroenpun et al., 2015). RLFS motif density was calculated across DNA 
sequences using BEDtools coverage tool. 
DNase-seq and additional ChIP-seq data were used to characterize wide RNA 
pol II stalling events in embryonic stem cells and B-lymphoid cells. The width of 
DNase-seq peaks that overlapped with RNA pol II stalling events (from the same 
cell type) were compared with the ones that did not overlap and the 5% widest 
regions were identified. 
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4.10 Statistical tests (I, III) 
Binomial test was used in assessing statistical significance for observing breakpoint 
events overlapping a transcriptional feature (III). For example, in testing the 
enrichment of breakpoints at convergently transcribed (convT) regions, success in 
population was defined by the number of 1kb regions containing convT divided by 
all the analyzed 1kb regions, samples taken were all the regions with breakpoints, 
and sample success was defined as the number of regions with breakpoints 
overlapping convT regions divided by the number of all the breakpoint regions. 
Hypergeometric test was used to assess whether greater overlap frequency was seen 
between breakpoints and annotated genomic regions (III). For example, in assessing 
enrichment of breakpoints inside convT-enhancers, samples taken were all the 
convT-positive enhancers from all the enhancers, population success was all the 
enhancers with breakpoints, and sample success was a convT-positive enhancer with 
breakpoint. Hypergeometric test was also performed in assessing overrepresentation 
of ChIP-peaks in the vicinity of E/R-repressed genes or E/R regulated enhancers 
with RUNX1-peak in super-enhancer region (study I). The nonparametric Wilcoxon 
rank sum test (Mann-Whitney) was applied to assess quantified signal levels between 
categories (e.g. DRIP-seq signal between RLFS-negative and -positive regions) (III). 
Random sampling to 1000-fold was used in estimating the overlap between stitched 
breakpoint regions with transcriptional features (III). 
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5 RESULTS 
 
5.1 ETV6-RUNX1 functions mainly as a repressive transcription 
factor (I) 
We prepared an inducible E/R cell line model to study early effects of the putative 
aberrant transcription factor. Induction of E/R in Nalm6 cells led to an 18-fold 
expression level relative to REH preB-ALL cell line (which has endogenous fusion 
expression) and the protein was visible in western blot after four hours (Figure 5). 
We collected samples at 0, 4, 12 and 24 hours and performed GRO-sequencing assay 
for two induction series replicates (Table 1). Indirect effects were filtered out using 
E/R-mutant version (R201Q) that is not able to bind DNA via RHD (Runt)-domain 
in RUNX1 (Li et al., 2003). 
 
         
Figure 5.  ETV6-RUNX1 induction in the cell model. Adapted from Teppo et al., 2016 Genome 
Research. 
 
Overall, two-thirds of the observed changes in primary transcription at coding 
regions were repressive. We next studied active enhancer RNA regions nearby the 
coding genes for enrichment of specific transcription factor motifs (transcript-
centric approach; Figure 6A). ETS and RUNX1 motifs were enriched at the 
associated enhancers nearby the downregulated genes, whereas mainly ETS-factor 
motifs were enriched nearby the upregulated genes (study I, Figure 2A). In addition 
to the RUNX motif, we saw enrichment of RUNX1 ChIP-peaks (analyzed from 
SEM preB-ALL cell line) nearby the downregulated genes (Figure 6B). At least one 
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enhancer with evidence of RUNX1 site (motif or ChIP peak) was detected for almost 
all the genes (103/108) identified by the transcript-centric approach (study I Table 
S2). Either RUNX1 motif or ChIP-peak was identified for 315 of the 467 putative 
(top 5) enhancers and 244 of the enhancers contained ETS motif. We also saw 
enrichment of ETS-RUNX motif at RUNX1-peaks near the downregulated genes 
(study I Figure 2C). 
We next examined GRO-seq signal at the top 1000 RUNX1 ChIP-peak regions. 
The nascent RNA signal was specifically downregulated in the E/R-sample and not 
in the E/R-mutant version compared to the LUC control (Figure 6C). The signal 
was also gradually downregulated in the induction time series (study I Figure 3B).  
 
Figure 6.  A) A representation of the two approaches used to define ETV6-RUNX1 regulated regions 
in study I. B) RUNX1-peaks from a ChIP-seq study were enriched nearby the 
downregulated genes. C) GRO-seq signal from the Nalm6 cell model illustrated at 
RUNX1-motif centered ChIP-seq peaks. Adapted from Teppo et al., 2016 Genome 
Research. 
 
A B 
C 
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5.2 Noncoding RNAs in ETV6-RUNX1 leukemia (I-II) 
Our analysis revealed genomic regions at which transcription changes after induction 
of E/R. These changes included annotated genes, both coding and non-coding, as 
well as yet to be annotated putative long non-coding RNAs and enhancer RNAs. 
These can be intragenic (antisense transcripts read from the opposite strand of a 
gene) or intergenic (between annotated genes). Our analysis also revealed novel 
transcription start sites (TSSs), tails (RNA polymerase running longer than the 
annotated gene), and promoter antisense transcription (pat).  
In addition to eRNAs described earlier, we found 57 novel E/R-regulated long 
non-coding transcripts. These were further manually classified as potential eRNAs 
(29, based on size and visual examination), or lncRNAs (28) (study I Table S4 online). 
15 of the 57 transcripts studied here showed similar change when we compared the 
expression in E/R patients vs. other preB-ALL-patients in RNA-seq data. Nine of 
the 28 lncRNAs were antisense of annotated genes, including a transcript antisense 
to IGLL1. We also found E/R regulation for seven annotated lncRNAs, including 
LOC728175 and LOC374443. 
We compiled a list of B-cell super-enhancers using H3K27ac data accompanied 
with the most prominent RUNX1-bound sites in SEM and HSC cells (refer to Table 
1), and quantified GRO-seq signal from the E/R induction model at these sites. This 
allowed us to examine regulation directly at putative enhancer sites (enhancer-centric 
approach, Figure 6A). Of the 534 enhancers defined by H3K27ac and found 
regulated by E/R in GRO-seq (study I Figure S3 online), 59 were super-enhancers 
(study I Table S3 online), and the expression level of 28 of them correlated with a 
nearby gene (study I Table S2 online). RUNX1 ChIP-peaks were found to enrich in 
super-enhancer regions over all H3K27ac sites (4.4-fold). Similarly, E/R-regulated 
enhancers that contained RUNX1-peaks were enriched to super-enhancer sites (6-
fold) (study I Figure 3C). Overall, two thirds of the regulated super-enhancers were 
annotated from CD19+/CD20+-cells and two-thirds were downregulated (study I 
Table S3 online; study I Figure 3D). 
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5.3 ETV6-RUNX1 affects genes related to transmembrane 
signaling (I) 
We analyzed gene ontology enrichment of the E/R-regulated enhancer regions and 
coding genes. Cell adhesion and transmembrane signaling as functional annotation 
terms were enriched in both analyses. We also tested whether the coding genes found 
regulated in our cell model were differentially expressed between E/R patients and 
other preB-ALL patients. For this we used microarray datasets, consisting of E/R, 
t(1;19), t(9;22), KMT2A-rearranged, and high hyperdiploid cases. Total of 133 of the 
183 genes were detected in the dataset, and 35 of them were found to be significantly 
altered between the patient subgroups. Of the 35 genes, 13 had similarly differential 
expression in another patient cohort in RNA-seq analysis.  
For example, direct regulation of ITGA4 gene, encoding an integrin subunit and 
related to adhesion, was consistently downregulated in E/R samples, and we showed 
its regulation at mRNA level and in ChIP-seq (study I Figure 5B). Consistently 
downregulated genes included IL21R, LAT2, LAIR1, CLEC14A, CLEC2D, 
CMTM7, all of which are transmembrane proteins related to immunoregulation. 
5.4 R-loops and convergent transcription co-occur with RNA 
polymerase II stalling (III) 
For a general overview on transcriptional features in the genome (see Table 1 for the 
data produced and used), we first assessed the co-occurrence of R-loop forming 
sequences (RLFS) and convergent transcription (convT) with RNA pol II stalling 
sites (Table 2). 30% of the RNA pol II stalled regions contained RLFS which was a 
significant overlap when compared to random regions. High local RLFS motif 
density was associated with GRO-seq signal intensity and both elevated at TSS and 
TTS sites (study III Figure 3 supplement 1 online). We also saw higher incidence of 
RNA pol II stalling in the sense strands in regions with higher antisense transcription 
(study III Fig 3B). We assessed whether the presence of RLFS motif at TSSs is 
associated with DRIP-seq signal level (DNA-RNA hybrids) and found a 2.1-fold 
increase. Similarly, DRIP-seq signal was elevated at TSS sites with convergent 
transcription. These results showed that transcription stalling occurs at sites with 
convergent transcription and RLFS motifs, and is associated with R-loop formation. 
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Table 2.  Enrichment of RLFS motifs and convergent transcription at RNA pol II stalling sites 
and at DNA-RNA-hybrid sites. 
 
RLFS MOTIF CONVERGENT TRANSRIPTION 
RNA POL II 
STALLING 
(B-LYMPHOID) 
30%; 
p < 0.001 for the overlap belonging to the 
random distribution (16%) 
(study III Fig 3A) 
10 - 50% 
of convT regions overlapped with RNA pol II 
stalling; overlap increased with increasing 
convT level quartile (study III Fig 3B) 
RNA POL II 
STALLING 
(ES CELLS) 
29%; 
p < 0.001 for the overlap belonging to the 
random distribution (12%) 
(study III Fig 3A) 
5 - 35% 
of convT regions overlapped with RNA pol II 
stalling; overlap increased with increasing 
convT signal level quartile (study III Fig 3B) 
DRIP-SEQ 
(ES CELLS) 
2.1-fold 
elevation in DRIP-seq signal; 
p < 2.2 x 10-16 
for the signal levels coming from the same 
population (study III Fig3C, source data 2) 
1.7-fold 
elevation in DRIP-seq signal; 
p < 2.2 x 10-16 
for the signal levels coming from the same 
population (study III Fig3D, source data 2) 
 
Next we tested whether wide open chromatin regions were associated with RNA 
pol II stalling sites. For the interpretation of open chromatin sites, we retrieved 
DNase-seq data from B-lymphoid and embryonic stem (ES) cell lines and analyzed 
it together with the stalling sites (analyzed from GRO-seq from the respective cell 
types). Wider DNase-seq signal was observed at sites overlapping with RNA pol II 
stalling (876 bp in B-lymphoid, and 412 bp in ES cells; study III Fig 3 source data 2 
online). We then compared the 5% widest RNA pol II stalling sites to the widest 
peaks from DNase-seq and ChIP-seq for histone markers. We found that the 
features with the highest odds for co-occurrence at RNA pol II stalling regions were 
pol II Ser5P, DNase hypersensitivity, H3K4me3, and H3K36me3 (odds ratios > 10; 
study III Figure 4C and source data 1 online). 
5.5 Transcriptional features at genomic breakpoint regions (III) 
Coordinates for structural variation (SV) breakpoints in 51 ETV6-RUNX1-positive 
patients were retrieved (Papaemmanuil et al., 2014) and analyzed together with 
nascent RNA signal generated by using GRO-sequencing. For the quantification of 
SV regions, the genome was sorted into topologically associated domains (TADs) 
based on chromosome conformation data from a B-lymphoid cell line (Rao et al., 
2014). This resulted in 354 (of the total of 2900) TADs with at least one breakpoint 
among the E/R patients. 64% of the TADs contained more than one breakpoint 
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event among the patients (study III supplemental data 1 online). Initial observations 
for the specific transcription signal feature - RNA pol II stalling and convergent 
transcription - were gained by visually examining the most frequent breakpoint sites. 
Some of these sites did not contain previously annotated lncRNA although long 
transcripts were expressed based on the GRO-seq data. We also noticed that the 
breakpoints were often located a few kilobase from the TSS, with simultaneous 
transcription on both strands at these sites. We suspected that several of them might 
be intragenic enhancers. In addition, convergent transcription at intragenic 
breakpoint sites was associated with elevation in GRO-seq signal, that we 
hypothesized as being stalled RNA pol II (example of elevated signal in Figure 7A). 
These observations led us to perform genome-wide analysis of convergent 
transcription and RNA pol II stalling at the breakpoint regions resolved from the 
ETV6-RUNX1-positive preB-ALL patients. Convergent transcription and pol II 
stalling were enriched at TADs with the most frequent breakpoints (41/73 with 
convT-level over background, p = 0.00038; 42/73 with RNA pol II stalling, p = 
0.014) (Figure 7B). 
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Figure 7.  A) GRO-seq signal at an example region with recurrent breakpoints in ETV6-RUNX1 preB-
ALL (locus with PAX5 and ZCCHC7 genes in chromosome 9). Zoomed view on ZCCHC7 
shows an example of local elevation in the signal with transcription on both strands. B) 
Topologically associated domains (TADs) with breakpoints were assigned into quartiles 
based on breakpoint frequency per TAD size (number of breakpoints per kilobase). 
Convergent transcription (left) and RNA pol II stalling (right) were enriched in TADs with 
frequent breakpoints. Adapted from Heinäniemi et al., 2016 eLife. 
 
 
 
 
A 
REH (E/R+) 
B-lymphoid cells 
KOPN8 
(KMT2A-re) 
  patient 
  (hyperdiploid) 
  REH 
  (E/R+) 
super-enhancer 
breakpoints
convT 
convT 
pol II stalling 
convT 
%
 of
 T
AD
 
%
 of
 T
AD
 
Breakpoint frequency quartile 
  RNA pol II stalling B 
 55 
We then took the breakpoints without recombination signal sequence under 
investigation to study a potential RAG-independent mechanism (416 non-RSS/NR-
breakpoints, of which 124 intragenic). We found enrichment of breakpoints at 
regions with RNA pol II stalling and convergent transcription (Figure 8A; Table 3). 
Non-RSS-breakpoint recurrence, defined as a 1kb window with more than one 
breakpoint, increased the percentage of overlap with pol II stalling and convergent 
transcription (Figure 8A).   
We then analyzed the breakpoints with RSS motif (335 R-breakpoints, of which 
156 intragenic) for overlap with the transcriptional features. 56% of the breakpoints 
overlapped with pol II stalling at intragenic regions and 44% with genome-wide 
convergent transcription (Table 3). The overlap with RNA pol II stalling was more 
clear for the recurrent breakpoints (68% of the recurrent regions with stalling) 
(Figure 8B). Similarly, the overlap with convergent transcription was considerable in 
the recurrent breakpoint sites, up to 91% at regions with four or more breakpoints. 
The regions with RLFS motifs or annotated TSSs showed less marked co-occurrence 
(Figure 8B). The presence of both convT and RNA pol II stalling best characterized 
the recurrent intragenic breakpoints (43/48). 
 
Table 3.  The percentages of breakpoints that overlap with convergent transcription or RNA 
pol II stalling. 
 BREAKPOINTS WITHOUT RSS BREAKPOINTS WITH RSS 
CONVT 
(B-LYMPHOID) 
9 % (39 of 416) vs. 3.9% 
background; p =  5.16 x 10-7 
44% (149 of 335) vs. 3.9% background; 
p < 2.2 x 10-16 
RNA POL II STALLING 
(B-LYMPHOID) 
INTRAGENIC REGIONS 
 
29% (36 of 124) vs. 12% 
background; 
p = 4.09 x 10-7 
56% (87 of 156) vs. 12% background; 
p < 2.2 x 10-16 
 
 
We also studied the expression levels of RAG and AICDA across a preB-ALL 
transcriptome dataset and noticed 10.8-fold higher median expression of RAG1 in 
the ETV6-RUNX1 subtype (Figure 9A). Known classical subtypes clustered 
separately based on the global gene expression in an unsupervised analysis of sample 
similarities (study III Figure 5). AICDA expression was more prevalent in patients 
without any classic cytogenetics (study III Figure 5F and G). 
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Figure 8.  The percentages of breakpoints that overlap with RNA pol II stalling, convergent 
transcription (convT), R-loop forming sequences (RLFS), or transcription start sites (TSS) 
at regions with A) non-RSS-breakpoints, and B) RSS-breakpoints, resolved from ETV6-
RUNX1 patients (Papaemmanuil et al., 2014). RSS = recombination signal sequence. The 
overlap is shown separately for breakpoints binned by the recurrence in the dataset. 
Adapted from Heinäniemi et al., 2016 eLife. 
 
Figure 9.  RAG1, RAG2, and AICDA expression in different preB-ALL subtypes based on the 
combined microarray studies with a total of 1382 patients. MLL-fusion = KMT2A-
rearranged subtype. Adapted from Heinäniemi et al., 2016 eLife. 
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6 DISCUSSION 
 
6.1 ETV6-RUNX1 target genes 
The second most common characterizing alteration in childhood leukemia, ETV6-
RUNX1 translocation, results in an aberrant fusion of two hematopoietic 
transcription factors. A few studies have therefore focused on its transcriptional 
consequences. However, many of the outcomes in terms of targeted genes have not 
been consistently reproducible across studies with different cohorts or cell models. 
There could be several potential reasons. First, when the putative target genes are 
deduced by comparing patient expression profiles, the results depend much on what 
the control group is comprised of. Heterogeneity of the subtypes may be one reason 
as to why reported gene sets discriminating between ALL and AML differed almost 
completely between early studies (Golub et al., 1999; Moos et al., 2002; van Delft et 
al., 2005). As high hyperdiploid is the most common subtype in preB-ALL (besides 
E/R), they are likely overrepresented in many datasets, and thus some of the 
differential expression results may more describe high hyperdiploids than the E/R 
subgroup. In our study, we only tested a subset of genes for differential expression 
in an RNA-seq study and across microarray studies. In the RNA-seq cohort, the 
control group comprised of almost only hyperdiploid cases. However, the 
microarray data contained a better representation of subtypes. Cell differentiation 
status also differs between ALL subtypes (Andersson et al., 2010; Chen et al., 2016). 
Gene expression profiles of the E/R cases resemble most closely the normal proB 
cell state (Andersson et al., 2010), while the KMT2A-rearranged cases are more 
immature (early lymphoid) and the TCF3-PBX1 subtype more mature preB-cells 
(Chen et al., 2016). Thus, differential gene expression results may partly reflect the 
cell differentiation status and not the leukemia. Considering expression profiles 
during the differentiation of human B-cells (Mehtonen, Teppo, et al., manuscript), 
many of the genes that were listed as being E/R-related in e.g. a report by Gandemer 
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et al., 2007 seem to define normal proB-cells. Cautious prediction on their possible 
role in leukemia is therefore necessary. 
In addition to comparison of expression profiles between patients, cell models 
may generate different results depending on the genomic background of the chosen 
cell line. The clearest differences are between studies in human and mouse cells 
which are not advisable to be compared at gene level. Additional differences may 
stem from different overexpression or silencing level and the time of perturbation 
in the model. There are a few studies that have reported silencing of the E/R fusion 
in REH cells (a human E/R-positive preB-ALL cell line) (Fuka et al., 2011; Zaliova 
et al., 2011; Mangolini et al., 2013; Ghazavi et al., 2016). In Zaliova et al., siRNAs were 
used to silence E/R down to 42% of the control level, yet no significant differentially 
expressed genes were found in the microarray study. This is in contrast to the report 
by Fuka et al., where 50-80% silencing of E/R resulted in 777 genes deregulated in 
both REH and AT2 cell lines (with rather low correlation between the cell lines), and 
52% of the genes were upregulated after knockdown. This study used an shRNA 
sequence that matched the wild type RUNX1 and was also shown to silence RUNX1 
down to 46% (Zaliova et al., 2011) which probably had some effect on the results. 
Ghazavi et al. reported approximately 50% silencing of E/R resulting in 134 
lncRNAs deregulated, of which 30% were upregulated at knockdown. In our study, 
we managed to silence the E/R in REH down to 40% using lentivirally mediated 
shRNA that targeted evenly the ETV6 and RUNX1 sides of the fusion point. The 
silencing level may not have been enough for reliable estimation of changes in 
nascent RNA transcription genome-wide as only a few genes were found altered. 
However, some potential target genes were altered at mRNA level as measured by 
qPCR. Although a better knockdown level would have been favorable, complete 
knock-off of E/R may not be possible for experiments, as E/R-positive leukemic 
cells have been suggested to be dependent on the expression (Montano et al., 2019 
preprint). 
Our cell model with inducible E/R fusion was based on a preB-ALL cell line 
Nalm6. By the experimental setup, we aimed to clarify the target genes behind the 
phenotypic differences as compared to other subtypes, and to reveal the genomic 
target sites of ETV6-RUNX1 in the genome. The use of inducible expression vector 
allowed a controlled study design without unwanted long-term effects. We also used 
a version of E/R with a mutated DNA-binding domain as a control to exclude 
effects not caused by RUNX1-mediated DNA binding. This approach led to 
exclusion of around 15% of putative target genes. ETV6-RUNX1 was present in the 
cells for a relatively short time (less than 24 hours) which probably decreased the 
 59 
amount of indirect effects in transcription as compared to models with constitutively 
expressed transgenes. Nalm6 cell line resembles cells at preB differentiation state. 
Even though the cell line is relatively close to E/R-positive leukemic cells, the 
expression changes that we observed are affected by its cell state and unique genomic 
alterations. For example, we could not capture putative E/R-mediated 
downregulation at genes that are only expressed in earlier cell states. The selection 
of the model cell line is always a compromise and in an ideal world, one would have 
several different models that could help to better identify changes that are specific 
to background. 
Direct genome-wide regulation by transcription factors can be interrogated by 
using chromatin immunoprecipitation (ChIP-seq). This method is widely used but is 
dependent on the antibody specificity and sensitivity to recognize the correct sites. 
It is common that only a few percent of TF binding motifs in a cell are actually 
bound by the TF (Spitz and Furlong, 2012). Moreover, binding of a TF at a certain 
site is not a direct measure of regulation of nearby genes. To address these 
challenges, we employed global nuclear run-on sequencing to decipher targets of 
E/R by measuring changes in nascent RNA transcription levels genome-wide. 
Nascent RNA expression at enhancer correlates with its activity and can thus be used 
to reveal activity of the regulatory region. The GRO-seq based method allowed more 
correct interpretation of the involvement of each putative enhancer site in the 
regulation. TF motif and ChIP-peak enrichment analyses suggested that E/R acts 
via RUNX1-dependent enhancer sites in the case of downregulated genes. This is in 
accordance with previous studies reporting mainly repression by the E/R which may 
be related to its protein-protein interactions with co-repressors (Fenrick et al., 1999; 
Uchida et al., 1999). In comparison, after silencing of E/R in another study, a nearby 
RUNX1 ChIP peak was found in similar levels for both up- and downregulated 
genes, and no enrichment of RUNX1 motif was seen at the gene promoters (Fuka 
et al., 2011). This report used RUNX1 ChIP-seq data from human megakaryocytes 
and mouse early hematopoietic cells and may reflect differences in the cell models 
as well as illustrate the need to confirm findings with several data types. 
In addition to the RUNX1-domain mediated downregulation of a part of the 
genes, we saw clear enrichment of ETS motifs at the deregulated sites after inducing 
the E/R. This suggests that these genes are not regulated through the RUNX1 RHD-
domain but by ETV6 or other ETS-factors. Interestingly, the fusion protein does 
not contain the ETS-domain for DNA-binding by ETV6. It is known that ETS 
proteins (including ELF, ELK, ERG, and SPI) favor a similar DNA-binding motif, 
and ETV6 can heterodimerize with several of the members through the PNT 
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domain (Fenrick et al., 1999). Therefore, although it is not possible to conclude with 
this data, other ETS proteins than ETV6 could be behind the upregulated genes in 
our experiment. This idea has been presented in a study where both E/R and ETV6 
were needed to repress a promoter containing several TF binding sites, and ETV6 
could be replaced with either ETS1 or FLI1 (Fears et al., 1997). Expressing ETV6 in 
REH cells also led to both ETS- and RUNX1 motif enrichments at ETV6 binding 
sites, possibly revealing binding sites for E/R (Neveu et al., 2018). The same study 
identified enrichment of ETS-IRF and IRF motifs at the binding sites. Similarly, 
RUNX1 and ETS factors have been shown to occupy a shared motif (Hollenhorst 
et al., 2009). Interestingly, the DNA-binding deficient, RHD-domain mutated E/R 
version was not able to exclude these putatively non-RUNX1-mediated (ETS-factor 
dimerization) effects, although no defects in the putative PNT-domain mediated 
interactions were introduced.  
The non-rearranged version of ETV6 is deleted in many but not all the cases of 
E/R leukemia. The deletion of ETV6 is also a common feature in E/R relapses. 
Thus far, ETV6 is reported to be always deleted in the ETV6-RUNX1-like subtype 
and has been suggested to be the main driver event (Lilljebjörn et al., 2016; Zaliova 
et al., 2017). The E/R-like cases resemble E/R leukemia in gene expression profile, 
which indicates that not only the E/R protein influence the profile. For example, a 
gene previously reported as E/R-specific (Ross et al., 2003), CLIC5, was shown to 
be downregulated by ETV6 (Neveu et al., 2016); therefore, its high expression in the 
E/R subtype seems to be due to loss or inactivation of the normal ETV6 allele. 
Negative correlation between ETV6 deletion and duplication of ETV6-RUNX1 
(duplication of der21(t12;21)) has been shown, suggesting that the two events are 
redundant. E/R seems to be more potent if it is expressed higher than ETV6, i.e. it 
is the ratio of these two that matters (McLean et al., 1996; Lilljebjörn et al., 2010). 
However, it has been suggested that even if the other ETV6 allele is not deleted, it 
is not expressed in the E/R disease (Patel et al., 2003; Gunji et al., 2004). Therefore, 
studies could benefit from looking at its RNA level expression in addition to the 
genetic alterations at the locus.  
Soon after the E/R translocation was discovered, it was concluded that only one 
of the products, E/R, is consistently expressed in the t(12;21) cases, as the reciprocal 
RUNX1-ETV6 was detected in only 10/22 patients (McLean et al., 1996). It was also 
reported that adding E/R, RUNX1-ETV6, or them together, was insufficient to 
induce leukemia (or factor independent growth) in mouse HSC cells (Andreasson et 
al., 2001). However, subsequent studies have mentioned expression of the RUNX1-
ETV6 in approximately 75% of the cases  (Nakao et al., 1996; Stams et al., 2005) and 
 61 
the expression level of RUNX1-ETV6 has been reported as an independent 
prognostic factor in E/R leukemia (Stams et al., 2005). As RUNX1-ETV6 contains 
the DNA binding domain ETS, and only the first exon of RUNX1, it could affect 
gene regulation as an aberrant ETS-factor. It was also suggested to share structural 
similarities for FUS-ERG fusion (in AML, Andreasson et al., 2001), which was 
shown to bind DNA together with a complex containing other ETS factors, RUNX1 
and TAL1, suggesting the fusion may affect regulation via these complexes (Sotoca 
et al., 2016). Some E/R cases have additional RUNX1-fusions and simultaneously 
lack the RUNX1-ETV6, suggesting the translocations occur during the E/R 
translocation by a complex three-way manner (Lilljebjörn et al., 2016). Off note, the 
most widely used E/R-positive cell line REH was reported not to express the 
reciprocal fusion and to have deletion in the other ETV6 allele (Uphoff et al., 1997). 
This might be relevant in any future experiments where the overall play between the 
ETS-factors, RUNX1, and the fusions might be studied.  
Genes that regulate B-cell differentiation are often targets of structural variations 
in ALL (Mullighan et al., 2007). We noticed that E/R regulated 7% (56) of the super-
enhancers resolved from CD19+ or CD34+ cells, with a preference to downregulate 
the expression. This exemplifies a way for an aberrant TF to interfere with gene 
regulation and contribute to differentiation impediment. TCF3-HLF, another fusion 
in preB-ALL leukemia, was shown to hijack the binding sites of HLF and rewire the 
enhancer landscape by targeting genes that represent features of proB- to preB 
transition (Huang et al., 2019). Alterations in TFs and other genes that are important 
in B cell development may have direct consequences to treatment efficacy. This was 
described in glucocorticoids which were shown to suppress B-cell checkpoint genes 
to push cells through developmental blocks (Kruth et al., 2017). 
In conclusion, our analysis yielded a list of putative E/R responsive genomic sites, 
parts of which are seen to be similarly regulated in primary patient cells when 
compared to other subtypes. By considering the approach and the innate limitation 
and strengths in each reported study on the ETV6-RUNX1 function, it might be 
possible to capture the target genes and pathways most essential in the disease. The 
possible roles of them in the leukemogenesis or in the phenotype of E/R disease 
would need to be studied further in the future. 
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6.2 Enhancers in leukemia 
During the studies, we generated nascent RNA profiles, which include all the newly 
transcribed RNAs in the genome, for several preB-ALL cell lines and primary patient 
samples. This data is especially suitable for studying transcriptional regulation and 
features. We noticed that regions with high number of breakpoints in preB-ALL 
contained previously unannotated non-coding RNA transcription. The genome-
wide nascent RNA profiles may provide sites of interest for further examination. 
Large projects are also currently focusing on identifying pathogenic noncoding 
variants in many cancers (Gutierrez-Camino, Martin-Guerrero and García-Orad, 
2017). That is increasingly possible with improved annotation and high-throughput 
methods. Genome-wide association studies have revealed a few risk loci for 
childhood leukemia, many of which lie in noncoding regions of the genome 
(Ellinghaus et al., 2012; Vijayakrishnan et al., 2018). For example, in leukemia, a 
susceptibility locus for childhood leukemia near IKZF1 gene was shown to localize 
to a B-cell super-enhancer, while the enhancer was also shown to have differential 
activity and protein binding (Brown et al., 2019). This exemplifies how a putative risk 
SNPs or somatic mutations in non-coding regions could be selected for further 
scrutinization with the help of improved enhancer annotation. In addition to 
mutations, individual enhancers have been reported to be altered in leukemia by 
translocations, amplifications, insertions, and deletions, reported especially on T-
ALL, CLL, and AML (reviewed in Bhagwat, Lu and Vakoc, 2018).  
Enhancers can affect gene expression both locally and from further distance by 
chromatin looping. When linking potential enhancers to genes after E/R induction, 
we only inferred local associations and did not consider the three-dimensional 
folding of chromatin. Defining interactions in three dimensions would be possible 
by using a chromosome conformation capture method such as HiC (Lieberman-
Aiden et al., 2009). By defining enhancers using nascent RNA transcription-based 
prediction, we were however able to capture more reliable pool of active regulatory 
regions than what would have been possible by analyzing TF/target gene co-
expression or by ChIP-seq alone. Gene-enhancer distance metric have been used 
before to assign enhancer-gene pairs (Visel et al., 2007; Fishilevich et al., 2017) and 
combining it with eRNA/target co-expression (Andersson et al., 2014) probably 
decreases false positive hits.  
The enhancer landscape in human hematopoietic cells from blood has been 
mapped using RNA-seq and ATAC-seq profiles and was shown to act as a good 
discriminator between cell states (Corces et al., 2016). Enhancer profiling based on 
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H3K27ac has been utilized in some leukemia studies (McKeown et al., 2017; Wong 
et al., 2017). We have noticed that different genetic preB-ALL subgroups can be 
clustered based on their enhancer RNA (GRO-seq) profiles (Heinäniemi et al., 
unpublished). RNA-sequencing data has recently been utilized in identification of 
novel subtypes in ALL, including the so-called phenocopies (i.e. cases that have 
similar gene expression profile but lack a trademark genetic lesion such as a fusion 
gene). Epigenomic analyses seem to be able to similarly distinguish between subtypes 
(Nordlund and Syvänen, 2018). In fact, the so-called E/R-like subgroup was first 
noticed in a DNA methylation based classification (Nordlund et al., 2015) before it 
was reported using gene expression data (Lilljebjörn et al., 2016).  
 Studies reporting lncRNA profiles are emerging for different cell types and 
cancers. LncRNA profile based classifications of ALL subtypes have also been 
reported (Fernando et al., 2015; James et al., 2019). LncRNAs have been examined 
specifically in the E/R subtype using microarray data (Ghazavi et al., 2016). Putative 
lncRNAs, from our study and others, could be further investigated from the GRO-
seq data from patient cells. Further studies are needed to decipher any functional 
annotation to the putative E/R-related lncRNAs.  
Enhancers could be utilized in treatment by targeting the co-factor proteins 
transcribing these regions. For example, BET inhibitors target a subgroup of BRD-
protein bound enhancers, depending on other TFs and some still unknown factors. 
Also, kinase units in Mediator protein complex or general transcription factors could 
be inhibited, or the balance of histone deacetylases (HDAC) and acetyltransferases 
(HATs) could be altered for reprogramming. (Reviewed in Bhagwat, Lu and Vakoc, 
2018). Targeting an enhancer or cofactor present specifically in cancer could have 
minimal amount of side effects, such as was proposed for TRIM33 cofactor that 
binds with PU.1 specifically at an upstream enhancer of the pro-apoptotic gene 
BCL2L11 in preB-ALL (Wang et al., 2015).  
6.3 Transcriptional features at breakpoint regions 
The use of next generation sequencing technologies has markedly increased the 
knowledge on the transcription of the genome. Transcriptional features, such as R-
loops, have been linked to genomic instability (Sollier et al., 2014; Hatchi et al., 2015). 
On the other hand, secondary alterations in E/R leukemia have been suggested to 
predominantly arise from RAG enzyme mediated off-targeting in sites other than 
the immunoglobulin genes (Papaemmanuil et al., 2014). RAG1 and RAG2 are 
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normally expressed during B-cell development for recombination of the 
immunoglobulin gene regions. They are also expressed in leukemic cells, especially 
in the E/R subtype. 
We investigated the structural variation sites in ETV6-RUNX1-positive preB-
ALL by analyzing transcriptional features (from GRO-seq data) at breakpoint 
regions (from WGS data). Transcription start sites (TSSs) in precursor B-cells have 
been considered susceptible to double strand breaks, mediated by H3K4me3 that is 
recognized by the RAG2 enzyme (Matthews et al., 2007; Teng et al., 2015). However, 
we noticed the breakpoints often resided a few kilobases from the TSS. Our analysis 
showed that the breakpoints overlap with RNA pol II stalling and convergent 
transcription, especially in case of recurrent breakpoint sites. We showed signals at 
the recurrent loci of, PAX5, BTG1, CDKN2A/B, and RAG1/2 , all of which are 
often hit by deletions in preB-ALL (Mullighan et al., 2007; Papaemmanuil et al., 2014). 
Some of the regions may present novel enhancer RNAs or lncRNAs. We also 
showed genome-wide associations between elevated R-loop signal, convergent 
transcription, and RNA pol II stalling in normal and leukemic human cells. Although 
all the features are a part of the normal transcriptional process, genomic loci with 
recurrent breakpoints were particularly enriched with them. RNA pol II stalling was 
also associated with H3K4me3. Wide H3K4me3 regions have been suggested to 
ensure transcriptional consistency of key genes in cell identity and function 
(Benayoun et al., 2014). 
We classified the structural variation breakpoints into two groups based on the 
presence of an RSS motif. Both RSS- and non-RSS breakpoint sites were found to 
be enriched at stalled RNA pol II and convergent transcription sites. No clear 
difference in associations with transcriptional features were seen between the two 
breakpoint types, however, the breakpoints with RSS-motif had especially high 
concurrence of the features, indicating that there might be a higher demand for the 
exposure of the exact RSS motif for the RAG enzymes. This is supported by the 
notion that RAG-mediated cleavage occurs on unpaired and unwound DNA 
(Akamatsu and Oettinger, 1998). In contrast, non-RSS breakpoints could develop 
during transcription elongation and convergent transcription by mechanisms 
dependent on the exposure of the region in general. 
R-loops are expected to be formed in regions where RNA pol II is stalling 
(Skourti-Stathaki and Proudfoot, 2014; Jenjaroenpun et al., 2015). In addition to R-
loops, convergent transcription has been hypothesized to cause pauses in 
transcription due to collisions between the crossing polymerases (Prescott and 
Proudfoot, 2002). Although we only saw a slight enrichment of breakpoints to R-
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loop forming sequence sites (RLFS), we showed that they overlap with RNA pol II 
stalling events, and there was an increased signal level of DRIP-seq at RLFS-positive 
sites compared with RLFS-negative sites in ES cells. At the time, DRIP-seq data was 
not available for B-lineage cells but instead we used RLFS sequence prediction 
(Jenjaroenpun et al., 2015). The modest enrichment of breakpoints to RLFS sites 
may be influenced by the wide proportion of genome, especially the TSS sites, that 
is prone to R-loops as predicted by the program (15646 TSSs with RLFS-motif, 8220 
without) and reported by others (Ginno et al., 2013; Lim et al., 2015; Sanz et al., 2016). 
Additional mechanisms seem to be needed to result in breakage. For example, 
factors affecting the stability of the DNA:RNA hybrids could play a role. One of 
these factors is topoisomerase that functions in rewinding the strands behind RNA 
pol II, inhibiting R-loop formation (Atkin, Raimer and Wang, 2019). Defects in RNA 
processing after transcription could slow down the rewinding of DNA at R-loop 
prone sites and thereby expose to breaks. Indeed, quite recently, mutations in genes 
affecting RNA splicing that results in RNA pol II accumulation at certain mis-spliced 
loci have been suggested in leukemogenesis in AML (Yoshimi et al., 2019).  
We used data from embryonic stem cells to show a general overlap of 
DNA:RNA-hybrids with RLFS motifs along with transcriptional features. We also 
showed overlap between stalling and convergent transcription using ES cell data with 
the idea that general properties of transcription are not dependent on cell type. When 
the overlap between the breakpoints in E/R leukemic cells and the transcriptional 
features in stem cells was analyzed, we did not see clear enrichments. This reflects 
cell type specific expression of the genome.  
Our analysis comprised of data from B-lymphoid cell lines and preB-ALL 
leukemic cells (primary and cell lines). Nascent RNA signals were used to estimate 
the transcription occurring at the breakpoint sites before the breakage. Our study 
shows associations between transcriptional features, but the putative causes behind 
the associations and their regulation were not explored. In addition to ETV6-
RUNX1, we also studied breakpoints resolved from other preB-ALL subtypes. 
Although only 7% of the breakpoints in KMT2A-rearranged cases had RSS motif 
evidence (Andersson et al., 2015), we saw similar enrichment of convergent 
transcription and pol II stalling as in the case of ETV6-RUNX1. Similar 
transcriptional features were also seen for the breakpoints studied from the 
hyperdiploid and hypodiploid cases. This indicates that comparable transcriptional 
vulnerability may underlie the generation of the secondary alterations in these 
subtypes. The analysis could be extended in the future by using a model where GRO-
seq signal was produced from preleukemic precursor B-cells and the structural 
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variation sites from the established leukemic cells were later resolved. Additional 
breakpoint data from more patients would also give more certainty for the 
recurrence of breaks inside specified regions. 
Our study provides evidence on how genomic regions, especially with a 
nucleotide composition resembling RSS-motifs, are further selected for breakages 
recurrently seen at B-cell specific genomic sites. Recurrence is often used to define 
“driver genes” which are proposed to be particularly essential for the cancer 
progression. However, regarding the emerging evidence on transcriptional and 
epigenomic features, at least some of the recurrently altered genes could instead just 
be more prone to double strand breaks at that specific cell type and state and not all 
of them necessarily act as active players in leukemogenesis. 
6.4 RAG and AID in secondary structural alterations 
Current evidence pinpoints the role of RAGs especially in the E/R-positive preB-
ALL. We noticed high expression of RAG1 especially in the E/R subtype, in line 
with previous reports (Ross et al., 2003). This could partly reflect the proB cell state 
of the E/R cells, although RAG1 has also been suggested to be directly regulated by 
the E/R in a mouse model (Swaminathan et al., 2015). E/R-positive preleukemic 
cells were also reported to have increased Rag1 and Rag2 levels compared to proB 
cells in wild type mice in another study (Rodríguez-Hernández et al., 2017). Higher 
proportion of structural variations with RSS-motif have been reported in E/R-
subtypes than in others (Zhang et al., 2012; Papaemmanuil et al., 2014; Andersson et 
al., 2015), indicating that the RAG-mediated mechanism may be more prevalent in 
E/R-positive cells. Signs of RAG off-targeting have however been reported in 
individual genes also in other leukemia subtypes (Aplan et al., 1990; Marculescu et al., 
2002; Raschke et al., 2005; Mullighan et al., 2008; Iacobucci et al., 2009; Novara et al., 
2009; Waanders et al., 2012).  
Epidemiologic data show strong association between day-care attendance (used 
as a surrogate for exposure to common infections in early life) and reduced risk of 
acute lymphoblastic leukemia, while the risk of other childhood cancers is not 
affected (Urayama et al., 2010). Already a hundred years ago, general infections were 
suspected as a cause of leukemia (reviewed in Greaves, 2018). Both RAG and AID 
enzymes were linked to secondary mutations in preB-cells with repeated 
inflammatory stimuli (Swaminathan et al., 2015), which provided mechanistic 
evidence as to how overly strong inflammatory stimuli later in childhood may 
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increase the risk of secondary events. Abnormal cytokine production has also been 
shown to favor outgrowth of E/R-positive progenitor B cell clone (Ford et al., 2009). 
In addition, relocating E/R-positive mice into a non-sterile room was sufficient to 
induce leukemic formation in an E/R mouse model (Rodríguez-Hernández et al., 
2017). Evidence of RAG-mediated secondary breakpoints were also seen in a human 
E/R iPS model (Böiers et al., 2018). 
AICDA (AID) is not normally expressed in bone marrow precursor cells 
(Gazumyan et al., 2012) but its expression is induced in the presence of inflammatory 
agents in preB cells (Rosenberg and Papavasiliou, 2007; Swaminathan et al., 2015). 
AICDA normally functions in mature germinal center B-cells during somatic 
hypermutation process introducing point mutations to immunoglobulin heavy chain 
gene, making antibodies more variable. Its function is dependent on active 
transcription at the site (Alt et al., 2013). Intragenic enhancer RNAs have previously 
been linked with AID-mediated genomic instability in lymphomas (Meng et al., 
2014). After combining samples from independent gene expression microarray 
studies, we saw unusual expression of AICDA in a subgroup of preB-ALL patient. 
These patients mostly did not belong to any of the classic subgroups. AICDA 
expression has been suggested to be associated with a high-risk disease phenotype 
in a previous work (Swaminathan et al., 2015). Given that AID is known to be 
targeted to stalled RNA pol II and convergent transcription sites (Yamane et al., 
2011; Meng et al., 2014;  Wang et al., 2014), it may be possible that it is behind some 
of the oncogenic alterations among high-risk patients. PreB-ALL clones have also 
been shown to consistently carry somatically mutated IGH variable gene segments, 
which is indicative of AID activity (Bonaventure et al., 2017). However, we did not 
specifically study if any of the genes deleted in the WGS dataset was a known AID 
off-target or whether there were sequence-specific clues of it. AID is similar to 
APOBEC cytidine deaminase proteins of which mutational signatures are found 
widely in cancers, also in leukemia (Rebhandl et al., 2014; Wagener et al., 2015; Li et 
al., 2017). Therefore, this protein family may function in preB-ALL in general, and 
their relevance in leukemogenesis could be studied further in the future. 
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6.5 Do we still need more studies on ETV6-RUNX1 leukemia? 
Several studies have been conducted on the ETV6-RUNX1-positive childhood 
leukemia and new evidence on its role as a differentiation staller has emerged. There 
are two main clinical aspects that would still benefit from additional knowledge on 
the disease: overtreatment and late relapses. E/R leukemia is suspected to be 
overtreated which causes unnecessary side-effects, but at the same time late relapses 
occur. Adjustment of the treatment regime may not be wise as long as excellent 
predictors for poor response or relapse are lacking. We are currently running a study 
where we compare E/R-positive patients with good early therapy response to those 
with suboptimal therapy response. We hope that this will give insights into whether 
and which of the genomic alterations contribute to therapy failure or increased risk 
of relapse. This type of data could help in optimizing therapy for the E/R patients 
in future: to decrease chemotherapy agents for the ones with good-prognostic 
genomic features and to increase therapy for the ones with poor-prognostic features. 
The E/R fusion junctional region has been suggested to function as an antigen 
(Yotnda et al., 1998; Chang et al., 2017) and E/R-directed neoepitope-reactive T-cells 
were recently detected in ETV6-RUNX1-positive patients (Zamora et al., 2019). If 
the E/R fusion protein itself proves to be targetable, we may not need additional 
knowledge on the molecular biology of the E/R leukemia to combat the E/R-
positive clones. ETV6-RUNX1 has been considered a promising target for its high 
clonality and dependency of cells on its expression. E/R is clearly a first hit; thus, it 
is indeed likely to be found in every single leukemic cell and even in preleukemic 
cells. E/R-positive cancer cell lines such as REH are also suggested to be dependent 
on the fusion expression (Diakos et al., 2007; Montano et al., 2019), meaning, the 
cells would go through apoptosis if it is silenced.  
Transcription factors, such as ETV6-RUNX1, could also be targeted by small 
molecule drugs. Most successful examples of TFs as drug targets function as 
receptors, such as retinoic acid receptor (RAR) in acute promyelocytic leukemia and 
glucocorticoid receptor (GR, NR3C1) in ALL. Drugs could also be designed to 
inhibit essential protein-protein-interactions in specific leukemic subtypes, like the 
interaction between the histone methyltransferase KMT2A (MLL) and its 
coactivators Menin and Ledgf (Uckelmann et al., 2020), or between the fusion CBFB-
SMMHC and RUNX1, without disturbing interaction between the normal CBFB 
and RUNX1 (Illendula et al., 2015; Bushweller, 2019). In conclusion, studies focusing 
on targeting abnormal transcription factor fusions directly could have high impact 
on the next generation of leukemia treatment. 
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7 SUMMARY AND CONCLUSIONS 
The ETV6-RUNX1-positive leukemia displays a characteristic gene expression 
profile, but the direct genome-wide transcriptional consequences have mostly 
remained elusive. Knowing these changes could help explain how the fusion 
predisposes carriers to leukemia and how it affects the leukemic cell phenotype. We 
aimed to uncover these issues by genome-wide analysis of nascent RNA 
transcription after induction of E/R in leukemic cells. We examined changes in the 
expression levels of both annotated and novel gene areas and linked putative 
enhancer regions to the differentially expressed genes. Our results suggest that the 
repressive function of ETV6-RUNX1 is partly mediated by RUNX1 binding sites at 
promoters and enhancers. We also showed repressive effect on the B-cell related 
enhancer sites of the genome. This may represent a way for E/R to slow down 
differentiation of precursor B cells that carry the fusion and thereby increase the 
probability to gain secondary structural variations. In addition, induction of E/R 
caused alterations in genes related to signaling with the microenvironment. Some of 
the direct effects could play a role in the features of E/R leukemia. 
Many of the genetic alterations in ETV6/RUNX1-leukemia are suggested to be 
caused by illegitimate activity of the RAG and AID enzymes. Both enzymes function 
specifically during the lymphocyte development and are responsible for generating 
vast diversity of antibodies. RAG enzymes are abundantly expressed in the E/R 
subtype and a part of the breakpoint regions are marked with RAG recognition signal 
sequences. AICDA is not normally expressed in precursor B cells but is known to 
be induced by inflammatory stimuli and could therefore contribute to alterations in 
precursor leukemia. We found clear associations between certain transcriptional 
features, namely convergent transcription and RNA polymerase II stalling, and DNA 
breakpoint sites in precursor B-ALL. These sites were also associated with open 
chromatin and DNA:RNA hybrids (R-loops). Genes that are necessary for B-cell 
differentiation are often marked with abundant enhancer RNA transcription and are 
recurrently altered in leukemia. Our results support a hypothesis that transcriptional 
features leave the genome vulnerable to secondary genomic alterations in precursor 
B-cells. Further studies are needed to validate the findings and for the possible 
application in prevention and/or treatment of childhood ALL. 
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Approximately 20%–25% of childhood acute lymphoblastic leukemias carry the ETV6-RUNX1 (E/R) fusion gene, a fusion of
two central hematopoietic transcription factors, ETV6 (TEL) and RUNX1 (AML1). Despite its prevalence, the exact genomic
targets of E/R have remained elusive. We evaluated gene loci and enhancers targeted by E/R genome-wide in precursor B
acute leukemia cells using global run-on sequencing (GRO-seq). We show that expression of the E/R fusion leads to wide-
spread repression of RUNX1 motif–containing enhancers at its target gene loci. Moreover, multiple super-enhancers from
the CD19+/CD20+-lineage were repressed, implicating a role in impediment of lineage commitment. In effect, the expression
of several genes involved in B cell signaling and adhesion was down-regulated, and the repression depended on the wild-type
DNA-binding Runt domain of RUNX1. We also identified a number of E/R-regulated annotated and de novo noncoding
genes. The results provide a comprehensive genome-wide mapping between E/R-regulated key regulatory elements and
genes in precursor B cell leukemia that disrupt normal B lymphopoiesis.
[Supplemental material is available for this article.]
Childhood acute lymphoblastic leukemia (ALL) is a heterogeneous
disease consisting of distinct clinical subtypes characterized by
specific chromosomal translocations ormutations. Themost com-
monALL subtypes are hyperdiploid and ETV6-RUNX1 (E/R) fusion
gene positive pre-B-ALL, which both comprise ∼20%–25% of the
cases (Inaba et al. 2013). Both leukemias have been suggested to
arise from a progenitor cell in utero and typically advance into
overt disease after accumulating additionalmutations during early
childhood (Wiemels et al. 1999; Bateman et al. 2015). The E/R
fusion can be detected also among healthy newborns with preva-
lence estimates ranging from 0.01% to 1% (Mori et al. 2002;
Greaves et al. 2011; Lausten-Thomsen et al. 2011; Zuna et al.
2011).
After 20 years since the discovery of the E/R fusion (Romana
et al. 1994; Golub et al. 1995), the mechanism(s) by which it
contributes to the development of B-ALL remains not fully under-
stood. E/R is a fusion of two essential hematopoietic transcription
factors (TF): ETV6 (TEL) (Wang et al. 1998) and RUNX1 (AML1)
(Wang et al. 1996). The translocation between Chromosomes 12
and 21, t(12;21), fuses theN terminus of ETV6 to nearly full-length
RUNX1, thus retaining the DNA-binding domain of RUNX1
(Runt). The E/R fusion is suggested to function as an aberrant TF:
The transactivating function of RUNX1 is lost, and the fusion pro-
tein is converted into a repressor through the ETV6 moiety that
recruits corepressors (SIN3A or NCOR) and epigenetic modifiers
(HDACs) (Hiebert et al. 1996; Fears et al. 1997; Fenrick et al.
1999; Song et al. 1999; Uchida et al. 1999; Guidez et al. 2000;
Hiebert et al. 2001; Morrow et al. 2007). During the past decade,
a number of microarray studies were performed exploring the
gene expression profiles of E/R-positive patient samples (Yeoh
et al. 2002; Ross and Zhou 2003; Fine et al. 2004; Andersson
et al. 2005, 2007; Gandemer et al. 2007). However, these studies
generated only a limited number of common genomic targets of
E/R, and the functions of E/R have remained elusive.
Global run-on assay followed by next generation sequencing
(GRO-seq) is a recently described method that allows for genome-
wide detection of primary transcript levels by directly measuring
nascent RNA production, including transcription at regulatory el-
ements (Core et al. 2008). At these regions, RNA polymerase II
(RNAP II) generates so-called enhancer RNAs (eRNAs) that show
dynamic activation patterns reflecting regional regulatory activity
(Core et al. 2008; Kaikkonen et al. 2013). Enhancers contain bind-
ing sites for multiple sequence-specific TFs that can be revealed
through profiling dynamical eRNA expression and de novo motif
discovery. In the context of lineage determination, a unique subset
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of enhancers termed super-enhancers (SE) has been distinguished.
They consist of enhancers with clustering of binding sites for mul-
tiple TFs and high histone K27 acetylation levels, reminiscent of
locus control regions characterized at beta-globin or immune
gene loci (Li et al. 2002; Whyte et al. 2013; Pott and Lieb 2014;
Adam et al. 2015). Recently, aberrant enhancer activity at the
TAL1 gene locus was shown to drive leukemogenesis in T-ALL
(Mansour et al. 2014). However, the majority of cancer-relevant
regulatory elements remain uncharacterized.
Here we applied GRO-seq on an inducible cell model to eluci-
date the genomic targets of the E/R fusion in precursor B-ALL.
Results
ETV6-RUNX1 is predominantly a repressive fusion TF
To study the molecular functions and targets of the E/R fusion in
ALL, we generated a doxycycline-inducible human E/R expressing
cell line using an E/R-negative precursor B-ALL cell line Nalm-6
(Nalm6-E/R) (Fig. 1A; Supplemental Fig. S1A–E). Induction with
doxycycline for 24 h increased the E/RmRNA level by 18-fold com-
pared to REH cells (in which E/R is expressed endogenously)
(Supplemental Fig. S1A), and at protein level, E/R was detectable
as early as 4–8 h after induction (Fig. 1B). Since the E/R fusion re-
tains the DNA-binding domain of the RUNX1 protein (Runt), we
generated another cell line with a targeted mutation (Nalm6-E/
Rmut): Substitution of an arginine with glutamine (R201Q) in hu-
man RUNX1 reduces DNA-binding affinity of the Runt domain by
1000-fold (Li et al. 2003; Morrow et al. 2007). Moreover, a recipro-
cal cell line was created in which endogenous E/R is silenced by
∼60% (REH-shE/R) (Supplemental Fig. S1F).
We applied the GRO-seq assay on our inducible cell model to
investigate early E/R-mediated transcriptional events. After 0, 4,
12, and 24 h of E/R induction, nuclei were extracted, and GRO-
seq was performed with a high level of concordance (r2 = 0.96) be-
tween two independent experiments (Fig. 1C). Mature transcripts
Figure 1. An inducible cell culturemodel uncovers early transcriptional changes downstream from the ETV6-RUNX1 fusion protein. (A) The doxycycline-
inducible cell culture model (Nalm6-E/R) with two controls (Nalm6-E/Rmut and Nalm6-LUC) is schematically illustrated and the sampling time points in-
dicated (see also Supplemental Fig. S1). Mutation at the DNA-binding domain of E/R is marked with a star. (B) Expression of E/R fusion protein after dox-
ycycline induction at indicated time points (a representative Western blot of two replicates). The H3 antibody was used as a loading control. (C) Highly
consistent results were obtained from biological replicates, as shown by a correlation plot depicting the GRO-seq signal from Nalm6-LUC cells. Pearson
r2 values for the biological replicate pairs of all samples were between 0.96–0.98. (D) A heatmap illustrating magnitude and direction of changes in the
GRO-seq signal for the annotated transcripts altered in the E/R sample (and not in E/Rmut) at 24 h. Log2 fold changes of indicated samples relative to
Nalm6-LUC are shown in color with shades of blue and red indicating down-regulation and up-regulation, respectively. E/R-mediated changes were pre-
dominantly repressive (for genes, see Supplemental Table S5).
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as measured by RT-qPCR showed considerable concordance with
primary transcription in GRO-seq (Supplemental Table S1).
Overall, two-thirds of theDNA-binding-dependent transcriptional
alterations at 24 h were repressive (Fig. 1D).
ETV6-RUNX1–mediated repression occurs at enhancers
carrying RUNX1 binding sites
GRO-seq allows TF binding sites to be inferred by investigating se-
quence-specific DNA motifs within enhancer regions that display
expression of eRNAs. We explored changes of eRNA expression in
the vicinity of E/R-regulated genes that, based on the mutant E/R
results, depended on direct DNA-binding (for transcript-centric
list, see Supplemental Table S2 for coordinates) and tested for the
overrepresentation of TF motifs (see Supplemental Material,
“Genomic regions used in analysis” and “TF motif enrichment
analysis”). As shown in Figure 2A, enhancers containing the ETS
motif were enriched at both up- and down-regulated loci, whereas
the RUNX1 motif ranked highly in the repressed group. As an in-
dependent confirmation, we retrieved ChIP-seq profiles for
RUNX1 in an ALL cell line (SEM) and for RUNX1, ERG, and FLI1
(the latter two representing ETS factors) in hematopoietic stem
cells (HSC) (GSE42075, Wilkinson et al. 2013; GSE45144, Beck
et al. 2013). There was significant enrichment of RUNX1 peaks
in the ±400 kb vicinity of regulated genes, as shown in Figure
2B, agreeing with the motif enrichment analysis (Fig. 2A). Again,
RUNX1 peaks were associated with E/R-mediated repression (Fig.
2B). The result remained consistent when less stringent peak cut-
offs were tested (Supplemental Fig. S2). Among the enhancers as-
sociated with E/R-regulated genes at ±400 kb from the altered
transcription start site (TSS) of a transcript, 67% (315 of 467) con-
tained either a RUNX1 motif or a RUNX1 binding site (ChIP peak
in HSC or SEM cells). Notably, we found evidence of a nearby E/R-
regulated enhancer for 96% of genes identified by the transcript-
centric approach (104/108) and for all but one, at least one en-
hancer region with evidence of RUNX1 binding or motif
(Supplemental Table S2).
A previous work indicated that RUNX1 and ETS factors can
also occupy a shared ETS-RUNX motif (Hollenhorst et al. 2009).
We observed marked enrichment of repressed RUNX1 binding
sites harboring ETS-RUNX motif in both SEM and HSC cells (five-
fold, Fig. 2C). ERG ChIP peaks centered by either ERG motif (Fig.
2B) or ETS-RUNXmotif (Fig. 2C) showed enrichment in the E/R-re-
pressed category, agreeing with the eRNA-based motif analysis. In
contrast, the up-regulated genes lacked enrichment of the studied
ChIP peaks (RUNX and ETS factors). The TF motif and ChIP peak
enrichment results suggest that E/R acts mainly through binding
to a RUNX1 motif and that a subset of genes may be coregulated
with ETS factors or indirectly by other TFs.
ETV6-RUNX1 targets super-enhancers associated
with CD19+/CD20+-cell identity
To further scrutinize the motif and ChIP peak findings (Fig. 2), we
explored the eRNA signal distribution upon E/R induction from
top RUNX1 peaks in SEM cells. As shown in Figure 3, A and B, re-
pression of eRNA signal centered to RUNX1motif occurred specif-
ically upon wild-type E/R expression, reaching the maximal effect
at the 24-h time point.
Given the role of RUNX1 in HSC differentiation (for review,
see Lutterbach and Hiebert 2000), we next compiled annotated B
cell andHSCenhancers based onH3K27ac data (distinguishing be-
tween “regular” enhancers and super-enhancers as in Hnisz et al.
2013), and included the most prominent RUNX1-bound sites in
SEM and HSC cells (Supplemental Fig. S3A). The GRO-seq signal
was then quantified at these sites. This “enhancer-centric” ap-
proach allowed us to pinpoint regulation by E/R that directly con-
siders alterations of eRNA (Supplemental Fig. S3B,C). We next
tested whether the RUNX1 peaks in SEM cells were generally en-
riched at SE regions and found enrichment over all H3K27ac-pos-
itive regions (4.4-fold, P-value 5 × 10−44) (Fig. 3C). Importantly,
E/R-regulated sites (based on the eRNA level analysis) with
RUNX1 peaks were also enriched at SE regions (6.0-fold, P-value
1.6 × 10−10). Motivated by this observation, we compared the pro-
portion of SEs from CD34+ cells and CD19+/CD20+ cells, which
represent HSC and later stage of B cell differentiation, respectively.
The amount of affected SE regions in CD19+/CD20+ cells was 1.5-
fold higher compared to CD34+ enhancers, and 65% of the SEs
were repressed (Fig. 3D; Supplemental Table S3). These findings
indicate the role for the E/R fusion as an impediment for B cell
differentiation.
In total, among the 534 E/R-regulated H3K27ac regions re-
vealed by the enhancer-centric analysis, 59 were SEs (for the SE-
coordinates, see Supplemental Table S3), and 28 of them (47%)
correlated with an alteration at a nearby gene (for the list, see
Supplemental Table S2). Intriguing examples of repressed SEs
with multiple RUNX1 peaks are the two loci shown in Figure 3E,
Figure 2. Enrichment of TFmotifs at enhancers in the vicinity of E/R-reg-
ulated genes. (A) Enriched TF motifs at putative enhancer regions within
400 kb of the transcription start site (TSS) of E/R-regulated genes are
shown (binomial test with FDR < 0.01 and enrichment in >5% of regions).
P-value, best-known matching TF motif, and the percentage of regions
containing the motif are indicated. The similarity score to known TF motifs
is shown in parentheses. (B,C ) Enrichment of ChIP peaks nearby (max 400
kb from TSS) all expressed genes (gray) or those that were either down-
regulated (blue) or up-regulated (red) by E/R. Horizontal bars show the
percentage of genes associated with a ChIP peak containing either the in-
dicated TF motif (in B) or the ETS-RUNX motif (in C ). P-value of the hyper-
geometric test is shown for statistically significant enrichment in the
repressed group (P < 0.05). The most prominent ChIP peaks from each
data set were used for the analysis. See Supplemental Figure S2 for addi-
tional details.
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containing cancer-related genes SEPT9
and VDAC1 (Peterson and Petty 2010;
Brahimi-Horn et al. 2015).
GRO-seq establishes noncoding
transcript targets of ETV6-RUNX1
Recent findings have indicated a role for
misexpression of long noncoding RNAs
(lncRNAs) in various steps of tumorigen-
esis (Yang et al. 2014). In addition to the
eRNAs, our GRO-seq profiling revealed
28 novel E/R-regulated lncRNA tran-
scripts, which were manually classified
as either antisense RNAs (14) or inter-
genic RNAs (14) to depict their putative
function (Supplemental Table S4). One
of the most robustly E/R down-regulated
and annotated lncRNA was LOC728175
(uncharacterized transcript), which is
associated with a SE region in CD19+/
CD20+ cells (Fig. 4A). Down-regulation
of LOC728175 was confirmed by RT-
qPCR at mature RNA level after E/R
induction (Fig. 4B). In evaluating the
clinical relevance of this finding, we ana-
lyzed its expression in patient samples.
RNA-seq measurement revealed that
LOC728175 expression was lower among
E/R-positive patients (n = 9), compared to
other precursor B-ALL subtypes (n = 8)
(Fig. 4C). Similarly, an E/R-regulated
noncoding transcript near the SE region
of CLEC2D locus (Fig. 4D) was repressed
among E/R-positive patients (Fig. 4E,F).
Overall, among the de novo transcripts
regulated by E/R in GRO-seq (57 tran-
scripts), 15 showed concordant change
in expression (adjusted P < 0.05)
(Supplemental Table S4).
ETV6-RUNX1 regulates cell
adhesion and transmembrane
signaling pathways
As SEs are essential in differentiation,
their enrichment suggested significant
consequences for cellular pathways. The
enhancer-centric approach in parallel to
transcript-centric approach jointly impli-
cated 183 coding and 13 noncoding an-
notated transcripts as E/R targets in a
Runt DNA-binding domain-dependent
manner (Supplemental Table S5). To un-
veil the pathways implicated, we per-
formed gene ontology analyses for the
transcript-centric gene list using the
DAVID software (Huang et al. 2009) and
for the enhancer-centric regulatory re-
gion list by using the GREAT software
(see Supplemental Material; McLean
et al. 2010). Interestingly, genes related
to cell adhesion and transmembrane or
Figure 3. eRNA transcription profiles reveal E/R targets and repression at SE regions. Histograms of
GRO-seq coverage are shown at RUNX1-bound genomic regions comparing control (LUC), E/R mutant
(E/Rmut), and wild-type E/R samples (A) and across the time series of E/R induction (B). Signal profile rep-
resents the most prominent intergenic RUNX1 ChIP peaks from SEM cells centered by the RUNX1 motif.
Early repression of eRNAs is evident at the center of RUNX1-bound sites upon expression of E/R but not E/
Rmut. (C) Enrichment of RUNX1 ChIP peaks in SEM cells at SE regions over regular H3K27ac regions is
shown. The fold enrichment at SE regions is indicated for all peaks (P-value <10−50), top 1000 peaks
(P-value 5.2 × 10−44), and E/R-regulated RUNX1 peaks (P-value 1.6 × 10−10). (D) Proportion of E/R-reg-
ulated SE regions in CD34+ or CD19+/CD20+ cells is shown as bar plots. Down-regulation and up-regu-
lation are indicated in blue and red, respectively. In total, 37 of 500 SEs in CD19+/CD20+ were regulated
by E/R, a 1.5-fold excess compared to CD34+ cells (22 of 452 SEs in CD34+). (E) GRO-seq signal tracks at
representative E/R-regulated SEs are shown. Repression of eRNA signal at prominent RUNX1 ChIP peaks
(highlighted in the figure) is observed in the vicinity of SEPT9 and VDAC1 genes. Transcript variants 10
and 11 of SEPT9 are shown in the RefSeq track. Two biological replicates of each GRO-seq sample
(Nalm6-LUC, Nalm6-E/R, Nalm6-E/Rmut) are shown with different shades of color, and signals above
and below the axis indicate plus and minus strands, respectively. RUNX1 ChIP peaks in SEM cells are
shown in light red overlaid with the input control in shades of blue and purple. SE track is based on
CD19+/20+ cell data from Hnisz et al. 2013. Layered H3K27ac track indicates active enhancers and is
shown as an overlaid signal from seven cell lines retrieved from ENCODE (The ENCODE Project
Consortium 2012). Color key: GM12878, red; H1-hESC, yellow; HSMM, green; HUVEC, light blue;
K562, blue; NHEK, purple; NHLF, pink.
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intracellular signalingwere highly ranked among functional anno-
tation groups in both analyses (Fig. 5A; for detailed results, see
Supplemental Table S6).
This prompted us to examine the genes related to cell adhe-
sion and signaling more closely. Knockout of ITGA4, a gene that
belongs to the enriched integrin signaling pathway (Fig. 5A) and
encodes a transmembrane subunit of the VLA4 receptor, results
in a differentiation block prior to pro-B cell stage in mouse
(Arroyo et al. 1996). A locus containing ITGA4 is among the E/R-
regulated SE regions that contain a ChIP peak for RUNX1 (Fig.
5B), suggesting direct binding. As shown in Figure 5C, expression
of the mature ITGA4 transcript was repressed by E/R containing
the wild-type Runt domain and up-regulated in REH shE/R-knock-
down cells.We confirmed direct binding of wild-type E/R at ITGA4
promoter, coinciding with SE, with a ChIP experiment using ETV6
antibodies (Fig. 5D). The direct effect was further supported by the
lack of ChIP-enrichment of the E/Rmut sample.
We also investigated E/R targets between different RUNX1 fu-
sions and observed LAT2 (linker for activation of T-cells family
member 2), a signaling transmembrane protein, as a shared target
for E/R and the RUNX1-RUNX1T1 fusion (Brdicka et al. 2002;
Janssen et al. 2003; Duque-Afonso et al. 2011a). In acute myeloid
leukemia, binding of the RUNX1-RUNX1T1 fusion results in
widespread alterations throughout the epigenome (Ptasinska
et al. 2012, 2014). A binding site for RUNX1-RUNX1T1 (Duque-
Afonso et al. 2011b) at intronic region 3 of LAT2, which contains
prominent peaks in RUNX1-ChIP assay, wasmarkedly repressed in
GRO-seq by the E/R fusion (Fig. 5E). Repression of mature LAT2
transcript was evident after E/R induction, whereas up-regulation
was detected in REH shE/R-knockdown cells (Fig. 5F). Both
Figure 4. E/R-regulated noncoding genes retain altered expression in patient samples. (A) GRO-seq and ChIP-seq signals (as in Fig. 3E) indicate down-
regulation of LOC728175 transcription by E/R, likely through a RUNX1 binding site located at TSS. (B) E/R-mediated down-regulation of LOC728175 in
Nalm6-E/R cells as measured by RT-qPCR after 24 h of E/R induction. Expression was normalized to the housekeeping gene GAPDH. A representative ex-
periment is shownwith technical variation (lowest and highest datumwithin 1.5 × IQR). (C ) RNA-seq normalized count values for LOC728175 among E/R-
positive (t12;21) and E/R-negative (other) patients indicate lower expression in the E/R-positive group (adjusted P-value 0.37; E/R, n = 9; other, n = 8). (D)
GRO-seq and ChIP-seq signals shown at a locus containing three repressed genes (LOC374443, CLEC2D, and a de novo transcript E/R54) and colocalizing
with RUNX1-binding sites. Tracks are as in Figure 3E. (E) RNA-seq normalized count values for LOC374443 and CLEC2D show that decreased expression is
maintained at the diseased state (LOC374443 adjusted P-value 0.020; CLEC2D adjusted P-value 0.027). No reads mapped to E/R54. (F ) Combined micro-
array data indicate repression of CLEC2D among E/R-positive patients. In each comparison, statistical significance (Mann-Whitney U test) was tested against
E/R-positive subtype: (∗∗∗) P < 0.001; (∗∗) P < 0.01. Tukey whiskers are shown for each box plot (1.5 × IQR).
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ITGA4 and LAT2were consistently repressed in a large patient data
set among E/R-positive patients (Fig. 6A).
ALL patient data sets discern ETV6-RUNX1 targets
In examining the persistence of observed changes in overt disease,
we compiled a large single-platform gene expression data set from
the GEO microarray repository, including 664 precursor B-ALL
samples of all ages and with known genetics (Supplemental
Material; Heinäniemi et al. 2013; Liuksiala et al. 2014). This was
alsomotivated by the limited overlap between previousmicroarray
studies in patients (Supplemental Fig. S3D; Supplemental
Material) and cell culture models (Fuka et al. 2011; Linka et al.
2013). With the unified sample set, a quarter (35/133) of the E/R
fusion targets identified by the GRO-seq and measured in the mi-
croarray data set were found differentially expressed between E/R-
positive and E/R-negative ALL samples (Supplemental Table S7).
The correlation between the log2 fold changes of the 35 differen-
tially expressed genes was significant (Pearson’s correlation coeffi-
cient 0.529 with a P-value of 0.0011) (Fig. 6B). In a majority of the
genes (23/29), concordant alterations were observed in RNA-seq
analysis of a cohort of pediatric ALL patients consisting of nine
E/R-positive and eight other precursor B-ALL patients (13/29
with adjusted P < 0.05) (Supplemental Table S7).
Discussion
Enhancers represent key control switches that regulate initiation
of transcription at nearby gene loci by integrating signals from
multiple TFs (Arner et al. 2015). Transcription of eRNA is consid-
ered the most precise mark of functional looping between an acti-
vated enhancer and its regulated gene promoter, and the dynamic
changes observed in eRNA levels allow elucidation of key TFs upon
cell differentiation and environmental stimuli (Wang et al. 2011;
Kaikkonen et al. 2013). We present here the first application of
eRNA quantification to elucidate aberrant transcriptional activity
downstream from a fusion TF. With our controllable cell model
coupled to GRO-seq, we were able to identify E/R targets at both
regulatory regions and at protein-coding and noncoding genes.
To establish a link between regulatory region activity and gene
transcription downstream from E/R, a correlation-based approach
was applied to link enhancers to target genes and combined with
motif annotation and ChIP-seq data. Further, we used themutated
E/R to exclude effects that did not involve direct DNA binding.
Complementary experimental validation using an ETV6 ChIP as-
say showed that a promoter region of ITGA4 was bound by the
E/R fusion and not by its mutated form. This demonstrates how
the initial regulatory map based on GRO-seq signal correlation
can be further validated and refined.
Directly measuring nascent RNA production, GRO-seq by-
passes issues of antibody specificity and cross-linking efficiency
Figure 5. Transmembrane signaling is affected by E/R. (A) Excerpt of the
most significantly enriched gene ontology and pathway terms for E/R-reg-
ulated transcript-centric and enhancer-centric analyses (see also
Supplemental Table S6). (B) GRO-seq and ChIP-seq signals at the ITGA4 lo-
cus are shown as in Figure 3E. The annotated SE region present in both
CD19+/CD20+ cells and CD34+ cells (Hnisz et al. 2013) harbors a promi-
nent RUNX1 peak downstream from the TSS. This RUNX1 peak is referred
to inD. The primary transcript is repressed by E/R. (C) ITGA4mRNA expres-
sion level as measured by RT-qPCR after 24 h of E/R induction (Nalm6-E/R)
or after silencing of endogenous E/R in REH cells (REH-shE/R). A represen-
tative experiment with technical variation (1.5 × IQR) is shown. Expression
is normalized to the housekeeping gene GAPDH. (D) ETV6 ChIP assay with
qPCR (primer sites are in the middle of the RUNX1 peak highlighted in B)
validates the binding of E/R after 24 h induction, while E/Rmut, LUC, or
nonspecific IgG antibody shows no enrichment in comparison to the con-
trol region at the GAPDH promoter area. A representative figure of two in-
dependent ChIP experiments is shown. (E) LAT2 transcript is repressed in
Nalm6-E/R cells (refer to Fig. 3E for tracks). Dashed boxes indicate the
TSS and intron 3 of LAT2. (F) Expression of LAT2 mRNA relative to house-
keeping gene HMBS as measured by RT-qPCR after induction of E/R for 24
h or after silencing of endogenous E/R in REH cells. A representative exper-
iment is shown with technical variation (1.5 × IQR).
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associated with ChIP assays (Slattery et al. 2014). Moreover, map-
ping between an enhancer and gene transcription is achieved
more directly than by integrating mature transcript levels. By de-
tecting de novo eRNAs in the vicinity of annotated E/R-regulated
genes, and in an alternative approach by quantifying eRNA levels
at previously characterized enhancers, we observed a rapid repres-
sion of prominent RUNX1 binding sites, and RUNX1 and ETSmo-
tifs, as underlying the global changes in eRNA levels and gene
transcription upon E/R induction. Typically, the gene loci that
were concomitantly repressed harboredmultiple E/R-regulated en-
hancers with prominent RUNX1 peaks. Significant regulatory ef-
fects at enhancers translated into significant alterations of
transcription at nearby genes in one-third of genomic loci. Lack
of more complete concordance may reflect complex regulatory
mechanisms or imply a role for E/R in epigenetic remodeling
that impact the region with a delay.
Recently, a subset of T-ALL patients was found to harbor mu-
tations near the oncogenic TAL1 locus that leads to establishment
of a highly active SE via MYB binding (Mansour et al. 2014). We
observed enrichment of E/R-regulated RUNX1 binding sites in
SEs. Moreover, several affected binding sites localized to gene
loci with an established role in cancer, including SEPT9 and
VDAC1. Intriguingly, SEPT9 is a leukemic fusion partner for
KMT2A (MLL) and associated with oncogenic signaling pathways
in many cancers (e.g., by interacting with HIF-1-alpha) (Peterson
and Petty 2010), and the knockout of VDAC1 in mouse induces
tumor growth (Brahimi-Horn et al. 2015). Accompanying these
potential oncogenic changes, repression of super-enhancers asso-
ciated with CD19+/CD20+ cells could underlie the differentiation
arrest at the pro-/pre-B cell stage in E/R-positive patients and pro-
vide further evidence implicating regulatory regions in cancer de-
velopment (Hnisz et al. 2015).
Our main finding that approximately two-thirds of E/R tar-
gets were repressed is in accordancewith early reports that suggest-
ed a repressive role for E/R (Hiebert et al. 1996; Fenrick et al. 1999;
Guidez et al. 2000). Although the majority of the E/R targets were
repressed, one-third of them were up-regulated, possibly through
other TFs such as ETS factors as suggested by motif analysis, and
a few of the genes were regulated independently of DNA binding
through the Runt domain, suggesting indirect effects (data not
shown). One potential caveat in our experimental setup is the ec-
topic expression of E/R, which may allow nonspecific DNA bind-
ing. To moderate possible cell-line–specific effects and to aid in
distinction of clinically relevant targets, we integrated data from
patient samples. We were able to pinpoint a considerable number
of genes targeted by E/R within hours of induction that were also
present in primary ALL patients carrying the t(12;21) transloca-
tion. In future, it would be informative to evaluate E/R targets dur-
ing various stages of early B lymphopoiesis to better understand
the dynamics of disease initiation.
In conclusion, we demonstrate that E/R functions as a repres-
sive TF at genomic sites containing the RUNX1motif. Based on our
results and literature (Schindler et al. 2009; van Delft et al. 2011),
we suggest that E/R impairs B cell differentiation through tran-
scriptional reprogramming and renders pre-leukemic cells suscep-
tible to additional genetic hits for an extended period of time. The
results pave the way for further characterization of the TF network
that mediates commitment to B cell fate and the specific contribu-
tion of leukemic TF fusions derailing this process.
Methods
Cloning, cell culture, and chromatin immunoprecipitation
pLVX-Tight-Puro-ETV6-RUNX1 (E/R) construct was generated
by cloning ETV6-RUNX1 cDNA (a kind gift from Professor
Renate Panzer-Grümayer) into the inducible expression vector
(Clontech). Point mutation G1553Awas introduced by site-direct-
ed mutagenesis resulting in the E/Rmut construct. The shE/R con-
struct was generated by cloning short hairpin RNA (shRNA) oligos
targeting ETV6-RUNX1 (target sequence GAATAGCAGAATGC
ATACTT) into pLVX-shRNA1 vector (Clontech). Nalm6-cells
(ACC 128, DSMZ) were infected with the regulatory vector
TetOn and subsequently with one of the pLVX response vectors:
E/R, E/Rmut, or LUC (luciferase control) (Clontech). The expression
of E/R in Nalm6-cells was induced with 500 ng/mL doxycycline
(Clontech) and confirmed by RT-qPCR and Western blotting.
RT-qPCR was performed using iScpript (BioRad) and SsoFast
EvaGreen Supermix (BioRad), and the relative 2−ΔΔCT method
(Livak and Schmittgen 2001) was used for quantification.
Western blot to detect E/R was performed using anti-ETV6
(HPA000264, RRID:AB_611466, Atlas Antibodies). For chromatin
immunoprecipitation (ChIP), 2 × 107 cells per immunoprecipita-
tion were harvested after 24 h induction and cross-linked using
ethylene glycol bis[succinimidylsuccinate] (EGS) (Thermo Fisher
Scientific) and formaldehyde (J.T. Baker, Avantor). Two antibodies
against ETV6 were pooled for IP (sc-166835, RRID:AB_2101020
Figure 6. Patient data indicate that E/R-perpetuated changes persist at diagnostic samples. (A) Expression of ITGA4 and LAT2 in microarrays shows re-
pression among E/R-positive patients compared to other subtypes: (MLL) KMT2A (MLL) rearranged; (HD) hyperdiploid; (HSC) hematopoietic stem cells. In
each comparison, statistical significance (Mann-Whitney U test) was tested against the E/R-positive subtype: (∗∗∗) P < 0.001; (∗∗) P < 0.01; (∗) P < 0.05. (B)
Concordance between differentially expressed genes on GRO-seq and combined microarray (Pearson’s correlation coefficient 0.529, P = 0.0011)
(Supplemental Table S7).
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[Santa Cruz Biotechnology] and HPA000264, RRID:AB_611466
[Atlas Antibodies]).
Further details and all primer sequences are listed in
Supplemental Material.
GRO-seq assay and processing of GRO-seq and ChIP
sequencing reads
The nuclei isolation (yielding ∼5 × 106 nuclei per condition), the
nuclear run-on reaction, and library preparation were performed
as previously described (Wang et al. 2011, Kaikkonen et al. 2013;
Supplemental Material). The ChIP-seq data from human HSC
and SEM cells (GSE45144, Beck et al. 2013; GSE42075,
Wilkinson et al. 2013; originallymapped to hg18) were reanalyzed
starting from raw reads. See Supplemental Material for details of
processing and visualizing the GRO and ChIP sequencing reads.
Genomic regions used in analysis
ChIP-seq: Peak detection was performed using HOMER program
findPeaks style factor (http://homer.salk.edu/homer/ngs/peaks.
html) against the respective control (IgG or input). Due to the dif-
ferent number of peaks called from each experiment, the 1000
peaks with highest enrichment were used to represent prominent
binding of the TF in question (HOMER program getTopPeaks.pl)
(Supplemental Fig. S2). Hypergeometric P-values for RUNX1-
peak enrichments were calculated for greater or equal difference
than observed.
GRO-seq: TheHOMER program findPeaks.pl was used to iden-
tify de novo transcripts from GRO-seq data using a pooled read
library and allowing gaps at nonmappable regions. Transcript cat-
egories identified and further details are described in Supplemental
Material.
Differential expression analysis of GRO-seq transcripts
Transcript quantification is described in detail in the Supplemen-
tal Material.
For the transcript-centric analysis, transcripts expressed at a
level RPKM> 1 (reads per kilobase per million mapped reads) in
at least two samples and with at least 20 reads within the quanti-
fied region in any sample were used for statistical analysis, exclud-
ing snoRNAs. Differentially expressed transcripts were identified
using the R/Bioconductor package edgeR (Robinson et al. 2010).
A linear model was fitted to the RLE-normalized data using a
group-mean design matrix. Contrasts between the different
conditions were performed, and transcripts with at least 1.5-fold
change in expression level and adjusted P-value < 0.05
(Benjamini-Hochberg method using P-values from moderated t-
test) were defined as significantly regulated (Benjamini and
Hochberg 1995). The correlation and Euclidean distance between
the log2 fold change values observed for the transcript and dynam-
ically regulated eRNAs (as defined above) ±400 kb from TSS was
used to assign candidate regulatory elements for each transcript.
The transcript-centric analysis was coupled with TF motif enrich-
ment analysis ±400 kb from significantly regulated genes (for fur-
ther details, see Supplemental Material).
For the enhancer-centric analysis, the eRNAs passing the ex-
pression level-based cutoffs (RPKM 2.5 and at least 10 reads) at an-
notated B cell, HSC, and RUNX1-bound enhancers based on
previously reported H3K27ac ChIP-seq data (Hnisz et al. 2013),
and the top ChIP-seq peaks in HSC (GSE45144) and SEM cells
(GSE42075), were included in the statistical analysis, performed
as above. The eRNAs with adjusted P-value < 0.1 and lacking a re-
sponse in the E/Rmut sample were associated with nearby genes
based on log2 fold change values of eRNA and gene body transcrip-
tion, similarly as above. Further, only gene transcripts with signifi-
cant change (two-tailed t-test) between E/R 24 h and LUC were
reported. Notice that this approach performs multiple testing
corrections on eRNA changes and prioritizes E/R regulation at
enhancers, with no fold change cutoff for associated gene tran-
scripts applied, compared to the transcript-centric analysis. Con-
sistent with the gene transcription profiles, multidimensional
scaling of the eRNA profiles grouped biologically similar samples
together (Supplemental Fig. S3C), validating the enhancer-centric
approach as a complementary way to improve detection of E/R
targets.
Microarray data set and RNA sequencing
The microarray data were retrieved from the NCBI GEO database
representing healthy and malignant hematological samples hy-
bridized to Affymetrix GeneChip Human Genome U133 Plus 2.0
array (for GSE accession numbers, references, and further details
of data processing, see SupplementalMaterial). Differential expres-
sion was defined by a minimum absolute log2 fold change of 0.5
between group medians and maximum Q-value of 0.01.
Publicly available RNA-seq data for 17 primary BCP-ALL pa-
tients were obtained from the Gene Expression Omnibus data set
GSE79373. The data were available from nine BCP-ALL patients
harboring the ETV6-RUNX1 fusion gene and eight BCP-ALL pa-
tients without ETV6-RUNX1 (hyperdiploid n = 7, other n = 1).
Aligned reads were summarized using featureCounts (Liao et al.
2014). Differential expression was performed using the DESeq2
package in R (Love et al. 2014). Expression analysis was only run
on the regions selected based on GRO-seq: 35 E/R-regulated pro-
tein-coding genes (intersect of GRO-seq data and the combined
microarray analysis) and 57 de novo regions. See Supplemental
Tables S4 and S7 for normalized count values used in RNA-seq
box plots.
Data access
GRO sequencing data generated in this study have been submitted
to the NCBI Gene Expression Omnibus (GEO; http://www.ncbi.
nlm.nih.gov/geo/) under accession number GSE67519.
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ABSTRACT
Methodological advances that allow deeper characterization of non-coding elements in the genome have
started to reveal the full spectrum of deregulation in cancer. We generated an inducible cell model to
track transcriptional changes after induction of a well-known leukemia-inducing fusion gene, ETV6-RUNX1.
Our data revealed widespread transcriptional alterations outside coding elements in the genome. This
adds to the growing list of various alterations in the non-coding genome in cancer and pinpoints their role
in diseased cellular state.
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Approximately 80 % of the genome is transcribed into RNA
species in at least some cell type or at some stage of develop-
ment.1,2 Non-coding regulatory (non-housekeeping) RNAs are
currently deﬁned by their size, genomic location or presump-
tive function. Enhancer RNAs (eRNA), which have a length
span from 0.1 to 10 kb, mainly fall into the category of long
non-coding RNAs (lncRNAs) although they are better deﬁned
by their transcriptional regulatory function. Larger clusters of
enhancers with multiple transcription factor (TF) binding sites
and open chromatin marks are termed super-enhancers and
they deﬁne cell identity.3,4 Locations of enhancer elements are
often deduced from certain histone marks (H3K4me1,
H3K27ac), transcription factor binding proﬁles (p300), or open
chromatin states (eg. DNAse- and ATAC-seq). The develop-
ment of global nascent RNA sequencing techniques, such as
global run-on sequencing (GRO-seq),5 has revealed that tran-
scription of eRNAs is highly correlated with marks such as
H3K27ac (for review see ref. 6) and to transcription at nearby
gene promoters,7,8 and is considered the most reliable mark of
an active enhancer.7,9 The functions of eRNAs are yet unclear:
they can be passive byproducts of transcription or function
actively in recruitment of transcription factors (reviewed in
ref. 10), like in the case of Yin-Yang (YY)1.11
Misregulation of ncRNAs is common in cancer although
recurrent structural variations have been challenging to ﬁnd.
For example, in a study with whole-genome sequencing of 150
tumor/normal pairs of chronic lymphocytic leukemia, only one
recurrent non-coding mutation cluster was found at a potential
regulatory element.12 However, this may also reﬂect the lacking
annotations. We recently analyzed whole genome sequencing
data from precursor B-cell acute lymphoblastic leukemia
(pre-B-ALL) in the context of chromatin architecture and
found that the topologically associated domains with the
highest number of breakpoints contained unannotated
ncRNAs.13 Functional studies manipulating lncRNA produc-
tion in leukemia have shown diverse roles in cancer-related
pathways.14-16 In addition, functional studies on enhancers
have highlighted their overall role in cancer, as reviewed in
ref. 17. In leukemia, somatic mutation of a non-coding element
generated a MYB binding site upstream of oncogenic TAL1
locus, and a deletion of the mutated (but not wild type allele)
super-enhancer in a T-ALL cell line decreased expression of
TAL1 and impaired cell survival.18 Altered transcription at
enhancers may also result from structural or quantitative
changes in both enhancer elements and their regulating
proteins. Duplication of NOTCH1-driven MYC enhancer
was observed in T-ALL and its relevance demonstrated in
a mouse knockout model.19 Moreover, aberrations in chro-
matin structure and especially in insulator regions induce
abnormal gene expression, as exempliﬁed by activation of
TAL1 due to a deletion of upstream insulator element.20
Misregulated transcription during delicate differentiation
processes in haematopoietic precursors may also cause
cancer by predisposing to secondary mutations. Conver-
gent transcription and RNA polymerase II stalling strongly
correlate with structural variation clusters and seem to
provide vulnerable regions for RAG and AID mediated
double strand breaks in lymphoma and leukemia.13,21
Although ncRNA expression proﬁles using microarray or
RNA-seq have been published (eg. refs. 22-26), many
nascent transcripts have remained unnoticed because of
rapid degradation of several ncRNA species. New methods
to address this challenge have emerged, such as GRO-seq,
PRO-seq or TT-seq that enable monitoring various
nascent transcripts and engaged RNA polymerase II in
leukemia.27,28
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We addressed this issue in the ETV6-RUNX1 (E/R, TEL-
AML1) fusion positive leukemia,30 which represents 25 %
of pediatric acute lymphoblastic leukemias, and causes alter-
ations in gene expression that predispose to leukemia.29
With the help of an inducible E/R cell model and GRO-seq,
we explored dynamics of gene expression and the activity
of their regulatory elements simultaneously, exposing the
transcriptional circuitry downstream of the E/R fusion
(Fig. 1).30 We analyzed enhancers based on eRNA
correlation with GRO-seq signal change at differentially
expressed genes (transcript-centric approach). Secondly, we
generated an enhancer-centric approach that directly
applied the statistical framework on eRNA levels to identify
signiﬁcantly regulated enhancers (enhancer annotation was
based on H3K27ac and RUNX1 ChIP-seq data) and corre-
lated these changes to that of nearby transcripts. We found
at least one similarly altered putative enhancer element
within C/¡400 kb for almost all the deregulated coding
transcripts using transcript-centric approach. E/R regulated
approximately 20% of transcribed regions with RUNX1
ChIP peaks, and 5% of CD19/20 (B-cell)-related enhancers.
Interestingly, CD19/20 speciﬁc super-enhancers were mostly
downregulated, implying a way for E/R to arrest cell
differentiation.
It has been proposed that any transcription may possess
regulatory activity. A recent study showed that half of the
studied transcribed gene loci (12 lncRNA and 6 mRNA)
regulated a nearby gene in cis independently of whether the
locus was a coding or non-coding one.31 As the non-coding
genome is only weakly conserved,1,32 most non-coding
regions may function in a way which is not dependent on
the sequence of transcript itself but rather the sequence of
its promoter or its location in the genome. In the case of
E/R leukemia, we classiﬁed 57 deregulated novel lncRNAs
(over 5 kb long) as either potential eRNAs or lncRNAs
based on the GRO-seq signal. One fourth of the novel and
3 of 7 annotated transcripts were concordantly differentially
expressed in RNA-seq data with 8 E/R-positive and 9 other
subtype pre-B-ALL patients.30 For example, KCNQ1OT1,
which acts in epigenetic regulation,33-35 was upregulated in
our E/R cell model GRO-seq and the patient
RNA-seq data. Signal changes at ZEB1 and ZEB1-AS1 serve
as an example of a simultaneous downregulation of gene
and its promoter-associated RNA, with ZEB also being
linked to cancer36,37 and late B cell differentiation.38 Func-
tional roles of the novel transcripts in E/R leukemia
remains to be explored in future. Nascent RNA proﬁles of
diagnostic patient samples of distinct ALL subtypes will
give further insights into the derailed transcriptional net-
work downstream of the oncogenic TF fusions.
Already, thousands of regulatory lncRNA transcripts39
and hundreds of thousands of enhancer regions have been
found. It is now known that ncRNAs are widely speciﬁc to
a certain cell type and developmental stage. For example,
most lncRNAs that are expressed at various stages of mouse
B cell development are not expressed in a closely related T-
cell lineage.40 A recent study noted that distal regulatory
elements varied across distinct haematopoietic lineages so
that they are better discriminators of cell identity than
mRNA levels.41 This was also reﬂected in our work, where
we noticed that sample separation based on quantiﬁcation
of global eRNA transcription was equally good as that based
on quantiﬁcation of transcription at protein coding
regions.30 We can assume that the increasing knowledge of
the interplay between various elements of genome and their
transcriptional products will signiﬁcantly contribute to our
understanding of the diverse types of leukemia and cancer
in near future.
Figure 1. (A) A schematic representation of the ETV6-RUNX1 (E/R, TEL-AML1)
fusion protein resulting from a recurrent t(12;21) translocation in pediatric pre-B
acute lymphoblastic leukemia. ETV6-RUNX1 includes the pointed (PNT) domain of
ETS variant 6 (ETV6) but lacks the ETS domain that is involved in DNA binding of
the normal TF protein. The 480 aa long RUNX1 variant 1 (AML-1c, NP_001745) is
illustrated with the point mutation R201Q in the Runt domain which impedes its
DNA binding capability (this was used to generate E/Rmut in ref. 30). ID D Runx
inhibitory domain. (B) GRO-seq signal (nascent RNA transcription) is shown for E/R-
negative as red and E/R-positive samples as blue tracks at an example genomic
region. Signals above and below the axis indicate plus and minus strands, respec-
tively. RUNX1 ChIP peaks in SEM cells (GSE42075, ref. 42) and an enhancer marker
H3K4me1 ChIP-seq in B-cells (GM12878, ref. 2) are shown and coincide with the
GRO-seq signal. Three enhancer regions that are downregulated by E/R via
RUNX1-mediated binding are highlighted. Nalm6-E/R D 24h expression of E/R in a
pre-B-ALL cell line; REH D E/R-positive cell line; pre-B-ALL other D E/R-negative
patient; pre-B-ALL E/RC D E/R-positive patient.
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Abstract Progression of malignancy to overt disease requires multiple genetic hits. Activation-
induced deaminase (AID) can drive lymphomagenesis by generating off-target DNA breaks at loci
that harbor highly active enhancers and display convergent transcription. The first active
transcriptional profiles from acute lymphoblastic leukemia (ALL) patients acquired here reveal
striking similarity at structural variation (SV) sites. Specific transcriptional features, namely
convergent transcription and Pol2 stalling, were detected at breakpoints. The overlap was most
prominent at SV with recognition motifs for the recombination activating genes (RAG). We present
signal feature analysis to detect vulnerable regions and quantified from human cells how
convergent transcription contributes to R-loop generation and RNA polymerase stalling. Wide
stalling regions were characterized by high DNAse hypersensitivity and unusually broad H3K4me3
signal. Based on 1382 pre-B-ALL patients, the ETV6-RUNX1 fusion positive patients had over ten-
fold elevation in RAG1 while high expression of AID marked pre-B-ALL lacking common
cytogenetic changes.
DOI: 10.7554/eLife.13087.001
Introduction
In precursor lymphoblastic leukemia, primary genetic lesions often arise in utero (Wiemels et al.,
1999; Mori et al., 2002; Maia et al., 2003, Bateman et al., 2015), while the onset of overt disease
requires additional genetic alterations. Whole-genome sequencing (WGS) of ETV6-RUNX1 (also
known as TEL-AML1) positive acute leukemias suggested that the secondary lesions are predomi-
nantly caused by off-target activity of the RAG complex (Papaemmanuil et al., 2014). In a similar
fashion, the expression of the AID complex in more mature B cells is implicated in genomic instabil-
ity and development of lymphomas (Meng et al., 2014; Qian et al., 2014; Robbiani et al. 2015). To
date, WGS in leukemia have been reported from several pre-B-ALL subtypes (Andersson et al.,
2015; Holmfeld et al., 2013; Paulsson et al., 2015; Zhang et al., 2012), resulting in a comprehen-
sive characterization of the underlying genetic alterations. Therefore, the research focus on leukemia
genetics is moving into characterization of the mechanisms by which these lesions occur and the con-
sequences of the resulting clonal heterogeneity.
Antigen receptor genes are assembled from discrete gene segments by RAG-mediated V(D)J
recombination at sites of recombination signal sequences (RSS) during early lymphocyte
Heina¨niemi et al. eLife 2016;5:e13087. DOI: 10.7554/eLife.13087 1 of 26
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development (Gellert 2002; Schatz and Swanson, 2011). Cells incorporate multiple strategies to
control the action of the RAG complex to appropriate genomic loci: the expression of RAG1 and
RAG2 is limited to precursor stages of lymphocytes, the activity of the complex is attenuated during
S-phase of cell cycle, and RAG cleavage is directed towards RSS pair containing sequences
(Schatz and Swanson, 2011). The engagement of RAG2 is further limited by the histone modifica-
tion H3K4me3, which is typically found at transcription start sites (TSS) (Matthews et al., 2007;
Teng et al., 2015). However, RSS and RSS-like motifs are found only at around 7–40% of break-
points at SV (genomic imbalance, translocation or inversion) sites (Andersson et al., 2015;
Papaemmanuil et al., 2014). Furthermore, the RSS motifs and H3K4me3 occur frequently in the
genome suggesting that additional features, possibly even additional complexes including AID
(Swaminathan et al., 2015), are relevant for the genetic instability underlying leukemia SV.
In lymphomas, AID off-target effects localize to intragenic super-enhancer (SE) and promoter
areas characterized by transcription from both strands, i.e. convergent transcription (convT)
(Meng et al., 2014). Notably, VH gene segment recombination by RAG at the IgH locus coincides
with sense- and antisense transcription (Bolland et al., 2004), which could be relevant also at off-tar-
get sites. Secondly, stalled polymerases, which are found at exons, R-loops and actively paused at
TSS regions (Jonkers and Lis, 2015), expose single stranded DNA, recruiting AID via Spt5 binding
(Pavri et al., 2010). Furthermore, the polymerase complex displaces nucleosomes completely or
partially (the H2A/H2B moiety), which in vitro promotes cleavage by RAGs (Bevington and Boyes,
2013). Despite these intriguing findings, the relevance of transcription-coupled processes has not
been systematically characterized, and the clinical relevance of RAG and AID expression in the differ-
ent leukemia subtypes remains unclear. RNA polymerases engaged into primary transcription across
the genome can be measured using Global-Run-On sequencing (GRO-seq) (Kaikkonen et al.,
2013). Therefore, this method is ideally suited to distinguish features of transcription at SV sites,
including convT and RNA polymerase stalling. To this end, we acquired the first patient profiles of
nascent transcriptional activity in leukemic blasts representing seven cytogenetic subgroups and per-
formed integrative analysis of various genome-wide profiles and patient transcriptomes.
eLife digest Some of the most common cancers found in children are called precursor
leukemias, which may start to develop before birth. Cancerous cells often contain alterations to the
genetic information in their DNA. In precursor leukemias, the most common genetic changes involve
deleting, adding or rearranging segments of the DNA sequence.
Several researchers have sequenced the entire DNA of childhood leukemia cells, with the result
that almost all of the genetic alterations linked to these conditions have been catalogued. These
efforts have shown that certain DNA regions are particularly affected by mutations, but no one
knows why errors occur so frequently in these regions.
Recent evidence also suggests that transcription – the process of producing useful molecules
from a stretch of DNA – can play a role in generating genetic alterations. Heina¨niemi et al. have now
used a technique called global run-on sequencing to measure the extent of transcription in many
different types of leukemia cells. This revealed that in the error-prone DNA regions, two processes –
called convergent transcription and transcriptional stalling – interfere with transcription. Both
processes temporarily leave the normally double-stranded DNA unzipped as two single strands and
free of nucleosomes, which makes DNA more vulnerable to breaking. This would explain how pieces
of DNA might be lost, added, or moved to cause the genetic errors that lead to leukemia.
Further investigation revealed that two protein complexes called RAG and AID, which rearrange
segments of DNA in immune cells, are likely to cause the errors in the vulnerable DNA regions.
Different amounts of RAG and AID were present in different subtypes of leukemia cells, and these
amounts also varied with the risk classification of the disease. Further studies are now needed to
investigate the exact roles of these protein complexes. This could eventually help scientists devise
strategies to protect the DNA of people with leukemia from these errors, which could reduce the
risk of the cancer reoccurring.
DOI: 10.7554/eLife.13087.002
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Figure 1. Integrative analysis of transcription and high-recurrence SV sites highlights novel transcribed regions. (A) WGS data from the ETV6-RUNX1 (51
cases; Papaemmanuil et al., 2014), high hyperdiploid (16 cases; Paulsson et al., 2015), hypodiploid (20 cases; Holmfeldt et al., 2013) and MLL-
Figure 1 continued on next page
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Results
Integrative analysis of transcription and genomic instability in leukemic
cells
Transcriptional activity from ALL cells representing seven different pre-B-ALL cytogenetic subtypes
was assayed using GRO-seq (both primary patient and cell line samples, see Supplementary file 1
and Materials and methods), and jointly analyzed with WGS data from the ETV6-RUNX1 (51 cases;
Papaemmanuil et al., 2014), high hyperdiploid (HeH, 16 cases; Paulsson et al., 2015), hypodiploid
(20 cases; Holmfeldt et al., 2013) and MLL-rearranged (22 cases at diagnosis and 2 relapses;
Andersson et al., 2015) subtypes of precursor B-ALL. GRO-seq signals and breakpoint data are
shown in Figure 1—figure supplement 1 at the CDKN2A locus, a significant SV site in childhood
ALL (Sulong et al., 2009).
To systematically identify regions with high frequency of SV across the genome, topologically-
associated domains (TADs) were retrieved based on HiC data from B-lymphoid lineage cells
(Rao et al., 2014). TADs reflect the three-dimensional structure of chromatin. These natural bound-
aries to transcriptional activity were used to divide the chromosomes into subregions for analysis
(see Figure 1—source data 1 and Materials and methods). To link typical transcriptional activity pat-
terns and hotspots of genomic instability, we related the breakpoint frequency with chromatin
domains, as illustrated in Figure 1A (see also Figure 1—figure supplement 2).
The most frequent SV regions encompass novel transcribed regions
An increasing trend of transcriptional activity was observed when TADs were compared based on
breakpoint frequency quartiles (see Materials and methods, Figure 1—figure supplement 3). TADs
with highest SV count are shown in Figure 1 (see also Figure 1—source data 1 and Figure 1—
Figure 1 continued
rearranged (22 cases; Andersson et al., 2015) subtypes of precursor B-ALL was integrated with profiles of transcriptional activity assayed using GRO-
seq from ALL patient and cell line samples (see also Figure 1—figure supplement 1 and Supplementary file 1). HiC data from B-lymphoid cells
(Rao et al., 2014) was used to define TADs based on the HiC interaction frequency, shown as grey scale heatmap, in order to distinguish TADs with
highest frequency of SV. (B) The PAX5 and ZCCHC7 loci are located in the TAD shown that has high SV frequency in hyperdiploid, ETV6-RUNX1- and
MLL-fusion positive patients (4, 20 and 6 breakpoints, respectively, Figure 1—source data 1). The GRO-seq signal profiles from three pre-B-ALL
cytogenetic subtypes and normal B-lymphoblastoid cells are displayed as indicated in the figure (see also Figure 1—figure supplement 4 and
Figure 2—figure supplement 2). The y-axis shows the normalized read density (plus strand in red, minus strand in blue). convT regions regions are
indicated in purple and leukemia breakpoints in red. The TSS region of PAX5 overlaps convT that co-localized with an intragenic SE (B-lymphoblastoid
H3K27ac track is shown at the bottom). (C) A TAD with the same number of breakpoints (20) in ETV6-RUNX1 patients is shown with signal from REH
cells (see also Figure 1—figure supplement 4). Genomic annotations include the location of GENCODE transcripts (in green). A strong transcription
signal is visible that spans approximately 500 kb near the TAD boundary, lacking annotated transcripts. A zoom-in panel shows the most recurrent SV
site. (D) The TAD visualized represents a genomic region that harbors most SV in HeH (see Figure 1—figure supplement 5 for the hypodiploid SV
hotspot). The GRO-seq signal (track from patient 1) indicates a novel locus with abundant transcription in leukemic samples (refer to Figure 1—figure
supplement 4 for all GRO-seq profiles). The highest recurrence of SV occurs at the convT overlapping mid-region (zoom-in panel), which has also two
ETV6-RUNX1 breakpoints.
DOI: 10.7554/eLife.13087.003
The following source data and figure supplements are available for figure 1:
Source data 1. Identified topologically associated domains.
DOI: 10.7554/eLife.13087.004
Figure supplement 1. Transcriptional activity in leukemic cells from patients, cell lines and primary healthy B-lineage cells is captured in GRO-seq
signals.
DOI: 10.7554/eLife.13087.005
Figure supplement 2. Summary of data used in the integrative analysis.
DOI: 10.7554/eLife.13087.006
Figure supplement 3. Transcriptional activity in TADs binned by breakpoint frequency.
DOI: 10.7554/eLife.13087.007
Figure supplement 4. Data from all signal tracks for regions displayed in Figure 1.
DOI: 10.7554/eLife.13087.008
Figure supplement 5. TAD with frequent SV in hypodiploid patients.
DOI: 10.7554/eLife.13087.009
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figure supplement 4). The PAX5 and ZCCHC7 genes are located within a TAD region with 20 break-
points in the ETV6-RUNX1, 4 in HeH and 6 in MLL subtype (excluding the MLL-fusion itself)
(Figure 1B). Frequent SV were also found in TADs with no annotated coding genes (Figure 1C, 20
breakp in ETV6-RUNX1; Figure 1D, 4 breakp in HeH), yet GRO-seq exhibited transcription signal
spanning several hundred thousand base pairs in both regions, typical of long non-coding transcripts
(Sun et al., 2015). There was evidence of non-coding transcripts, based on Refseq and GENCODE,
but none matched the same location (refer to Supplementary file 2 for all genomic coordinates
shown; a TAD with frequent SV in hypodiploid subtype is shown in Figure 1—figure supplement 5).
The nascent ALL transcriptomes thus reveal novel transcribed regions as recurrent SV-associated
hotspots in the two most common ALL subtypes.
Convergent transcription and RNA polymerase stalling are prevalent at
genomic regions with frequent breakpoint events
The prevailing notion is that active transcription start sites (TSS) in pre-B cells are susceptible to RAG
off-targeting due to the H3K4me3 chromatin mark (Matthews et al., 2007; Teng et al., 2015). How-
ever, we noticed that the recurrent breakpoints often lied several kb downstream of TSS, as
highlighted in Figure 1B and D (see inserts), and coincided with simultaneous transcription on both
strands, ie. convT spanning a minimum of 100 bp. In closer examination of the signal data from leu-
kemia SV hotspots, many of these regions likely correspond to transcription from intragenic
enhancers that generate enhancer RNAs (eRNA) that are typically a few kb in size (Kaikkonen et al.
2013). In agreement, a significant enrichment of breakpoints in enhancers overlapping with convT
was observed (hypergeometric test P=0.00012 for intergenic and P=4.6e-08 for all enhancers identi-
fied based on eRNA signal, see Materials and methods and Figure 2—source data 1). An overlap-
ping eRNA transcript at the TSS region of PAX5, confirmed by the active enhancer chromatin
marker H3K27ac, led to convT extending nearly 20 kb, with SV sites located between 3.7–9.7 kb
downstream of the TSS (Figure 1B, see insert).
Secondly, convT in the vicinity of intragenic breakpoints was often associated with localized eleva-
tion in the GRO-seq signal, as exemplified at the ZCCHC7 and RAG loci (Figure 2A, see also Fig-
ure 2—figure supplement 1). The observed signal features were highly reproducible between
biological replicates and shared among a subset of cytogenetic groups (Figure 2—figure supple-
ment 2). We hypothesized that they represent RNA polymerase II (Pol2) stalling events. Previous
analyses of Pol2 stalling have focused on promoter proximal regions (Adelman and Lis, 2012). To
examine such events genome-wide and across gene bodies, we developed a general analysis
approach that identifies change points within gene regions and reports those with high elevation in
the signal level (see Materials and methods and Figure 2—source data 1 for the identified regions)
(Killick et al., 2012). As additional confirmation, we analyzed stalling from Pol2 ChIP-seq in the REH
and Nalm6 cell lines (Figure 2A). To distinguish between different Pol2 complexes (Zhou et al.,
2012), antibodies against the serine 2 or serine 5 phosphorylated Pol2 were used (see
Materials and methods).
Genome-wide analysis of convT and Pol2 stalling (see Materials and methods and Figure 2—
source data 1) substantiated the relevance of these observations: considering the breakpoint fre-
quency per TAD size, the top ranked TADs in each ALL subtype represented genomic regions with
abundant convT and Pol2 stalling (Figure 2B). Significant enrichment was confirmed for the upper
quartiles (hypergeometric test P=0.00038 in ETV6-RUNX1, P=0.00018 in hyperdiploid, P=0.028 in
hypodiploid and P=0.00004 in MLL-rearranged). The increased overlap was found for breakpoints
with and without RSS motifs (denoted as R-breakp and NR-breakp, see Figure 2—figure supple-
ment 3 and Materials and methods) and it was preserved when total transcriptional activity was con-
sidered (Figure 2—figure supplement 4). Furthermore, the distinct transcriptional profile of
embryonic stem cells (ES) had lower overlap (Figure 2—figure supplement 5).
For comparison, chromatin segmentation of B-lymphoid cells was similarly analyzed (see Fig-
ure 1—source data 1 and Figure 2—source data 1). TADs with high number of breakpoints consis-
tently had significant overlap with chromatin segments representing active transcription (refer to
Figure 2—source data 1), supporting a transcription-coupled mechanism for the observed genetic
instability. We then distinguished regions with overlap to the transcriptional features defined here
within active promoters and enhancers. Comparing these against the TAD SV frequency quartiles
Heina¨niemi et al. eLife 2016;5:e13087. DOI: 10.7554/eLife.13087 5 of 26
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Figure 2. Convergent transcription and Pol2 stalling characterize genomic regions with high number of breakpoint events. (A) The GRO-seq signal in
the ETV6-RUNX1 positive REH cell line is shown to exemplify the co-occurrence of convT (in purple) and local elevation in GRO-seq signal (Pol2 stalling,
Figure 2 continued on next page
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(Figure 2—figure supplement 6), as before, revealed the most pronounced enrichment in convT/
Pol2 stall overlapping regions.
Next, we set out to define what may link convT and Pol2 stalling regions with AID and RAG
recruitment. The signal feature detection for convT (as in Meng et al., 2014) and Pol2 stalling (as
defined here) enables this on a genome-wide level.
R-loop formation and convergent transcription co-occur with Pol2
stalling
RNA polymerases are expected to stall at regions harboring R-loop forming sequences (RLFS)
(Skourti-Stathaki et al., 2014a; Jenjaroenpun et al., 2015). The sensitivity of DNA sequence to
form R-loops can be computationally predicted (Jenjaroenpun et al., 2015) (see
Materials and methods). These RLFS motif containing regions exhibited a significantly higher overlap
with Pol2 stalling sites when compared to random intragenic regions (Figure 3B, empirical P<0.001
in B-lineage and ES cells). A highly concordant local RLFS motif density and GRO-seq signal profile
was observed across gene regions (Figure 3—figure supplement 1A and B). The profiles peaked
near TSS, where the presence of RLFS motifs led to a significant elevation in the median GRO-seq
signal level (Figure 3—figure supplement 1, 2.1-fold increase in B-lineage cells, Wilcoxon rank sum
test P<2.2e-16, 95% CI 2.1–2.3). As a second mechanism, collisions due to convT may halt transcrip-
tion (Prescott and Proudfoot, 2002) in a dynamic and cell-specific manner. Accordingly, higher anti-
sense signal at convT regions (see Materials and methods) increased the overlap with Pol2 stalling
sites on the sense strand (Figure 3B), intriguingly exceeding that observed for RLFS motifs
(Figure 3A).
As an additional experimental validation of R-loops, we used DNA-RNA-immunoprecipitation
sequencing (DRIP-seq) results from ES cells (see Materials and methods) that correspond to detec-
tion of DNA-RNA hybrids (Ginno et al., 2013). The 2.1-fold elevation in median DRIP-seq signal con-
firmed that RLFS motifs favor DNA-RNA hybrid formation (Figure 3C, Wilcoxon rank sum test
P<2.2e-16, 95% CI 2.0–2.1, see Figure 3—source data 2 for each replicate). Moreover, DRIP-seq
quantification showed 1.7-fold higher median signal at convT-positive TSS regions (Figure 3D, Wil-
coxon rank sum test P<2.2e-16, 95% CI 1.6–1.7). These results demonstrate that transcription stall-
ing occurs at RLFS and convT regions in mammalian cells that associates with R-loop formation
based on evidence from ES cells.
Figure 2 continued
in light blue) at both R- and NR-breakp (in red and brown, respectively) that reside within intronic (ZCCHC7), TSS (RAG2) or putative enhancer regions
(RAG2). The elevated signal is also visible in Pol2 ChIP-seq signal (Pol2 S2P in green, Pol2 S5P in orange, input in grey). See also Figure 2—figure
supplement 1. The percentage of TAD spanned by convT (in B) or Pol2 stalling (in C) in pre-B/B-lymphoid cells is summarized as boxplots from TADs
divided into quartiles based on number of breakpoints per bp (see also Figure 1—figure supplement 3, Figure 2—figure supplement 3–6). The
quartile ranges are for exclusive lower and inclusive upper value in the range, as indicated. Refer to Figure 2—source data 1 for statistical analysis.
DOI: 10.7554/eLife.13087.010
The following source data and figure supplements are available for figure 2:
Source data 1. Identified convT and Pol2 stalling regions.
DOI: 10.7554/eLife.13087.011
Figure supplement 1. Data from all signal tracks for regions displayed in Figure 2.
DOI: 10.7554/eLife.13087.012
Figure supplement 2. The GRO-seq signal from replicate samples generated from ALL cells displayed at the PAX5/ZCCHC7 locus.
DOI: 10.7554/eLife.13087.013
Figure supplement 3. Signal feature span for TADs ordered separately by R-breakp or NR-breakp frequency.
DOI: 10.7554/eLife.13087.014
Figure supplement 4. Signal feature span normalized by total transcribed area for TADs sorted by breakpoint frequency.
DOI: 10.7554/eLife.13087.015
Figure supplement 5. Overlap of TADs with convT in ES cells.
DOI: 10.7554/eLife.13087.016
Figure supplement 6. TAD analysis using promoter and enhancer chromatin segments stratified by convT and Pol2 stalling.
DOI: 10.7554/eLife.13087.017
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Figure 3. Indication of transcription-coupled genetic instability at leukemia SV hotspots lacking RSS motifs. (A) Overlap between RLFS motif harboring
intragenic regions and detected Pol2 stalling sites in B-lineage and ES cells. The high overlap of RLFS-positive regions is statistically significant
compared to random regions (empirical P is indicated for 30% and 28% overlaps, respectively). (B) Overlap of detected Pol2 stalling sites also increases
based on the strength of antisense signal level for B-lineage and ES cell convT regions divided into quartiles. (C) The influence of RLFS at TSS on ES
cell DRIP-seq signal level is shown (Wilcoxon rank sum test P is indicated). Input signal levels are shown as control. (D) ES cell DRIP-seq signal is plotted
similarly as in C, from convT-positive and -negative TSS regions. The DRIP-signal is higher in convT-positive TSS (Wilcoxon rank sum test P is indicated,
TSS with convT N = 11774, TSS without convT N = 12092, refer to Figure 3—source data 2 for statistical analysis based on separate DRIP-seq
replicates). (E) The percentages of breakpoint regions with no RSS motifs overlapping intragenic Pol2 stalling sites found in B-lineage cells are shown as
barplots. The mean overlap observed in random sampling is indicated in grey bars (further statistical analysis is presented in Supplementary file 3).
Categories with increasing cut-off for recurrence (1: non-recurrent in dim color, >1 and above: recurrent in darker color) were tested. (F) Overlap with
RLFS, convT and annotated TSS is shown, as in E, for ETV6-RUNX1 NR-breakp (see also Supplementary file 3). (G) A schematic model illustrating how
transcription from both strands (convT) or RLFS can locally arrest the Pol2 complex leading to recruitment of DNA damage-sensing complexes to
R-loops, such as AID or BRCA (Alt et al., 2013, Hatchi et al., 2015), in an RSS-independent manner. (H) NR-breakp hotspot with the highest
recurrence (TPI1 locus) is shown. DRIP-seq signal (shown in tones of red overlaid with input control signal in blue), and RLFS motifs indicated as a
magenta bar track represent two levels of independent data that were integrated with GRO-seq data (signal from REH and ES cells is shown) to
characterize properties of convT and Pol2 stalling regions. The breakpoint data (NR-breakp in brown) and detected convT (in purple) and Pol2 stalling
in B-lineage cells (in blue) are shown. At the the recurrent breakpoint sites antisense transcription of neighboring gene (SPSB2 primary transcript) leads
to a broad convT region, as indicated in the figure. Elevated DRIP-signal indicates formation of DNA-RNA hybrids (see also Figure 3—figure
supplement 3).
DOI: 10.7554/eLife.13087.018
The following source data and figure supplements are available for figure 3:
Source data 1. Breakpoint clustering to regions.
DOI: 10.7554/eLife.13087.019
Source data 2. Statistical analysis of separate DRIP-seq and DNAse-seq replicates.
DOI: 10.7554/eLife.13087.020
Figure supplement 1. GRO-seq, RLFS and DRIP-seq signal profiles across genes.
DOI: 10.7554/eLife.13087.021
Figure supplement 2. Venn diagrams comparing SV within Pol2 stalling regions based on GRO- and ChIP-seq profiles.
DOI: 10.7554/eLife.13087.022
Figure supplement 3. Data from all signal tracks for regions displayed in Figure 3.
DOI: 10.7554/eLife.13087.023
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Transcriptional-coupled instability at RSS-independent SV hotspots
A mechanistic link between R-loops and AID off-targeting has been established in lymphomas
(Alt et al., 2013). With this in mind, we investigated regions where off-targeting could occur via R-
-loops by focusing on breakpoints without RSS-motifs (data shown in figures represents the 416
ETV6-RUNX1 NR-breakp, refer to Figure 3—source data 1 and Supplementary file 3 for all statis-
tical results). We observed significant genome-wide enrichment of breakpoints with the investi-
gated transcriptional features (Figure 3E and F, 29% overlap with Pol2 stalling within gene
regions, binomial test P=4.088e-07; 9% genome-wide overlap with convT, P=5.16e-07). This enrich-
ment of breakpoints to convT and Pol2 stalling regions was significant across a wide range of tran-
scriptional activity (refer to Supplementary file 3). Co-occurrence of breakpoints within a 1-kb
window was used to distinguish non-recurrent (one breakpoint) and recurrent (more than one
breakpoint) events (Figure 3—source data 1). Breakpoint recurrence was found to increase the
overlap with both Pol2 stalling (Figure 3E)and convT (Figure 3F). The mean overlap observed in
1000-fold random sampling (grey bars) confirmed the specificity of the overlap (note that Pol2
stalling is analyzed from intragenic regions only). The breakpoints in Pol2 stalling sites were con-
cordant with analysis using Pol2 ChIP-seq (by 78%) and they co-localized with both Ser2 and Ser5
phosphorylated forms of Pol2 complex (Figure 3—figure supplement 2). A schematic model sum-
marizing the possible underlying mechanisms based on these results is shown in Figure 3G. The
distinct integrated genomic profiles are collectively depicted at the TPI1 loci, representing an SV
hotspot with the highest number of NR-breakp in ETV6-RUNX1 cases (Figure 3H, see also Fig-
ure 3—figure supplement 3 and Figure 2A). At the breakpoint region, both RLFS and convT are
visible and overlap the elevated DRIP-seq signal measured from ES cells.
Access to RAG cleavage sites increases at Pol2 stalling regions
Next, we focused on deciphering whether the transcriptional features associate with RAG off-target-
ing. We hypothesized that locally depleted nucleosomes around the Pol2 complex (Bevington and
Boyes, 2013) may enhance access to RSS/RSS-like sequences. To this end, we retrieved DNAse
hypersensitivity data from ENCODE (The ENCODE Project Consortium, 2012; see
Materials and methods). DNAse-seq signal peaks were significantly wider when overlapping with Pol2
stalling sites (Figure 4A). A 876 bp (95% CI, 855–896) increase was observed in B-lymphoblastoid
cells and 412 bp (95% CI, 395–429) in ES cells (Wilcoxon rank sum test P<2.2e-16 in both cell types,
see also Figure 3—source data 2). This was reproducibly observed using peaks located within gene
TSS, body or end regions (Figure 4A). We selected TSS regions with RSS motifs for closer examina-
tion and found that Pol2 stalling sites at these TSS were significantly wider than at other TSS
(Figure 4B), with a difference of 259 bp (95% CI, 79–475 bp, Wilcoxon rank sum test P=0.0024). Thus,
wide Pol2 stalling increases the likelihood of RSS motif occurrence in accessible chromatin. The width
of stalling did not correlate positively (Pearson’s correlation 0.11; 95% CI, 0.09 to 0.13) with the
transcription level of the corresponding gene, indicating that stalling events, and not just active tran-
scription, are important. We further analyzed the top 5% of widest Pol2 stalling regions by comparing
them to widest peaks from DNAse hypersensitivity and ChIP for histone marks (see
Materials and methods). The odds ratios for the overlap are visualized as a heatmap (see Figure 4C,
OR>10 is shown in darkest color tone, refer to Figure 4—source data 1 for more statistics). In addi-
tion to DNAse-seq and Pol2 ChIP peaks, the H3K4me3 was found among the top category, confirmed
also by ChIP-seq data acquired from REH and Nalm6 cells (Figure 4—source data 1).
Next, the ETV6-RUNX1 R-breakp (335; 156 intragenic) were analysed for the genome-wide over-
lap with the transcriptional features. A 66% overlap was found with Pol2 stalling at intragenic regions
(binomial test P<2.2e-16) and a 44% genome-wide overlap with convT (binomial test P<2.2e-16, see
also Figure 3—source data 1 for joint analysis across pre-B-ALL subtypes). The overlap with Pol2
stalling had high agreement between GRO-seq and ChIP-seq (Figure 3—figure supplement 2) and
it increased at recurrent R-breakp (Figure 4D). In addition, overlap with convT (Figure 4E) was con-
siderable (91%) at regions with 4 or more breakpoints. In comparison, regions with RLFS motifs or
annotated TSSs showed less marked enrichment (up to 36%) (Figure 4E). Similar, as for NR-breakp,
the significant overlap with transcriptional features was preserved at a wide range of expression lev-
els (Supplementary file 3). A schematic model that links the obtained results with vulnerability to
RAG cleavage is shown in Figure 4F. As in Figure 3I, the different profiles are depicted at the SV
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Figure 4. SV with RSS motifs localize to Pol2 stalling regions with broad open chromatin regions. (A) DNA access based on DNAse-seq peak width
(GM12878 or H1 ES from ENCODE) is compared between regions with no Pol2 stalling (no color) and overlapping Pol2 stalling (light blue, cell-specific
Pol2 stalling coordinates are listed in Figure 2—source data 1) at TSS, body and end region of transcripts (refer to Figure 3—source data 2 for
statistical analysis based on separate DNAse-seq replicates). (B) The TSS stalling width is compared between TSS harboring R-breakp and TSS with no
breakpoints (Wilcoxon rank sum test P is indicated, TSS with R-breakp N = 38, TSS without breakpoints N = 11957, 95% CI for size difference 67–491
bp). (C) The 5% widest Pol2 stalling regions were overlapped with similarly defined widest peaks in different ChIP- and DNAse-seq data (refer to
Figure 4—source data 1 for details and all statistics). The odds-ratio (OR) for the overlap is visualized in color from discrete categories (<5; 5–10; >10,
with darker color tones indicating higher OR). Pol2 S5P, DNAse-seq and H3K4me3 peaks had highest OR based on both B-lineage and ES cell data. D
and E: The percentages of R-breakp overlapping Pol2 stalling (as in Figure 3E) or RLFS, convT and annotated TSS (as in Figure 3F) are shown as
barplots, respectively. Overall, the recurrence was higher compared to NR-breakp and therefore two categories for recurrent R-breakp are shown (>2;
>4). The overlap with convT reaches 91% at highly recurrent R-breakp hotspots (source data can be found in Figure 2—source data 1, S6 and statistics
Figure 4 continued on next page
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hotspot with the highest number of R-breakp (Figure 4G BTG1 locus, see also Figure 4—figure sup-
plement 1). Further examples in Figure 4—figure supplement 2 show RSS-dependent clustered
deletions as defined in (Papaemmanuil et al., 2014). Overall, the presence of both convT and Pol2
stalling best characterized the recurrent ETV6-RUNX1 breakpoints with RSS motifs (101/148; com-
pared to 20/70 without motif), with 90% (43/48, empirical P=0.002) co-occurrence at intragenic sites
(see also Supplementary file 4).
AID expression marks pre-B-ALL lacking common cytogenetic changes
To elucidate the potential for RAG and AID mediated genetic instability in leukemia blasts, we com-
pared the expression of the genes RAG1, RAG2 and AICDA across a transcriptome data set with
1382 pre-B-ALL patients (Figure 5—source data 1, Figure 5). Among samples with annotation of
cytogenetic subtype (N = 1008), the ETV6-RUNX1 cases (N = 153) exhibited 10.8-fold higher median
level of RAG1 expression relative to other cases with annotated cytogenetic type (Wilcoxon rank
sum test P<2.2e-16, 95% CI 8.6–13.6-fold, Figure 5A) and also high RAG2 expression (Figure 5B).
Moreover, AICDA expression was also detected in a specific subset of patients. It was highest in the
’other’ group (N = 267) that does not carry recurrent fusion genes or karyotypic changes (Figure 5C,
no statistical evaluation was performed as majority of signal values were below detection level of 4.2
in log2 scale). As comparison, we carried out unsupervised analysis of sample similarities based on
the global gene expression profiles. To visualize these molecular subtypes in two dimensions, we uti-
lized the t-Distributed Stochastic Neighbor Embedding (t-SNE) method (van der Maaten and Hin-
ton, 2008) (see Materials and methods, refer to Figure 5—source data 1 for coordinates). The
t-SNE map places highly similar samples in close proximity. The discrete expression states (high;
low; not detected) of RAG1, RAG2 and AICDA were evident in distinct groups (Figure 5D–F,
respectively, the annotated ALL subtypes are colored in Figure 5G). Upon further examination, high
levels of AICDA expression were particularly prevalent in sample clusters that corresponded to high
risk cases from two independent ALL datasets (hypergeometric test P=7.19e-47, Figure 5H, see
Supplementary file 5 for patient characteristics). The highest level of AICDA expression was pre-
sented by a relapsed ALL case, and the RAG1 and RAG2 expression levels were 3.09- and 1.93-fold
increased at relapse, respectively. Based on the integrated patient profiles, the expression of AID
and RAG is distinct in leukemia subtypes and clinical prognosis groups.
Discussion
Next generation sequencing technologies have enabled the elucidation of mechanisms regulating
transcription and the analysis of genetic alterations across different cancer genomes. Precursor leu-
kemias are unique in that they often harbor SV and have relatively few mutations (Roberts and Mul-
lighan, 2015). Recently, a functional role of transcription in genomic instability has begun to emerge
(Hatchi et al., 2015; Sollier et al., 2014). The maturing lymphoid cells are vulnerable to off-target
effects downstream of RAG and AID activity that is required for immune gene rearrangement
(Meng et al., 2014; Qian et al., 2014, Papaemmanuil et al., 2014, Swaminathan et al., 2015). The
Figure 4 continued
for genes binned by their transcription level in Supplementary file 3). (F) A schematic model illustrating how the transcriptional features may lead to
the recruitment of RAG1 and RAG2 based on RSS-motif recognition and chromatin. Pol2 stalling associated with DNA accessibility and wide deposition
of the H3K4me3 mark. (G) R-breakp hotspot with the highest recurrence (BTG1 locus) is shown. B-lymphoblastoid and ES cell tracks from DNAse-seq
and H3K4me3 from pre-B-ALL cells (Nalm6) represent signals with highest overlap to wide Pol2 stalling (other tracks as in Figure 3H, see also
Figure 4—figure supplement 1).
DOI: 10.7554/eLife.13087.024
The following source data and figure supplements are available for figure 4:
Source data 1. Overlap of wide Pol2 stalling regions with unusually wide peaks representing other chromatin features.
DOI: 10.7554/eLife.13087.025
Figure supplement 1. Data from all signal tracks for regions displayed in Figure 4.
DOI: 10.7554/eLife.13087.026
Figure supplement 2. GRO-seq signal profile at multiple clustered deletion regions.
DOI: 10.7554/eLife.13087.027
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Figure 5. Expression of AID and RAG across molecular subtypes of leukemia. The log2 expression signal is summarized as boxplots for (A) RAG1 (B)
RAG2 and (C) AICDA across the pre-B-ALL subtypes (N = 153 BCR-ABL1, N = 153 ETV6-RUNX1, N = 151 hyperdiploid, N = 198 MLL rearrangement,
Figure 5 continued on next page
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present study represents a systematic investigation of SVs detected in acute pre-B-cell leukemia
using WGS in the context of global transcriptional activity in leukemic cells. We identified specific
transcriptional features, namely convergence of transcription and Pol2 stalling, as key factors under-
lying secondary genetic lesions frequently seen in precursor B leukemias.
Pol2 stalling and convT strongly associate with recurrent breakpoint sites across the genome and
at gene loci implicated in leukemia such as CDKN2A and PAX5 (Sulong et al., 2009). While protein-
coding secondary hits required in disease progression have been recognized for some time, our inte-
grative analysis identified several putative long non-coding RNAs and eRNAs, which merit further
investigation. Earlier work has linked eRNAs generated from intragenic superenhancers with AID-
mediated instability in lymphomas (Meng et al., 2014), proposing that convT leads to arrested tran-
scription, in agreement with experimental evidence from yeast cells (Prescott and Proudfoot,
2002). Similarly, it has been shown that Pol2 stalling and R-loops expose ssDNA for AID targeting
(Huang et al., 2007, Pavri et al., 2010, Alt et al., 2013). We show for the first time that leukemia
breakpoints similarly display significant enrichment to enhancers overlapping convT. We further
demonstrate a link between convT and elevated R-loop levels and Pol2 stalling on a genome-wide
level, with evidence from normal and leukemic human cells. These mechanisms of transcription-cou-
pled genetic instability, earlier implicated in lymphomas (Pavri et al., 2010; Meng et al., 2014;
Pefanis et al., 2014) and breast cancer (Hatchi et al., 2015), therefore have relevance in multiple
different cancer types.
Breakpoints carrying RSS-like recognition motifs for RAG1 showed high overlap with the vulnera-
ble regions as defined by convT and Pol2 stalling. Therefore, we propose that also RAG1 access to
its target sites is related to the fidelity of elongation. Previous studies investigating motif recognition
and genome-wide binding profiles of RAGs have shed light on the mechanisms how this complex is
recruited to DNA (Bevington and Boyes, 2013, Teng et al., 2015); however these studies have
been carried out using normal cells or mouse models that limit their integration with patient WGS
data. The chromatin mark H3K4me3 typically found at active promoters serves as a docking site for
RAG2 (Matthews et al., 2007, Teng et al., 2015). RAG-mediated cleavage further requires recogni-
tion of RSS motifs by RAG1 (Schatz and Swanson, 2011). Our results revealed that TSS that carry
breakpoints with an RSS motif differ from unaffected TSS by the presence of unusually wide Pol2
stalling. We show that Pol2 stalling sites, in general, have increased DNA accessibility. Further, the
top 5% of widest stalling regions are characterized by unusually broad DNAse hypersensitive regions
and H3K4me3 signal. Unique regulation of Pol2 pausing and elongation has been recognized to be
related to broad H3K4me3 domains across a wide variety of cell types (Benayoun et al., 2014,
Scheidegger and Nechaev, 2016). Together, these properties of Pol2 stalling sites may favor both
the recognition and cleavage by the RAG complex.
In this study, we developed a genome-wide approach to capture Pol2 stalling events across gene
bodies using change points analysis. This extends previous approaches to detect promoter-proximal
pausing events (reviewed in Adelman and Lis, 2012) to analysis of slowing down of Pol2 within the
full transcribed region. The feasibility of our approach was confirmed by high overlap of detected
regions with RLFS rich regions that represent known structural obstacles to the progression of tran-
scription (Skourti-Stathaki et al., 2014a; Skourti-Stathaki et al., 2014b). Furthermore, analysis of
Pol2 stalling from Pol2 ChIP-seq profiles acquired in pre-B-ALL cells had high agreement with the
Figure 5 continued
N = 267 other, N = 82 TCF3-PBX1). Wilcoxon rank sum test p-value is indicated for differential RAG1 expression in the ETV6-RUNX1 subtype (N = 153,
patients with cytogenetic subtype information N = 1008) (in A). (D–F) Alternative representation of discrete expression states for RAG1, RAG2, and
AICDA, respectively (red: high, pink: low, grey: not detected). The data points shown as a t-SNE map correspond to the full set of pre-B-ALL patient
samples (N = 1382) (see also Figure 5—source data 1). Their relative positions are defined by the transcriptome similarity. The sample groups can be
compared to annotated cytogenetic types, as colored on the same map in (G, H). The location of high-risk samples (N=295) from two independent
studies is indicated in color on the same map (COG studies GSE7740 in red and GSE11877 in black, see also Supplementary file 5). Hypergeometric
test p-value is indicated for enrichment of detected AICDA expression in the high risk studies (N = 112, refer to Supplementary file 5 for population
statistics).
DOI: 10.7554/eLife.13087.028
The following source data is available for figure 5:
Source data 1. pre-B-ALL transcriptome samples.
DOI: 10.7554/eLife.13087.029
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GRO-seq profiles. The slowing of Pol2 upon transition from initiation to elongation, measured by the
Pol2 Ser5 phosphorylation, occurs at AID hypermutation sites within the IgH-V region (Wang et al.,
2014a). We show that this type of Pol2 stalling had high overlap with leukemia breakpoints.
While RAG has a well-established role in pre-B cells, expression of AID represents a recently dis-
covered threat for lymphoid precursor genome integrity. (Swaminathan et al., 2015) showed that
infection-triggered attenuation of IL-7 receptor signaling led to strong AID expression, thus expos-
ing pre-leukemic cells to additional off-targeting events. Moreover, a negative effect on patient sur-
vival and increased relapse frequency were observed in high AICDA expressing leukemia patients
(Swaminathan et al., 2015). We found that high expression of RAG1/2 or AICDA is markedly dis-
tinct between different subtypes of pre-B-ALL at the leukemia state. Prevalent AICDA expression
was a distinguishing feature of high risk pre-B-ALL cases, in line with the previous data
(Swaminathan et al., 2015). Furthermore, the molecular profiles of patients belonging to the cyto-
genetic subtype designated as ’other’, had high similarity, placing them in close proximity on the
t-SNE map. This genetically heterogeneous category of rare cytogenetic types had a distinct eleva-
tion in AICDA expression. Further investigation of the WGS profiles focusing on this patient category
may shed light on whether AICDA expression could serve as a putative underlying factor that may
spur the diversity of DNA lesions in these patients. Similarly, the over ten-fold higher RAG1 expres-
sion could also be relevant for the prevalent development of leukemia carrying the ETV6-RUNX1 ini-
tiating fusion. The RAG locus is under complex regulation of local chromatin looping by SATB1
(Hao et al., 2015) that controls silencing and activating regulatory elements and was shown to
directly control the elevated RAG1 expression in mice. The enhancer activity in patient blast cells, as
captured here in the nascent transcriptomes, will help understanding the regulation of such key loci
in detail.
As more data on SV becomes available across cancers, further efforts should be made to eluci-
date the contribution of different complexes in transcription-coupled genomic instability and to
develop strategies for dampening their levels and activity. Translation of these measures into clinical
practice could impact treatment efficacy by decreasing clonal heterogeneity and relapse risk.
Materials and methods
GRO-seq samples
Primary bone marrow or blood samples from pediatric precursor B-ALL patients that represented
different cytogenetic subtypes were used for GRO-seq assay (refer to Supplementary file 1 for cyto-
genetic and blast count data). The study was approved by the Regional Ethics Committee in Pirkan-
maa, Tampere, Finland (#R13109). The study was conducted according to the guidelines of the
Declaration of Helsinki, and a written informed consent was received by the patient and/or guardi-
ans. In addition, three ALL cell lines (REH, Kopn-8 and Nalm-6) representing different genetic sub-
types (ETV6-RUNX1 fusion, MLL rearrangement and ’other’) were included to complement the
dataset. REH (ACC-20), Nalm6 (ACC-128), and Kopn8 (ACC-552) cell lines were obtained from the
Leibniz-Institut DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (Germany).
Mycoplasma status was defined negative by PCR (PCR Mycoplasma Test Kit I/C, PromoCell GmbH,
Germany) for all cells. The cell lines were authenticated by PCR of known fusion genes: ETV6-RUNX1
in REH, MLL-MLLT1 in Kopn8, and the lack of recurrent fusions in Nalm6. In addition, the generated
genome-wide results can be used in verification of cell line specific markers. We reasoned that a col-
lection of samples that represent both primary blasts and cell lines of different cytogenetics types
(and genetic complexity) would be ideal to capture the patterns of transcriptional activity in the lym-
phoid lineage and leukemic cells. Furthermore, 4–8 replicates were collected from a subset of sam-
ples to ensure reproducibility of the results (Figure 2—figure supplement 2). In cell culture studies,
same cell lines with similar conditions are defined as biological replicates, as nuclei were extracted
from temporally independent experiments. For nuclei extractions in co-culture experiments, same
cell lines with different culture conditions but with same time points were processed simultaneously.
For example, total of eight extractions from REH cells were performed (’Sample name’ column), in
six slightly different culture conditions (’Cell culture type’ and ’Time point (h)’ columns), and with
two replicate samples collected for two conditions in independent experiments (’Biological replicate’
column). There were no technical replicates in the sense that multiple nuclei extractions would have
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been made from the same biological replicate. Patient samples (N = 7) collected represent different
cytogenetic subtypes and were used as additional confirmation at individual gene loci: for most sub-
types N = 1, except hyperdiploid N = 2; ETV6-RUNX1 is represented also by the REH cell line; and
replicate samples were generated for Patient 1 that correspond to cultured and freshly isolated cells.
(Re-analyzed GRO-seq data: lymphoblastoid data is from three donors; ESC data is from two inde-
pendent experiments where several technical replicates were pooled). For cell culture conditions
and further details, see Supplementary file 1. The nuclei isolation was performed as previously
described (Kaikkonen et al., 2013), yielding ~1–5106 nuclei per condition. The REH, Nalm6, lym-
phoblastoid and ES cell samples that represent very deeply sequenced data, were used in the
genome-wide analysis (Supplementary file 1, GEO accession numbers for deposited pre-B-ALL
data: GSE67519 and GSE67540).
GRO-seq assay
Cells were suspended in 10 ml of swelling buffer (10 mM Tris-HCl, 2 mM MgCl2, 3 mM CaCl2 and
2 U/ml SUPERase Inhibitor [Thermofisher, Carlsbad, CA, USA] RNAse inhibitor) and let swell for 5
min. The cells were pelleted for 10 min at 400  g and resuspended in 500 ml of swelling buffer sup-
plemented with 10% glycerol. Subsequently, 500 ml of swelling buffer supplemented with 10% glyc-
erol and 1% Igepal was added drop by drop to the cells while being vortexed gently. Nuclei were
washed twice with 10 ml of swelling buffer supplemented with 0.5% Igepal and 10% glycerol, and
once with 1 ml of freezing buffer containing 50 mM Tris-HCl pH 8.3, 40% glycerol, 5 mM MgCl2 and
0.1 mM EDTA. Nuclei were counted and centrifuged at 900  g for 6 min and suspended to a con-
centration of 5 million nuclei per 100 ml of freezing buffer, snap-frozen and stored -80˚C until run-on
reactions. The nuclear run-on reaction buffer (NRO-RB; 496 mM KCl, 16.5 mM Tris-HCl, 8.25 mM
MgCl2 and 1.65% Sarkosyl (Sigma-Aldrich, Steinheim, Germany) was pre-heated to 30˚C. Then each
ml of the NRO-RB was supplemented with 1.5 mM DTT, 750 mM ATP, 750 mM GTP, 4.5 mM CTP,
750 mM Br-UTP (Santa Cruz Biotechnology, Inc., Dallas, Texas, USA) and 33 ml of SUPERase Inhibitor
(Thermofisher, Carlsbad, CA, USA). 50 ml of the supplemented NRO-RB was added to 100 ml of
nuclei samples, thoroughly mixed and incubated for 5 min at 30˚C. GRO-Seq libraries were subse-
quently prepared as previously described (Kaikkonen et al., 2013). Briefly, the run-on products
were treated with DNAse I according to the manufacturer’s instructions (TURBO DNA-free Kit, Ther-
mofisher, Carlsbad, CA, USA), base hydrolysed (RNA fragmentation reagent, Thermofisher, Carls-
bad, CA, USA), end-repaired and then immuno-purified using Br-UTP beads (Santa Cruz
Biotechnology, Inc., Dallas, Texas, USA). Subsequently, a poly-A tailing reaction (PolyA polymerase,
New England Biolabs, Ipswich, MA, USA) was performed according to manufacturer‘s instructions,
followed by circularization and re-linearization. The cDNA templates were PCR amplified (Illumina
barcoding) for 11–14 cycles and size selected to 180–300 bp length. The ready libraries were quanti-
fied (Qubit dsDNA HS Assay Kit on a Qubit fluorometer, Thermofisher, Carlsbad, CA, USA) and
pooled for 50 bp single-end sequencing with Illumina Hi-Seq2000 (GeneCore, EMBL Heidelberg,
Germany). GRO-Seq reads were trimmed using the HOMER v4.3 (http://homer.salk.edu/homer) soft-
ware (homerTools trim) to remove A-stretches originating from the library preparation. From the
resulting sequences, those shorter than 25 bp were discarded.
ChIP-seq assay
ChIP-seq was performed using antibodies against the Ser2 and Ser5 phosphorylated forms of Pol2
and against the histone mark H3K4me3 in REH (N = 1) and Nalm6 cells (N = 2). Ser5 phosphorylation
is present before the Pol2 is released to active elongation and it diminishes within the gene body
and is greatly reduced downstream of the poly(A) site, where Ser2 phosphorylation is predominantly
found (Zhou et al., 2012). For ChIP, 40 million cells were crosslinked with 1% formaldehyde for 10–
15 mins. The reactions were quenched by adding glycine to a final concentration of 125 mM, and
the cells were centrifuged and washed twice with ice-cold PBS. For ChIP 5 or 10 million cells were
used (Pol2 or H3K4me3, respectively). Nuclei were extracted by washing cell pellet twice with 1 ml
of MNase buffer (10 mM Tris ph 7.4, 10 mM NaCl, 5 mM MgCl2, 0.5% IGEPAL CA-630 [Sigma-
Aldrich, Steinheim, Germany], 1x protease inhibitor cocktail [PIC, Roche, Basel, Switzerland], 1 mM
PMSF [Thermofisher, Carlsbad, CA, USA]). Nuclei were spun down (1500  g, +4˚C, 5 min) and sus-
pended into 90 ml of MNase buffer supplemented with 5 mM CaCl2 and 0.1% Triton-X. Different
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amounts of MNase (0.5–20 U; #88216, Thermofisher, Carlsbad, CA, USA) was added to the nuclei in
10 ml volume and incubated at 37˚C for 10 mins. To stop the reaction, 100 ml of 2x Lysis buffer was
added to the reaction (1% SDS, 40 mM EDTA, 100 mM Tris-HCl pH 8.1) and samples were sonicated
using Bioruptor (Diagenode) for 5 cycles (30 s - 30 s) to break the nuclei. The lysate was cleared by
centrifugation and supernatant was diluted with RIPA buffer (for Pol2 antibodies, 1X PBS, 1% NP-40,
0.5% Sodium deoxycholate, 0.1% SDS, PIC) or dilution buffer (for H3K4me3; 20 mM Trix-HCl pH 7.4,
100 mM NaCl, 2 mM EDTA, 0.5% TritonX, PIC). The diluted lysate was pre-cleared by rotating for
2 h at 4˚C with 60 ml 80% CL-4B sepharose slurry (GE Healthcare, UK). Before use, sepharose was
washed twice with TE buffer, blocked for 1 hr min at room temperature with 0.5% BSA and 20 mg/ml
glycogen in 1 ml TE buffer, washed twice with TE and brought up to the original volume with TE.
The beads were discarded, and 1% of the supernatant were kept as ChIP input. The protein of inter-
est was immunoprecipitated by rotating the supernatant with 3–5 mg antibody overnight at 4˚C.
Antibodies against Ser2P (cat# ab5095, RRID:AB_304749) and Ser5P (cat# ab5131, RRID:
AB_449369) were purchased from Abcam (Cambridge, MA, USA). The Ab was captured using 25 ml
blocked Protein G Sepharose 4 Fast Flow (GE Healthcare, UK) and rotating the sample for 2 hr at
4˚C. Sepharose was blocked as CL-4B above, except that it was rotated overnight at 4˚C. The beads
were pelleted (1 min, 1000g, 4˚C) and the supernatant discarded. The beads used to bind Ser2P/
5P Ab were washed five times with 5X LiCl IP wash buffer (100 mM Tris pH 7.5, 500 mM LiCl, 1%
NP-40, 1% Sodium deoxycholate) and twice with TE in 0.45 mm filter cartridges (Ultrafree MC,
Millipore, Bedford, MA, USA). The beads used to pull down H3K4me3 Ab were washed three times
with wash buffer I (20 mM Tris/HCl pH 7.4, 150 mM NaCl, 0.1% SDS, 1% Triton X-100, 2 mM EDTA),
twice with buffer II (20 mM Tris/HCl pH 7.4, 500 mM NaCl, 1% Triton X-100, 2 mM EDTA) and buffer
III (10 mM Tris/HCl pH 7.4, 250 mM LiCl, 1% IGEPAL CA-630, 1% Na-deoxycholate, 1 mM EDTA),
once with TE + 0.2% TritonX and twice with TE. Immunoprecipitated chromatin was eluted twice
with 100 ml elution buffer (TE, 1% SDS). The NaCl concentration was adjusted to 300 mM with 5 M
NaCl and crosslinks were reversed overnight at 65˚C. The samples were sequentially incubated at
37˚C for 2 h each with 0.33 mg/ml RNase A and 0.5 mg/ml proteinase K (both from Thermofisher,
Carlsbad, CA, USA). The DNA was isolated using the ChIP DNA Clean & Concentrator (Zymo
Research, Irvine, CA, USA) according to the manufacturer’s instructions. Sequencing libraries were
prepared from collected DNA by blunting, A-tailing, adaptor ligation as previously described
(Heinz et al., 2010) using barcoded adapters (NextFlex, Bioo Scientific, Austin, TX, USA). Between
the reactions, the DNA was purified using Sera-Mag SpeedBeads (Thermofisher, Carlsbad, CA,
USA). Libraries were PCR-amplified for 15–16 cycles, size selected for 230–350bp fragments by gel
extraction and single-end sequenced on a Hi-Seq 2000 (Illumina) for 50 cycles.
Processing of GRO-seq, ChIP-seq, DRIP-seq and HiC sequencing reads
The GRO-seq data from lymphoblastoid cells (GSE39878, Wang et al., 2014b; GSE60456,
Core et al., 2014), ES cells (GSE41009, Sigova et al., 2013), DRIP-seq data from ES cells
(GSE45530, Ginno et al., 2013) and HiC data from human lymphoblastoid GM12878 cells
(GSM1551571, GSM1551572, GSM1551574, GSM1551575; Rao et al., 2014) were downloaded
from SRA (raw reads) and processed similarly as the new samples: reads were quality controlled and
subsequently aligned to the human hg19 reference genome version. Specifically, the quality of raw
sequencing reads was confirmed using the FastQC tool (http://www.bioinformatics.babraham.ac.uk/
projects/fastqc/) and subsequently bases with poor quality scores were trimmed (requiring a mini-
mum 97% of all bases in one read to have a min phred quality score of 10) using the FastX toolkit
(http://hannonlab.cshl.edu/fastx_toolkit/). Samples sequenced on multiple lanes were pooled after
quality control. Read stacks were collapsed from ChIP-seq files using fastx (collapse). The Bowtie
software (bowtie-0.12.9v0.1.x) (Langmead et al., 2009) was used for aligning the GRO-seq, ChIP-
seq and DRIP-seq reads to the human genome (version hg19). Up to two mismatches and up to
three locations were accepted and the best alignment was reported for each read. For the GRO-seq
reads this step was preceded by removing reads mapping to rRNA regions (AbundantSequences as
annotated by iGenomes) and discarding reads overlapping with so-called blacklisted regions that
represent unusual low or high mappability as defined by ENCODE, ribosomal and small nucleolar
RNA (snoRNA) loci from ENCODE and further manually curated for the human genome (bed file
with sequences is provided in Supplementary file 6).
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HiC
Reads from paired-end sequencing were separately filtered and aligned to the genome using bow-
tie. The reads were checked for MboI restriction sites before doing the alignments and the sequen-
ces after GATC sites were trimmed out to improve mappability. The HOMER v4.3 (http://homer.
salk.edu/homer) software was used in further processing of HiC-data. Paired-end reads were con-
nected and read pairs with exact same ends were only considered once and read pairs were
removed if they were separated by less than 1.5 the estimated sequencing insert length to remove
likely continuous genomic fragments or re-ligation events. Paired-end reads originating from regions
of unusually high tag density were left out by removing reads from 10 kb regions that contain more
than five times the average number of reads. Background model for normalization of HiC-data was
generated with 50 kb resolution. The topological domains were identified using the HOMER com-
mand’ findHiCDomains.pl’ using a resolution of 50 kb. This analysis is based on a statistic referred to
as the ‘directionality index’, which describes the tendency of a given position to interact with either
the chromatin upstream or downstream from its current position.
GRO-seq
Combined tagDirectories from GRO-seq samples were made by pooling the sequencing data for
each cell and sample type with fragment length set to 75. The findPeaks.pl program in the The
HOMER v4.3 software (http://homer.salk.edu/homer) was used to identify de novo transcripts from
GRO-seq data using pooled sequencing reads per sample type. Deeply sequenced REH, Nalm6 and
lymphoblastoid cells were used to define signal features in B-cell lineage and separate analysis was
carried out for ES cells (see Supplementary file 1). Gaps were allowed at non-mappable regions (-
style groseq -uniqmap).
ChIP-seq
Peaks were identified using findPeaks (-style histone –size 1000).
Signal tracks
BedGraph and bigWig files were generated with reads in each sequencing experiment normalized
to a total of 107 mapped reads. The bigWig files were further converted to track hubs and visualized
as strand-specific, overlaid MultiTracks as a custom Track Hub in the UCSC Genome browser.
Genomic regions used in analyses
The hg19 genome version from UCSC (available from iGenomes) was used to specify chromosome
lengths in the analysis. The gene annotations from Refseq and UCSC known gene tables were
retrieved using the UCSC Table Browser (hg19, GRCh37 Genome Reference Consortium Human Ref-
erence 37 (GCA_000001405.1)). Unique transcript coordinates were used in analysis, that is, any
transcripts sharing the same start and end coordinate were considered together. The TSS regions
were defined as +/- 1 kb regions around the annotated start coordinate. Only transcripts mapping
to canonical chromosomes were kept, also those on chrM were removed.
Enhancers
Super-enhancer coordinates from CD19+, CD20+ and HSC cells were obtained (Hnisz et al., 2013)
and merged for visualization of tracks. De novo enhancer detection was performed from the deeply
sequenced REH, Nalm6 and lymphoblastoid cells based on the transcript identification result. Tran-
scripts with length <15 kb and the characteristic bidirectionality or co-localization with enhancer
locations defined using DNAse and chromatin marker data were used to distinguish eRNAs (see Fig-
ure 2—source data 1 for data).
Analysis of SV in context of chromosome subregions
TADs reflect the three dimensional structure of chromatin, forming natural boundaries that divide
the chromosomes into sub-regions. To identify TADs with highest frequency of breakpoints, HiC-
data analysis was performed using HOMER 4.3. As our goal is to generate a natural division of the
genome into sub-regions that are relevant in context of transcriptional regulation, this approach is
superior to arbitrarily assigning sub-regions based on fixed windows. The pre-B-ALL breakpoints and
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annotation data (Andersson et al., 2015; Holmfeldt et al., 2013; Papaemmanuil et al., 2014;
Paulsson et al., 2015) were analyzed in context of TADs. Specifically, TADs were overlapped with
subtype-specific breakpoints (Figure 1—source data 1 presents TADs sorted based on the count of
breakpoints). Subsequently, TADs with breakpoints were divided into quartiles based on breakpoint
frequency per bp to analyze enrichment of feature overlap that exceeds the genomic background
level. To obtain the total transcribed area width within each TAD, the TAD coordinates were over-
lapped with the detected GRO-seq transcripts (bedtools intersect -wao). The combined SV data rep-
resents in total 1680 breakpoints and is the most comprehensive collection of pre-B-ALL SV that we
are aware of.
Chromatin segmentation data
BroadChromHMM chromatin segmentations were obtained from GM12878 and H1 ES cells includ-
ing the following segment types: 1_Active_Promoter, 2_Weak_Promoter, 3_Poised_Promoter,
4_Strong_Enhancer, 5_Strong_Enhancer, 6_Weak_Enhancer, 7_Weak_Enhancer, 8_Insulator,
9_Txn_Transition, 10_Txn_Elongation, 11_Weak_Txn, 12_Repressed", 13_Heterochrom/lo,
14_Repetitive/CNV, 15_Repetitive/CNV. The sizes of the segments of each type were used to calcu-
late the total span from the genome. Each segment type was then overlapped with a combined bed
file specifying convT and Pol2 stalling regions. Overlapping and non-overlapping pieces were
returned and analyzed separately (bedtools intersect, followed by bedtools subtract with the over-
lapping pieces given as parameter b).
Distinguishing breakpoints based on RSS-like motifs or recurrence
Two types of breakpoints were distinguished based on RSS motif annotation to result in the follow-
ing region assignment: regions containing a consensus RSS/heptamer sequence motif were used to
categorize co-localized breakpoints as putative RSS-dependent breakpoints (R-breakp: 447 in total,
335 in the ETV6-RUNX1 subtype), while regions devoid of recognition sequence were used to clas-
sify RSS-independent lesions (NR-breakp: 938 in total, 416 in the ETV6-RUNX1 subtype). Regions
harboring unresolved breakpoints were left out from majority of analysis performed (285 regions har-
boring 295 breakpoints in the ETV6-RUNX1 subtype that were mainly isolated and non-recurrent).
The RSS assignment for other breakpoints was obtained in the following way: the resolved break-
points were extended to both sides by 10 bp, resulting in a 21 bp region. The MEME analysis in
Papaemmanuil et al. 2014 for 708 resolved breakpoints from ETV6-RUNX1 patients was replicated
and comparable sequence logos to that reported previously were obtained and used to annotate
RSS status. A p-value cut-off of 0.003 was chosen for the MEME motif scanning based on FIMO anal-
ysis of the ETV6-RUNX1 data.
To evaluate recurrence, the breakpoint ends at 1 kb distance were stitched together to form
regions (each with at least one breakpoint, see Figure 3—source data 1), annotating the number of
breakpoints inside (BEDTools mergeBed –d 1000 –n). Overlap of breakpoint regions with RLFS, TSS,
convT and Pol2 stalling regions were obtained using BEDTools with 1 kb window. The overlap fre-
quencies were compared to random sampling of similarly sized genomic regions. Further compari-
sons were performed separating recurrent (>1 breakpoint per stitched region) and non-recurrent
regions, and with increasing the cut-off for the number of breakpoint events per stitched region.
The same was repeated for breakpoints within genes binned into four categories based on their
transcription level. The transcript regions were quantified using data from REH, Nalm6, and lympho-
blastoid cells, and normalized by RPKM. The maximum expression value was to divide transcripts
into quartiles based on the expression level.
Signal feature analysis
The visual examination of SV sites served as the first step to define transcriptional features of poten-
tial relevance. This motivated the analysis of regions with overlapping transcription from both
strands (convT) and local elevations in the signal (Pol2 stalling), with detailed definitions given below.
For genome-wide analysis of signal feature overlap with SV, feature tracks from several samples
were combined. This approach was deemed most appropriate to address the dynamic nature of
transcriptional activity and to avoid missing regions that due to high recurrence of SV may be
deleted in subset of leukemic cells studied.
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ConvT
ConvT regions were identified as transcripts that overlap on opposite strands by at least 100 bp (as
in Meng et al., 2014). Subsequently, a combined bed track was created for the leukemic and lym-
phoblastoid samples using bedTools mergeBed command (-d 0). The data from ES cells (GSE41009)
served as an independent control. The level of convT was quantified using the HOMER program ana-
lyzeRNA.pl from both strands separately and normalized by region size. The minimum value
obtained per region (comparing + and - strands) was assigned as convT level.
Pol2 stalling
Change-point detection is the mathematical problem of finding abrupt changes in a signal, typically
applied in context of time series (Killick et al., 2012). Both approximate and exact methods exist for
estimating the point at which the statistical properties of a sequence of observations change. The
analysis of changepoints in the signal mean was carried out using functions implemented in the R
package ‘changepoint’ (Killick and Eckley, 2014). An exact method with favorable computational
cost was recently introduced in context of time-series data (Killick et al., 2012). This method called
PELT was selected to detect the changepoints from scaled (zero mean, equal variance) signal profiles
calculated at 50-bp resolution (generated bedGraph files are available under the GEO accession
GSE67540). The analysis was performed separately for each gene, using Bayesian Information Crite-
rion as a penalty term with the changepoint counted as a parameter (function cpt.mean with param-
eters penalty = ’BIC1’, method =’PELT’). The input dataset representing primary transcription
activity at gene loci was generated by overlapping the GRO-seq signal file strand-specifically with
transcript coordinates from UCSC and Refseq (see genomic regions used). The analysis only consid-
ered regions with annotation match (in minimum 5% of identified transcript covered by annotation; a
minimum of 50% overlap with the identified transcript; annotated and detected starts do not differ
more than 10 kb). In order to define Pol2 stalling sites, the signal level between changepoints were
compared to the median across the whole gene, and intervals above 90% quantile were reported as
stalled. For ChIP-seq, this cut-off was relaxed to 80% due to higher background signal. Notice also
that there is no strand information based on ChIP-seq. The analysis was carried out separately for
each of the deeply sequenced (REH, Nalm6 and lymphoblastoid) GRO-seq datasets and ChIP-seq
replicates and subsequently merged to one bed file specifying stalled region coordinates (bedTools
merge –d 100). The ES GRO-seq dataset GSE41009 was processed similarly and used as an indepen-
dent control. To study whether there was a relationship between the stalled region size overlapping
TSS regions and R-breakp frequency, the following intersects were calculated using BEDTools (inter-
sectBed -wa | uniq): (i) overlap of Pol2 stalling sites and TSS regions harboring R-breakp and (ii) over-
lap of Pol2 stalling sites and TSS regions not harboring R- or NR-breakp. Subsequently, the sizes of
Pol2 stalling sites in each coordinate file were calculated and the Wilcoxon rank sum test used for
evaluating statistical significance for the difference in Pol2 stalling width. Secondly, top 5% widest
Pol2 stalling sites were identified and compared to top 5% widest peaks from ChIP-seq and DNAse-
seq profiles (see below).
Signal comparison at gene regions
The HOMER command annotatePeaks.pl was used to create a transcriptional profile of active genes
(RPKM > 0.5) in ES, lymphoblastoid and REH cells by scaling the histogram to each region (i.e 0–
100%) using a bin size of 100. RLFS motif density was calculated across genes with the BEDtools cov-
erage tool. A density plot representing RLFS frequency across gene regions was then obtained as
above.
DRIP-seq and RLFS motif data for R-loop detection
Data from replicate DRIP-seq experiments with two different restriction enzyme digestions
(GSE45530) were used in the analysis. Log2 signal levels were quantified using HOMER at TSS
regions. Statistical significance was estimated separately for the two different restriction enzyme
digestions. RLFS motif search was performed using the software QmRLFS-finder that predicts R-loop
forming sequences based on structural models of known sequences (Jenjaroenpun et al., 2015).
The fasta input file was generated by extracting DNA sequences based on the hg19 genome
version.
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DNAse-seq data and additional ChIP-seq data to characterize wide Pol2
stalling events
The DNAse-seq peaks were first overlapped with the Pol2 stalling regions detected based on the
GRO-seq signal. Only peaks with a score above 15 were considered. The width of the overlapping
peaks was then compared to the width of peaks with no overlap using the Wilcoxon rank sum test.
Next, top 5% widest peaks were obtained from the DNAse-seq and ChIP-seq data (refer to Fig-
ure 4—source data 1). The overlap with 5% widest Pol2 stalling regions was subsequently evaluated
using the BEDTools fisher tool.
Transcriptome data
Gene expression data from pre-B-ALL studies was combined from microarray datasets retrieved
from the NCBI GEO database as part of a data collection representing both healthy and malignant
samples hybridized to hgu133Plus2 genome-wide microarrays (in preparation for submission). In
total, 1382 pre-B-ALL samples were included. Probe-level quality control was performed to exclude
samples with very high difference in data location or distribution as measured by median and inter-
quartile range of raw probe intensities. Samples that passed this filtering were processed using the
RMA probe summarization algorithm with probe mapping to Entrez Gene IDs (from BrainArray ver-
sion 18.0.0, ENTREZG), followed by bias correction using the R package ‘bias’. The Barnes-Hut-SNE
algorithm (computationally faster approximation of t-SNE) implementation from the R package
‘Rtsne’ (Krijthe, 2015) was used to discover near-optimal representation of sample distances in two
dimensions (using parameter values perplexity 30 and theta 0.5) using 15% genes with highest vari-
ance. The t-SNE method belongs to dimensionality reduction methods that include also traditional
methods such as Principal Component Analysis. The main objective of the method is to accurately
place highly similar samples (here based on the high-dimensional gene expression profile) to close
proximities in lower dimensions. The result can be visualized in two-dimensions as a scatter plot that
allows observing sample groups based on the molecular profiles. According to our experience, this
method provides better separation between sample groups compared to more traditional methods
for large heterogeneous sample collections. To identify whether a given gene was expressed or
unexpressed in a sample, a Gaussian finite mixture model (testing equal and variable variance mod-
els, best fit chosen by BIC) was fitted by expectation-maximization algorithm to the probe signals (R
package ‘mclust’, version 4.3, Fraley and Raftery, 2002).
Statistical tests
Statistical significance was estimated using several tests to ensure reliability, including tests that rely
on assumptions about data distributions and empirical tests that rely on randomization of data
points. The statistical tests used, exact values of N, definitions of center and dispersion and precision
measures are indicated in Results, in the respective supplementary tables or figure legends.
Binomial test
Test for independent random trials with binary (success/failure) outcome, with replacement. This test
was used to assess the statistical significance of observing breakpoint events overlapping a transcrip-
tional feature (Pol2 stalling or convT). Success in population was defined using 1 kb windows across
the genome. The windows overlapping the studied feature was divided by the total number of 1 kb
windows analyzed. E.g. in the Pol2 stalling analysis, the total number of windows overlapping Pol2
stalling regions divided by this number of 1 kb windows within gene coordinates (included to the
input for the change point analysis), define probability of success.
Hypergeometric test
Test for independent random trials with binary (success/failure) outcome, without replacement. This
test was used to assess the statistical significance of observing greater than or equal overlap fre-
quency between breakpoints and an annotated set of genomic regions. E.g. to test for enrichment
of breakpoints inside convT-positive enhancers, convT-positive enhancers with breakpoints define
sample success; all enhancers with breakpoints population success; and sample taken is all convT-
positive enhancers (from the population of all enhancers). The related Fisher’s test (implemented in
BEDTools fisher) was used to obtain similar statistics with odds ratios.
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Wilcoxon rank sum test (Mann-Whitney test)
A nonparametric two-sided Wilcox test was performed to estimate whether two samples (continuous
values, unknown distribution) come from the same population (R function wilcox.test). This test was
applied to quantified signal levels compared between categories.
Random sampling
This test can be used to obtain an empirical estimate of random overlap frequencies. The sampling
was performed 1000-fold within the same genomic context as used in the analysis. To estimate the
significance of overlap between stitched breakpoint regions with e.g. convT regions, the stitched
regions were allocated random genomic coordinates, thus preserving the size distribution and
breakpoint event frequencies within stitched regions. The observed random region overlap was
used as the empirical p-value estimate. Further, the z-test was used to evaluate whether there was
evidence to reject the null hypothesis that the observed feature overlap value would belong to the
empirical distribution obtained.
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